Genomic and proteomic characterisation of primary colorectal tumours in the Malaysian population / Lau Tze Pheng by Lau, Tze Pheng
 
 
 
GENOMIC AND PROTEOMIC CHARACTERISATION OF PRIMARY 
COLORECTAL TUMOURS IN THE MALAYSIAN POPULATION 
 
 
 
 
LAU TZE PHENG 
 
 
 
 
THESIS SUBMITTED IN FULFILMENT OF THE REQUIREMENT 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
 
 
 
FACULTY OF MEDICINE 
UNIVERSITY OF MALAYA 
KUALA LUMPUR 
 
 
 
 
2014 
Preface 
iii 
 
ABSTRACT 
Colorectal cancer (CRC) is a multifactorial disease whereby gene-gene and gene-
environment interactions contribute to its development and progression.  It is also 
polygenic in nature, hence a large number of genetic alterations, each conferring a small 
genotypic risk, determine the individual’s susceptibility to this disease.  Therefore, it is 
of clinical importance to identify potential CRC susceptibility gene candidates for 
improvement of future CRC screening and surveillance.  This can be achieved by 
screening low-penetrant genetic variants via case-control studies across populations 
worldwide.  Here, we investigated the association between several genetic variants and 
CRC susceptibility, i.e., the NOD2, XRCC1, EGF and VEGF genes, as well as the top-
ranked GWAS-identified CRC-associated common variants.  The genotyping of these 
genetic variants was performed via Real-Time PCR with TaqMan chemistry.  
Rs4939827 was the only common variant associated with CRC susceptibility with 
regards to our local population.  We also attempted to characterise the CRC tumour-
specific mRNA and proteomic profiles in our samples as both mRNA and protein 
expression patterns are more dynamic compared to the genetic codes.  Hence, to 
investigate the differential gene expression in the primary CRC tumours, we used a two-
step ACP-based PCR approach which was then followed by a confirmatory test with 
RT-qPCR.  We successfully characterised distinctive gene expression signatures for 
both early- and advanced stage CRC tumours.  The under-expression of ARPC2, 
together with the over-expression of RPL35, RPS23 and TIMP1, are the main features 
of early stage CRC tumours.  In contrast, the advanced stage CRC group is 
characterised by the over-expression of C6orf173, RPL35, RPS23 and TIMP1.  After 
performing comparison protein expression analysis using a combination of 2-D DIGE 
and LC-MS/MS platform, we identified 10 significantly over-expressed and 6 
significantly under-expressed proteins in the Stage II CRC neoplasms, but none was 
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reported for either Stage III or IV CRC tumours.  For decades, CRC has been a constant 
threat to the well-being of the human population notwithstanding the fact that it can be 
treated if detected at an early stage.  With the latest advances in the therapeutic 
management of metastatic CRC through the screening for KRAS mutation, we hope our 
findings may complement current CRC management efforts in the search of potential 
molecular markers for diagnostic, prognostic and treatment response predictive 
purposes. 
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ABSTRAK 
Kanser kolorektal adalah penyakit multifaktorial di mana interaksi antara gen-gen dan 
gen-persekitaran boleh menyumbang kepada perkembangannya.  Di samping itu, ia juga 
bersifat ‘poligenik’ di mana sebilangan besar perubahan dalam genetik dengan setiap 
satunya membawa risiko yang kecil akan menentukan kecenderungan seseorang 
individu untuk mendapat penyakit ini.  Oleh itu, adalah penting untuk mengenal pasti 
calon-calon gen yang berisiko bagi meningkatkan pemeriksaan dan pengawasan kanser 
kolorektal pada masa depan.  Tujuan ini dapat dicapai dengan menyaring pelbagai 
polimorfisme genetik yang mempunyai penembusan rendah dalam populasi melalui 
kajian kes-kawalan.  Dalam penyelidikan ini, kami telah menyiasat hubungan antara 
beberapa polimorfisme genetik dan kecenderungan untuk mendapat kanser kolorektal.  
Antaranya ialah gen-gen NOD2, XRCC1, EGF dan VEGF, serta polimorfisme genetik 
yang telah dikenal pasti berkaitan dengan kanser kolorektal melalui kajian GWAS.  
Penyaringan genetik ini telah dijalankan dengan menggunakan teknik “Real-Time PCR” 
yang berunsur “TaqMan”.  Kami mendapati bahawa hanya polimorfisme genetik 
rs4939827 yang berkaitan dengan kecenderungan untuk mendapat kanser kolorektal 
dalam populasi tempatan.  Selain itu, kami juga berusaha untuk menyiasat dan 
mewujudkan profil-profil transkriptomik dan proteomik bagi tumor kolorektal.  Ini 
adalah kerana corak ekspresi mRNA dan protein adalah lebih dinamik jika berbanding 
dengan kod-kod genetik.  Oleh yang demikian, kami menyiasat gen-gen yang 
mempunyai ekspresi mRNA yang berbeza dalam tumor kolorektal dengan 
menggunakan pendekatan PCR yang berasaskan ACP.  Seterusnya, ujian pengesahan 
dengan menggunakan teknik RT-qPCR juga dilaksanakan.  Kami telah berjaya 
memperolehi dua siri gen-gen yang merupakan tandatangan tersendiri bagi kedua-dua 
tumor kolorektal peringkat awal dan lewat.  Tumor kolorektal peringkat awal 
mempunyai gen ARPC2 yang berekspresi lebih rendah, serta gen-gen RPL35, RPS23 
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dan TIMP1 yang berekspresi lebih tinggi.  Manakala ciri-ciri utama bagi tumor 
kolorektal yang berperingkat lewat adalah gen-gen C6orf173, RPL35, RPS23 dan 
TIMP1 yang berekspresi lebih tinggi.  Selepas melaksanakan analisis corak ekspresi 
protein dengan menggabungkan teknik-teknik 2-D DIGE dan LC-MS/MS, kami telah 
mengenal pasti 10 protein yang berekspresi lebih tinggi dan 6 protein yang berekspresi 
lebih rendah bagi tumor kolorektal peringkat ke-dua sahaja.  Selama ini, kanser 
kolorektal telah menjadi ancaman kepada kesihatan manusia walaupun pada hakikatnya, 
penyakit ini dapat dirawat jika dikesan pada peringkat awal.  Dengan kemajuan terkini 
yang melibatkan penyaringan mutasi KRAS dalam pengurusan rawatan bagi tumor 
kolorektal yang bersifat metastatik, kami berharap agar penemuan kami dapat 
melengkapkan usaha-usaha dunia dalam memperolehi penanda molekul yang berpotensi 
untuk memajukan diagnostik dan rawatan bagi kanser kolorektal. 
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For decades, colorectal cancer (CRC) has been a threat to the wellbeing of humans 
worldwide, notwithstanding the fact that effective treatment and promising outcome(s) 
are possible if detected early enough.  CRC can arise either sporadically or in the setting 
of Mendelian-inherited syndromes which are etiologically and pathogenetically well-
established.  In contrast to the hereditary CRC syndromes, the genetic variants of low-
penetrance genes conferring modest risks were thought to contribute to the genetic 
predisposition of sporadic CRC.  As a majority of the CRC incidences are sporadic, 
medical scientists focused their research in trying to understand molecular changes 
underlying the carcinogenic process, hoping to improve its screening, diagnosis, 
treatment and prognosis (McDermott et al., 2011; Weitz et al., 2005).  At present, 
research on CRC in Malaysian patients is still scarce despite increased incidence and 
mortality rates over the years.  In fact most CRC studies are carried out in Western 
populations, which typically exhibit different genetic background and disease 
characteristics from our local population.  Hence, in the present study, we aim to 
investigate and characterise primary sporadic CRC tumours among our Malaysian 
cancer patients from the perspective of genomics, transcriptomics and proteomics. 
To date, CRC screening has only been targeted at high-risk individuals, i.e., those with 
family or personal history of CRC or other cancers.  As genetic predisposition is 
indispensable for multi-hit CRC carcinogenesis, investigations on the role of low-
penetrance genes, as well as the interactive relationships have become the center of 
attention (Kotnis et al., 2005).  It is envisioned that the identification of low-penetrance 
CRC susceptibility variants will improve the screening and detection for adenomas or 
early stage colorectal carcinomas in average-risk population (Winawer, 2007).  
Consistent with this notion, we aimed to investigate the potential association between 
15 single nucleotide polymorphisms (SNPs) of nine low-penetrance candidate genes or 
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chromosomal loci, and CRC susceptibility with regards to our Malaysian cohort via a 
case-control association study. 
In the first part of this study, the NOD2 gene was selected owing to its crucial role in the 
inflammatory conditions predisposing to CRC.  The low-penetrance genetic variants of 
the XRCC1, EGF and VEGF genes were also chosen as anomalies in the mechanisms of 
DNA repair, cell proliferation and angiogenesis, will trigger and promote the 
development and progression of CRC tumours (Carmeliet and Jain, 2000; Citri and 
Yarden, 2006; Hisamatsu et al., 2003; Hung et al., 2005).  Recently, GWA studies were 
performed and several common CRC risk variants were identified, i.e., the loci 8q24 
(rs6983267), 8q23 (rs16892766), 11q23 (rs3802842), 15q13 (rs4779584) and 18q21 
(rs4939827) (Broderick et al., 2007; Houlston et al., 2008; Jaeger et al., 2008; Tenesa et 
al., 2008; Tomlinson et al., 2008).  Several independent studies have replicated these 
associations, but their exclusiveness in the populations of the European and American 
ancestry, warrants more replication efforts in non-European populations, e.g., Malaysia 
(Curtin et al., 2009; Pittman et al., 2009; Pittman et al., 2008; Yeager et al., 2008). 
In the post-genomic era, both transcriptomic and proteomic profiling of cancer cells 
hold promises for a better insight into CRC oncogenesis.  Abnormalities in nucleotide 
sequences alone are insufficient to trigger and sustain the development and progression 
of tumour cells.  Further alterations at the mRNA and protein levels, i.e., transcription, 
translation, post-translational modification, subcellular localisation, proteolysis, etc., 
greatly influence numerous intracellular processes that impact CRC carcinogenesis 
(Habermann et al., 2008; Soreide et al., 2009).  In the present study, we aimed to 
characterise CRC tumour-specific mRNA and protein expression patterns in comparison 
to the adjacent ostensibly normal colonic tissues via comparative expression analyses. 
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The mRNAs (transcriptome) are intermediate molecules between DNA codes in the 
human genome and functional proteins that are actively involved in the cellular 
activities and determination of cellular phenotype.  The transcription rate of genes and 
the stability of the transcribed mRNAs are altered in response to certain stimuli or 
diseased state.  Therefore, the characterisation of the transcriptome of tumour cells will 
reflect the changes in the gene expression of the tumour genome that favours the cancer 
pathogenesis (Gerling et al., 2003; Pradet-Balade et al., 2001).  Hence, in the second 
part of our study, we have employed a combination approach consisting of a two-step 
annealing control primer (ACP)-based PCR and real-time reverse transcription PCR 
(RT-qPCR), in order to characterise the mRNA expression patterns for both early- and 
advanced stage primary CRC tumours.   
Meanwhile, the characterisation of stage-specific protein expression patterns for 
primary sporadic CRC tumours was performed via two-dimensional difference gel 
electrophoresis (2-D DIGE) in the third part of our study.  Since the synthesis of 
functional proteins involve regulation at different steps of translation, the structure, 
function and abundance of proteins cannot simply be predicted by the DNA blueprint 
and mRNAs (Habermann et al., 2008; Kalia and Gupta, 2005).  In fact, proteins are the 
functional end products of genes that act as actual mediators in all biological processes.  
Therefore, it is vital to study the cancer proteome to provide a more comprehensive 
view on carcinogenesis at the molecular level.  Hence, recent studies have looked into 
the cancer proteome for potential molecular marker(s) or target(s) to improve future 
cancer diagnosis, prognosis and treatment. 
On the whole, the present research consists of three main parts that covers the genomic, 
transcriptomic and proteomic aspects of primary sporadic CRC neoplasms in our 
Malaysian patients’ cohort, i.e., Part A, B and C, respectively.  There are a total of six 
chapters in this thesis, i.e., Introduction, Literature Review, Methodology, Results, 
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Discussion and, Conclusion and Recommendation.  And now, the journey of our CRC 
study begins on the next page! 
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2.1 A Glimpse of Cancer 
Cancer, which is the leading cause of morbidity and mortality worldwide, denotes to a 
group of diseases where there is uncontrolled proliferation and spread of abnormal cells 
(World Health Organisation [WHO], 2002).  In 2008, there was an estimated cancer 
incidence of 12.7 million cases, with the lung, female breast, colorectal, stomach and 
prostate cancers as the most common (48.3 % of all cancer cases diagnosed worldwide) 
(Figure 2.1).  Globally, lung and breast cancers had emerged as the most common 
neoplasm among men (16.5 %) and women (22.9 %), respectively (Ferlay et al., 2010). 
 
Figure 2.1: Global cancer incidences in both men and women (year 2008) (Chart 
generated according to Ferlay et al., 2010). 
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In the same year, cancer had accounted for 13 % (7.6 million deaths) of global mortality, 
in which the lung, stomach, liver, colorectal and female breast cancers contributed the 
most (Figure 2.2) (Ferlay et al., 2010).   
 
Figure 2.2: Global cancer mortality in both men and women (year 2008) (Chart 
generated according to Ferlay et al., 2010). 
Cancer was responsible for one in eight deaths worldwide, and thus is higher than the 
combined number of deaths contributed by AIDS, tuberculosis and malaria (World 
Health Organisation [WHO], 2008).  Likewise, it was the second most common (17 
million deaths) cause contributing to global non-communicable disease (NCD) deaths in 
2008 alone (World Health Organisation [WHO], 2011).  In Malaysia, cancer (11.28 %) 
is the third leading cause of deaths, following cardiovascular diseases (16.49 %) and 
septicaemia (13.38 %) (Omar and Ibrahim Tamin, 2011).  In 2010, there were an 
estimated of 62, 120 new cancer cases, and a total of 5, 349 deaths were caused by 
cancer (World Health Organisation [WHO], 2011a). 
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Cancer is predicted as a continuous threat to the well-being of the global population for 
the next few decades, in accordance to population growth and ageing.  By 2030, cancer 
incidence and mortality are projected to increase to 22 million cases and 13.2 million 
deaths, respectively.  It is speculated that two-thirds of all diagnosed cancer cases will 
occur in low- and middle income countries by then.  These are parallel to the forecasted 
changes in global population demographics for the next two decades (Ferlay et al., 2010; 
Soreide et al., 2009; World Health Organisation [WHO], 2008).            
In human malignancy, genetic abnormalities are the major determinant in the initiation, 
progression and invasion of cancer.  The carcinogenesis is triggered by external 
carcinogens (i.e., tobacco, asbestos, chemicals, radiation, etc.), infectious organisms, 
and internal factors (i.e., inherited genetic mutations, hormones and immune conditions).  
These risk factors act either simultaneously or sequentially in the initiation and 
progression of human malignancies.  In reality, cancer may arise years to decades after 
the initial exposure to etiological agents.  Hence, an individual’s risk of getting cancer 
increases with age, and virtually 77 % of all diagnosed cancer cases were those 55 years 
and older (American Cancer Society [ACS], 2012; World Health Organisation [WHO], 
2002).   
Cancer staging delineates the extent and spread of malignancy at the time of diagnosis.  
It is based on the size of the primary tumour and the presence or absence of 
disseminated cancerous cells in other parts of the body.  The TNM staging (Stages I – 
IV) and summary staging systems (in situ, local, regional and distant) are two cardinal 
cancer classification systems.  Generally, the former is widely applied in clinical 
settings, while the latter is used for the descriptive and statistical analysis of tumour 
registry data (Sobin et al., 2009; Young et al., 2001).   
Chapter Two – Literature Review 
10 
 
Cancer is one of the leading diseases with high morbidity and mortality rates in both 
developed and developing countries.  However, a large proportion of human 
malignancies can, in fact, be potentially prevented or detected at an early stage when the 
cancer is more treatable (Mackay et al., 2006; World Health Organisation [WHO], 
2008).  For instance, both cervical and colorectal cancers can be potentially prevented 
through the detection and subsequent removal of precancerous lesions.  This highlights 
the importance of disease screening in reducing cancer incidences and mortalities.  
Cancer screening refers to the testing of asymptomatic individuals in an attempt to 
detect any precancerous lesion(s) or early stage tumour(s) via rapidly-applicable tests, 
examinations or procedures.  Screening has been shown to be effective in detecting 
early stage tumours of cervical, colorectal, breast and prostate cancers (Winawer et al., 
2003; World Health Organisation [WHO], 2002).  The reduction in carcinogen exposure 
and an adoption of a healthy lifestyle can also potentially decrease the risk of 
developing cancers, as neoplastic development is augmented by certain environmental 
and behavioural factors (World Health Organisation [WHO], 2002). 
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2.2 Colorectal Cancer (CRC): Facts and Figures 
2.2.1 Colon and Rectum Anatomy  
Both the colon and rectum, together with the esophagus, stomach, small intestine, 
cecum and anus, form the human gastrointestinal tract.  As illustrated in Figure 2.3, the 
human colon is a muscular tube of about five feet long and is macroscopically divided 
into four anatomical sections, i.e., the ascending, transverse, descending and sigmoid 
colon (Haubrich et al., 1995; Morson and Dawson, 1979).  
 
 
 
Figure 2.3: Anatomical structure of the human large bowel (Adapted from: http:// 
www.nlm.nih.gov/medlineplus/ency/imagepages/8832.htm). 
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The human rectum, on the other hand, is about 12 cm long and begins approximately at 
the level of the third sacral vertebra.  The lumen of rectum is fusiform and indented by 
three prominent crescentic folds, i.e., the superior, middle and inferior valve of Houston.  
Clinically, these colonic segments and rectal valves serve as important landmarks in the 
designation of tumour location for CRC diagnosis (Haubrich et al., 1995). 
Microscopically, the walls of the colon and rectum comprises of four main concentric 
layers, which from the lumen outward, are the mucosa (consists of simple columnar 
epithelium, lamina propria and muscularis mucosae), submucosa, muscularis propria 
(comprised of inner circular and outer longitudinal layer of smooth muscle) and serosa / 
adventitia (DeVita et al., 1985; Haubrich et al., 1995; Morson and Dawson, 1979).  The 
bowel wall is innervated by two main nerve plexuses – the Meissner’s and Auerbach’s 
plexus, which lies within the submucosa and between the two layers of smooth muscle 
in the muscularis propria, respectively (Morson and Dawson, 1979).   
The human colon is supplied by the superior mesenteric artery from the cecum to 
splenic flexure, and the inferior mesenteric artery in the remaining colonic sections and 
recto-sigmoid junction.  On the other hand, the rectum is supplied by the superior rectal 
(branch of inferior mesenteric artery), middle rectal (branch of internal iliac artery) and 
inferior rectal arteries (branch of internal pudendal artery) (Griffiths, 1961).  In addition, 
both the colon and rectum are endowed with extensive lymphatic network, as well as 
numerous aggregates of lymphoid follicles (especially at the ileocecal junction, within 
the transverse mesocolon at both flexures area and within the pararectal spaces) (Ellis, 
1983).  The insight into these intricate vascular and lymphatic networks greatly assists 
in the understanding of tumour spread, and subsequent formulation of effective 
operative treatment and adjuvant therapy.  Furthermore, the innervating blood and 
lymphatic vasculature also serve as important features in CRC staging, together with the 
histological structures of the bowel wall.  
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2.2.2 Definition 
CRC is a clinical term denoting cancer of the colon or rectum origin.  In both the 
clinical and research setting, ‘right-sided / proximal CRC’ refers to neoplasms arising 
from colonic segments that are proximal to the splenic flexure, i.e., the cecum, 
ascending colon, hepatic flexure or transverse colon.  Conversely, the term ‘left-sided / 
distal CRC’ refers to those arising from the splenic flexure itself, descending colon, 
sigmoid colon or rectum (Haubrich et al., 1995; Morson and Dawson, 1979). 
2.2.3 Incidence and Mortality 
Worldwide, CRC is the third most common cancer with 1.2 million new cases expected 
to occur within the decade.  As depicted in Figures 2.4a and 2.4b, a marked regional 
difference of about 10-fold in CRC incidence rate was observed in both men and 
women globally.  For instance, the North Americans, Australians, New Zealanders and 
Europeans reported with higher CRC incidence rates, while countries in Africa and 
South Central Asia were relatively lower.  The incidence of CRC was notably higher in 
men than women with a ratio of 1.4:1.  CRC alone was responsible for 8 % of all cancer 
deaths worldwide (609, 000 deaths) in the same respective year.  There was, however, 
no noticeable gender variation in CRC mortalities (Ferlay et al., 2010).     
CRC has been long thought as a ‘westernised’ disease owing to its noticeably higher 
incidence in developed / high income countries.  Yet recently, the rate is stabilizing or 
declining in these high-risk regions, e.g., France, Australia, United States, New Zealand 
and Canada.  In the United States, the reduction in CRC incidence was contributed 
largely by the CRC screening programme, which allowed the prevention of CRC by 
detecting and removing the precancerous lesions (Center et al., 2009; Center et al., 
2009a; Edwards et al., 2010; Ferlay et al., 2010).  On the contrary, a greater increasing 
trend in CRC incidence is observed in those countries of historically lower risk, i.e., 
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Japan, Korea, China, Singapore and Eastern Europe.  This might be ascribed to the 
impact of westernisation that involves changes associated with CRC risk factors, such 
as increased prevalence of obesity and smoking (Center et al., 2009; Center et al., 2009a; 
Ferlay et al., 2010; García-Álvarez et al., 2007; de Kok et al., 2008; Martín et al., 2008). 
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Figure 2.4a: Estimated age-standardised CRC incidence rates among men for 2008       
(Source: Ferlay et al., 2010).  
 
Figure 2.4b: Estimated age-standardised CRC incidence rates among women for 2008 
(Source: Ferlay et al., 2010). 
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As opposed to the incidence rate, the CRC mortality rate has been declining in most 
countries owing to increased awareness in CRC screening and improved treatment for 
CRC patients, with the exception of Mexico and Brazil in South America, and Romania 
in Eastern Europe.  This could be due to relatively limited health resources and facilities 
(Center et al., 2009; Edwards et al., 2010; Sant et al., 2001).   
In Malaysia, cancers of the breast (14.0 %), colorectum (11.4 %), lung (11.3 %), cervix 
uteri (6.6 %) and nasopharynx (6.3 %) were the five most frequent for 2008.  CRC was 
ranked as the second and third most common cancer among Malaysian men and women, 
respectively (Figures 2.5a and 2.5b) (Ferlay et al., 2010).  A sex ratio of 1.3:1 was 
reported for CRC incidence rate, with 13.4 per 100, 000 in men and 10.2 per 100, 000 in 
women (Omar and Ibrahim Tamin, 2011).  The lung, colorectal, breast and stomach 
cancers, as well as leukaemia, were the five malignancies that contributed the most to 
cancer deaths in Malaysia (Ferlay et al., 2010). 
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Figure 2.5a: Age-standardised incidence and mortality rates of malignant diseases 
among Malaysian men in 2008 (Source: Ferlay et al., 2010). 
 
Figure 2.5b: Age-standardised incidence and mortality rates of malignant diseases 
among Malaysian women in 2008 (Source: Ferlay et al., 2010). 
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2.2.4 Clinical Manifestations 
Early stage CRC is asymptomatic, and more often than not, the manifested signs and 
symptoms are implication of a more advanced disease (American Cancer Society [ACS], 
2011).  As tumours grow, the obstruction and perforation of the bowel will eventually 
result in the warning signs and symptoms of CRC, e.g., bleeding and abdominal pain.  
Bleeding can present either directly as rectal bleeding, or indirectly as blood in the 
faeces and black-coloured stools (American Cancer Society [ACS], 2011; Goulston et 
al., 1986; Thompson, 2002).  Besides cramping pain in the lower stomach, CRC 
patients will also experience a change in bowel habits such as a new onset of 
constipation or diarrhoea that lasts for more than a few days.  The loss of weight and 
fatigue are not uncommon in most CRC patients.  Occasionally, anemia can also 
develop due to excessive blood loss in some severe cases (American Cancer Society 
[ACS], 2011; Garcia-Valdecasas et al., 1991; Haubrich et al., 1995; Thompson, 2002). 
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2.2.5 Histological Variants of Colorectal Carcinoma 
Adenocarcinomas constitute more than 90 % of all CRC carcinomas, while the 
remaining are those of rarer types, e.g., neuroendocrine, squamous cell, adenosquamous, 
spindle cell and undifferentiated carcinomas (Bosman et al., 2010).  The colorectal 
adenocarcinomas are characterised by glandular formation and most of them are 
moderately-differentiated (Figure 2.6).  Of all, less than 15 % are mucinous 
adenocarcinomas, which are featured with substantial quantity (> 50 % of the tumour 
volume) of extracellular mucin within tumours (Figure 2.7a).  There are also other rarer 
types of colorectal adenocarcinoma, such as signet-ring cell (< 1 % of all CRC 
carcinomas) and medullary adenocarcinoma (5 – 8 in every 10, 000 diagnosed CRC 
cases), as illustrated in Figures 2.7b and 2.7c respectively (Bosman et al., 2010; Morson 
and Dawson, 1979; Sasaki et al., 1987; Thirunavukarasu et al., 2010; Thompson and 
West, 2000).  
 
                           
Figure 2.6: Microscopic appearance of colorectal adenocarcinoma (Adapted from: http: 
//www.microscopyu.com/staticgallery/pathology/adenocarcinomaofcolon20
x02.html). 
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Figure 2.7: Histological appearance of mucinous (a), signet-ring cell (b) and medullary 
adenocarcinoma (c) (Adapted from: Fleming et al., 2012). 
 
 
Prominent 
intracytoplasmic 
mucin vacuole 
(a) 
(b) 
(c) 
Abundant 
extracellular 
mucin 
Vesicular nuclei 
with prominent 
nucleoli 
Chapter Two – Literature Review 
21 
 
2.2.6 Oncogenesis: The Classical Adenoma-Carcinoma Sequence 
Majority of, yet not all, CRC tumours evolve from adenomatous tissues.  Adenomas 
(neoplastic polyps) are premalignant lesions composed of dysplastic epithelia, in which 
the histological, biochemical and genetic alterations are parallel to carcinomas.  As a 
consequence, adenomas are widely accepted as the antecedent of most CRC carcinomas.  
It represents a fundamental intermediary within the continuum, from normal colonic 
epithelium to invasive carcinoma, of the classical adenoma-carcinoma sequence in CRC 
oncogenesis.  In reality, both adenomas and carcinomas tend to co-exist within an 
individual (Day and Morson, 1978; Dorundi and Bannerjea, 2008; Haubrich et al., 1995; 
Morson and Dawson, 1979; Muto et al., 1975; Zhang et al., 2012).   
Generally, there are three distinct histological subtypes of adenoma which vary in size, 
tissue architecture and malignancy potential, i.e., tubular, tubulovillous and villous 
adenomas.  Tubular adenomas, which are also referred to as adenomatous polyps, are 
the most common subtypes (75 – 90 %).  They are characterised by simple crypt-like 
dysplastic glands and < 25 % of villous components.  In contrast, the villous subtype is 
the least common (3 – 10 %) and composed of > 75 % of finger-like projections (villous 
components).  The tubulovillous adenoma, on the other hand, exhibits an intermediate 
histological pattern with 25 – 75 % of villous components, and broad, stunted villi (Jass 
and Sobin, 1989; Konishi and Morson, 1982; Morson and Dawson, 1979; Muto et al., 
1975; Shinya and Wolff, 1979).  As a rule, the sporadic colonic adenoma tends to occur 
singly, with an exception of several adenomas in about 25 – 50 % of patients and 5 – 50 
polyps in only a few patients.  It was previously reported that individuals with five or 
more adenomas during colonoscopy assessment were at an increased risk of developing 
CRC (Jass, 1989; Schuman et al., 1990).  Rarely, hundreds or even thousands of 
adenomas can be observed, e.g., in familial adenomatous polyposis (FAP) syndrome 
(Konishi and Morson, 1982; Morson and Dawson, 1979; Vatn and Stalsberg, 1982).      
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The thought that colonic adenomas precede CRC carcinomas was further evidenced by 
several findings.  First, adenomas tend to occur at a younger age than carcinomas, and 
are detectable in about one in three of all resected CRC specimens.  CRC patients with 
synchronous adenomas are at twice the rate of developing a second or metachronous 
tumour in the remaining parts of the bowel, if compared to those where the associated 
adenoma is absent (Bussey et al., 1967; Dorundi and Bannerjea, 2008; Morson and 
Dawson, 1972).  Thirdly, both the adenoma with a microscopical focus of carcinoma, 
and the invasive carcinoma with residual benign adenoma at one edge, are detected 
histologically in the clinical setting (Figure 2.8). 
 
 
Figure 2.8: Histology of ‘mixed’ CRC tumour (Adapted from: Oxentenko and Smyrk, 
2012). 
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On occasions, these ‘mixed’ tumours can be visualised macroscopically (Dorundi and 
Bannerjea, 2008; Muto et al., 1975).  Fourthly, more adenomas are progressively 
destroyed or transformed into malignant tissues as the carcinoma enlarges.  This was 
evidenced as both adenomas and adenocarcinomas were contiguously found in only 7 % 
of the T3 CRC tumours, but a quantity of adenomatous tissues were observed in almost 
60 % of the T1 tumours (Morson, 1966).  The malignant transformation of adenomas 
into carcinomas was also successfully demonstrated in vitro, and the removal of 
adenomas had effectively reduced the risk of developing CRC (Dorundi and Bannerjea, 
2008).  In addition, this adenoma-carcinoma sequence was further supported by the 
Vogelstein model from the viewpoint of molecular genetics (Vogelstein et al., 1988).   
2.2.7 Risk Factors            
Previous studies had reported several modifiable and non-modifiable risk factors that 
influence an individual’s risk of developing CRC.  The non-modifiable risk factors 
include increasing age, personal or family history of CRC or adenomatous polyps, 
personal history of chronic inflammatory bowel diseases (IBDs) [e.g., ulcerative colitis 
(UC) and Crohn’s disease (CD)] and certain hereditary syndromes [e.g., hereditary non-
polyposis CRC (HNPCC) and FAP] (Bernstein et al., 2001; Butterworth et al., 2006; 
Jasperson et al., 2010; Lynch and de la Chapelle, 2003).   
An individual’s risk of developing CRC begins to increase after the age of 40, rising 
sharply at 50 – 55 years old, and doubling with each succeeding decade, until it reaches 
the peak at 75 years old (Soreide et al., 2009; Winawer, 2007).  The incidence rate of 
CRC is more than 15 times higher among individuals of 50 years old and above, 
compared to those aged between 20 – 49 years.  This was evidenced as individuals of 50 
years old and older contributed to 90 % of new cases and 94 % of deaths overall.  Hence, 
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CRC is considered as a disease of advancing years and the average age at time of 
diagnosis is about 60 years old (American Cancer Society [ACS], 2011; Hall, 2007). 
Undeniably, genetic factors do play an important role in the development of CRC (~ 30 % 
of the total cases) (Dorundi and Bannerjea, 2008; Lichtenstein et al., 2000).  The 
familial clustering of CRC, which does not fulfill the strict criteria of typical hereditary 
CRC, has contributed to 20 – 25 % of total cases.  A two- to three-fold increased risk of 
getting CRC was reported in two or more first-degree relatives of CRC patients 
(Houlston and Peto, 1996; Knudson, 2002).  This familial risk was found to increase 
with the number of CRC-affected relatives, the closer the degree of kinship to the CRC 
patients, and a younger age-at-onset of the affected family members.  Family history of 
adenomas also accounts for a two-fold increased risk (Butterworth et al., 2006; 
Cunningham et al., 2010; Johns and Houlston, 2001; Kune et al., 1989; Lynch and de la 
Chapelle, 2003; Stewart and Kleihues, 2003).  Those previously diagnosed with 
colorectal carcinomas, approximately 1.5 – 3 % of them will develop second primary 
CRC in the first five years (Stewart and Kleihues, 2003).  In addition, individuals with 
previous history of small bowel, endometrial, breast or ovarian cancer, will also be at 
increased risk for CRC development.   
Numerous evidences on the other hand, have demonstrated an increased risk of 
developing sporadic CRC in patients with chronic IBD (Choi and Zelig, 1994; Ekbom 
et al., 1990; Gyde et al., 1982; Langholz et al., 1992).  Individuals with IBD tend to 
develop sporadic CRC 15 – 20 years earlier (median age of 54.5 years in CD patients 
and 43 years in those with UC) than the average-risk population (median age of 65 
years) (Choi and Zelig, 1994).  The magnitude of CRC risk was found to increase with 
an early age at the time of diagnosis for IBD, a longer disease duration, more severe and 
extensive area of inflammation (e.g., pancolitis) and the presence of dysplasia (Eaden et 
al., 2001; Gyde et al., 1982; Gyde et al., 1988; Itzkowitz and Harpaz, 2004; Lakatos et 
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al., 2006; Munkholm, 2003).  For instance, CRC risk is increased with disease duration 
among UC patients, i.e., from 2 % at 10 years after diagnosis, to 8 % and 18 % after 20 
and 30 years, respectively.  Furthermore, the estimated prevalence of CRC was noted to 
be 3.7 % among UC patients, and increased to 5.4 % in those with pancolitis (Eaden et 
al., 2001).     
Certain inherited polyposis and non-polyposis syndromes are responsible for excessive 
familial risk of CRC and contribute to hereditary CRC.  Among them, FAP and HNPCC 
syndromes, which follow the autosomal dominant Mendelian-inheritance pattern, are 
the most prominent inherited CRC-predisposing disorders (Lynch et al., 1991; Lynch 
and Lynch, 1985; Veale, 1965).  The former accounts for < 1 % of the total CRC burden, 
while another 4 – 6 % is contributed by the latter (Haubrich et al., 1995).  The hallmark 
of FAP syndrome is the presence of hundreds to thousands of adenomas (500 – 2500 in 
average), which are typically manifested earlier in the second and third decades of life.  
Notably, the penetrance of CRC approaches 100 %, and CRC arises at the age of 40 
years in most of the FAP patients if this large amount of adenomas is left untreated 
(Half and Bresalier, 2004; Kinzler and Vogelstein, 1996).  In view of the presence of 
this considerable amount of adenomas, the occurrence of multiple synchronous 
carcinomas are common, and virtually half of the FAP patients reported with CRC 
malignancy of more than one carcinoma (Bussey, 1975).    
As for HNPCC syndrome (also known as Lynch syndrome), the progress of malignancy 
from adenoma to carcinoma is accelerated and thus, the onset of CRC is usually at a 
younger age (an average of 45 years compared to 63 years in general population) 
(Lynch et al., 1991).  Patients with HNPCC syndrome are characterised with an 
increased risk of developing neoplasias at various specific extracolonic sites, i.e., 
endometrium, ovary, stomach, small bowel, hepatobiliary tract, pancreas, upper 
uroepithelial tract and brain.  Additionally, a high risk of developing second primary 
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CRC within 10 years of surgical resection has been reported in about 25 – 30 % of the 
HNPCC patients (Barrow et al., 2009; Cunningham et al., 2010; Hampel et al., 2008; 
Vasen et al., 1991; Vasen et al., 1999; Watson et al., 2008).  There is also a 50 % risk of 
developing CRC among the first-degree relatives of HNPCC patients (Lynch et al., 
1991).   
A wide variety of modifiable factors have also been associated with increased risk for 
sporadic CRC through epidemiological studies.  The list includes physical inactivity, 
obesity, diet high in red and processed meats, long-term cigarette smoking and heavy 
alcohol consumption (Ellis, 1999; Giannopoulos et al., 2008; Huxley et al., 2009; Lewis, 
2002; Pesta et al., 2007; Samad et al., 2005; Stewart and Kleihues, 2003).  Hence, CRC 
is considered to be preventable if one practices a healthy lifestyle by abstaining from the 
above-mentioned behavioural risk factors. 
2.2.8 Tumour Grading and Cancer Staging 
The histological grading of CRC carcinoma provides information on tumour growth rate 
and aids in patient prognostication.  Broadly, there are three different grades of 
malignancy, i.e., low, average and high, based on the degree of tubules differentiation, 
the morphology of cells and nuclei, as well as the number of mitotic figures.  If the 
tubular architecture and morphology are similar to the adenomatous epithelium, the 
tumour is considered as well-differentiated.  In contrast, poorly-differentiated tumours 
(20 %) exhibit irregular tubules or clumps of undifferentiated cells.  The remaining 60 % 
are moderately-differentiated tumours with varying degrees of abnormality in tubular 
architecture (Dorundi and Bannerjea, 2008).  As previously reported, the tumour grade 
of resected CRC specimens is closely associated with the extent of cancer spread.  For 
instance, the incidence of lymph node involvement is only 25 % among cases with low 
grade malignancy, 50 % in average grade CRC tumours and almost 80 % in those of 
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high grade.  On the other hand, the crude five-year survival rate of CRC patients is in an 
inverse relationship to the tumour grade, i.e., about 80 % for those with low grade 
tumours, 60 % for average grade cases, and only 25 % for CRC patients with high grade 
neoplasm (Morson and Dawson, 1979).   
In routine clinical practice, two cardinal systems are employed for CRC staging, i.e., the 
classical Dukes’ Classification System and the American Joint Committee on Cancer 
(AJCC) Tumour-Node-Metastasis (TNM) Staging System (Hall, 2007; Puppa et al., 
2010).  The Dukes’ Classification System was first proposed by Sir Cuthbert Dukes in 
1932.  Originally, the assessment on the degree of tumour infiltration through the bowel 
wall, as well as the presence or absence of lymph nodes involvement grounded the 
application of this system (Dukes, 1932).  Thereafter, several modifications by other 
investigators had further refined the staging criteria and thus, shaped the current Dukes’ 
Classification System (Astler and Coller, 1954; Kirklin et al., 1949).  In brief, the node-
negative CRC neoplasms are classified as Dukes’ A (tumours are confined within the 
muscularis propria) or B (tumours penetrate through the muscularis propria).  On the 
other hand, the CRC tumours with lymph nodes involvement are grouped as Dukes’ C, 
whereas the presence of distant metastatic spread is a hallmark of Dukes’ D (Astler and 
Coller, 1954; Dukes, 1932; Hall, 2007). 
On top of the Dukes’ Classification System, the AJCC TNM Staging System also plays 
an integral role in CRC staging (Hu et al., 2011; Treanor and Quirke, 2007).  The 
staging criteria and classification rules of this system have been perpetually revised over 
the years, and its latest version, the 7
th
 edition of AJCC Cancer Staging Manual was 
published recently (Edge et al., 2010; Gospodarowicz et al., 2004; Jessup et al., 2011; 
Sobin et al., 2009) (Table 2.1).  Likewise, the TNM Staging System also relies on the 
anatomical evaluation of primary tumours, i.e., the depth of bowel wall infiltration at 
time of diagnosis (T), the presence or absence of regional lymph nodes involvement (N), 
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as well as the presence or absence of metastatic spread to distal organs (M) (Edge et al., 
2010; Hu et al., 2011; Puppa et al., 2010) (Figure 2.9).  This system is relatively more 
comprehensive and allows a more detailed categorisation of CRC tumours, compared to 
the Dukes’ Classification System (Table 2.1).   
 
 
Figure 2.9: TNM staging of CRC primary tumours based on the degree of bowel wall 
infiltration, as well as the involvement of regional lymph nodes and distant 
organs (Adapted from: http://www.hopkinscoloncancercenter.org/CMS/ 
CMS_Page.aspx?CurrentUDV=59&CMS_Page_ID=EEA2CD91-3276-
4123-BEE B-BAF1984D20C7). 
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Table 2.1: The 7
th
 edition of AJCC TNM Staging System for CRC tumours, in 
comparison to the Dukes’ Classification System. 
Stage T N M Dukes’ System 
0 Tis N0 M0 - 
I T1 
T2 
N0 
N0 
M0 
M0 
A 
A 
IIA 
IIB 
IIC 
T3 
T4a 
T4b 
N0 
N0 
N0 
M0 
M0 
M0 
B 
B 
B 
IIIA 
 
IIIB 
 
 
IIIC 
T1-T2 
T1 
T3-T4a 
T2-T3 
T1-T2 
T4a 
T3-T4a 
T4b 
N1/N1c 
N2a 
N1/N1c 
N2a 
N2b 
N2a 
N2b 
N1-N2 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
C 
C 
C 
C 
C 
C 
C 
C 
IVA 
IVB 
Any T 
Any T 
Any N 
Any N 
M1a 
M1b 
- 
- 
 
Broadly, the TNM Staging System is applicable for both clinical (cTNM) and 
pathological (pTNM) staging of CRC primary tumours.  The cTNM staging is founded 
on the medical history of the patient, as well as results of various physical, imaging and 
endoscopic examinations.  On the other hand, the pTNM staging is performed post-
operatively via histological examination on resected specimens.  Therefore, this system 
allows the consolidation of both clinical information (which is obtained through 
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physical examination, radiologic imaging and endoscopic inspection) and surgical 
findings for cancer staging and patient stratification (Hu et al., 2011; Puppa et al., 2010).  
In addition, this TNM Staging System is not limited to the classification of untreated 
CRC primary tumours, but also applicable for those with neoadjuvant therapy by 
assigning a prefix “y”, eg., ycTNM and ypTNM staging (Brierley et al., 2006; 
Nagtegaal et al., 2007; Wittekind et al., 2001).      
In oncology, precise and reproducible cancer staging is vital for patient management 
and surveillance.  It allows the stratification of morbidity and mortality risks of 
individual patients in order to devise appropriate therapeutic intervention (Hu et al., 
2011).  For instance, no adjuvant therapy is required for CRC tumours of pT1-2N0 
stage (Puppa et al., 2010).  In addition, the tumour stage at the time of diagnosis also 
acts as an important prognosticator for cancer outcome, e.g., the overall survival of 
CRC patients and risk of CRC recurrences (Compton, 2003; Zlobec and Lugli, 2008).  
The 5-year survival is over 90 % among CRC patients of Dukes’ A stage, and reduces 
to merely 5 % in those of Dukes’ D stage (Braunwald et al., 2001).  For cases of pT4 
stage, where the CRC tumours have directly invaded into adjacent organs or perforated 
into visceral peritoneum, a worse prognosis and higher risk of local recurrence was 
reported (Treanor and Quirke, 2007).  As previously noted, there is also a higher 
recurrence rate post presumable curative resection for rectal tumours that have 
infiltrated into the entire rectal wall and involved nodal metastasis (Domergue et al., 
1989).  In summary, the fundamental idea in cancer staging is that the more advanced 
the cancer stage (which typically features a deeper bowel wall invasion, as well as 
metastatic spread to regional lymph nodes and distal organs), the poorer the patient 
prognosis, irrespective of the treatment regime (Gunderson et al., 2010; Hu et al., 2011).    
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2.2.9 Screening 
For decades, CRC remains a constant health threat to world population.  Nonetheless, it 
is considered as a potentially preventable and curable disease.  This is owing to the fact 
that most of CRC cases evolve from adenomatous polyps, which are detectable and 
removable to prevent subsequent neoplastic transition.  In reality, these colonic 
adenomas can be detected in about 11 – 40 % of average-risk individuals, and a 
significant reduction in CRC risk (75 – 90 %) has been reported following surgical 
removal of these preneoplastic lesions (Betes et al., 2003; Levine and Ahnen, 2006; 
Winawer et al., 1993).  On the other hand, the 5-year survival rate is as high as 90 % in 
patients with early stage CRC and thus, CRC is potentially curable if it is detected early 
(Braunwald et al., 2001).  Hence, the primary goals of CRC screening are to detect and 
remove precancerous lesions for cancer prevention, as well as to diagnose early stage 
CRC for effective cancer treatment and better patient survival.   
On account of its long time frame (2 – 30 years) for the progression from precancerous 
adenomas to invasive carcinomas, screening is thus the most important preventive 
measure for CRC.  A successful screening programme is critical in reducing CRC 
mortality by decreasing the incidence rate, as well as detecting CRC at an earlier, more 
treatable and potentially curable stage.  In most countries, periodic CRC screening is 
recommended for both men and women, who are aged 50 years and older, and in an 
average risk for developing CRC.  As for those with high-risk (e.g., history of colonic 
adenomas / CRC, IBDs and inherited genetic disorders), CRC screening is advised at an 
earlier age compared to the 50-years-old of the average-risk population (Levin et al., 
2008; Liu et al., 2011; Winawer et al., 2003; Winawer, 2007; World Gastroenterology 
Organisation [WGO], 2007). 
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The World Gastroenterology Organisation formulated guidelines for CRC screening by 
proposing several approaches, which conform to the differences in local resources, 
cultural preferences and national health policies of different countries worldwide 
(World Gastroenterology Organisation [WGO], 2007).  According to CRC screening 
guidelines developed by the American Cancer Society in collaboration with other 
organisations, the widely-available CRC screening methods are categorised into two 
distinct groups with different purposes.  The cancer detection group is comprised of 
tests that primarily detect CRC tumours, while another group for structural 
examinations is employed for the detection (and possibly removal) of both precancerous 
adenomatous polyps and CRC tumours.  The former group includes the guaiac-based 
fecal occult blood test (gFOBT), fecal immunochemical test (FIT) and fecal DNA test.  
Flexible sigmoidoscopy, colonoscopy, computed tomographic colonography (CTC) and 
double-contrast barium enema (DCBE) are categorised under the latter group (Levin et 
al., 2008). 
Colonoscopy is considered most advantageous over the other methods owing to its high 
sensitivity and specificity for direct examination of both adenomatous polyps and CRC 
tumours throughout the entire large bowel.  It also allows the simultaneous excision of 
precancerous polyps and biopsy sampling of CRC tumours.  Hence, this approach is 
thus far, considered as the ‘gold standard’ in CRC diagnosis and screening, 
notwithstanding the existence of several drawbacks, such as greater cost, time-
consuming, need of expertise, patients inconvenience and morbidity risk (Kahi and Rex, 
2004; Lieberman and Weiss, 2001; Rex et al., 1997; Winawer et al., 2003; Winawer, 
2007). 
In fact, CRC screening initiatives are still scarce in certain regions such as Africa, Asia 
and South America (American Cancer Society [ACS], 2012a).  Despite the availability 
of various screening methods and numerous evidences on its leverage, CRC screening 
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in average-risk population remains lagging when compared to mammography and Pap 
testing.  The low compliance to CRC screening programme is thought to be contributed 
by several factors, i.e., complexity in choosing appropriate screening approaches, 
requirement for considerable effort from both healthcare providers and CRC patients, as 
well as the unsatisfactory level of public awareness and acceptance related to this 
programme (Winawer, 2007).  
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2.3 Research Background 
2.3.1 Part A: SNPs Genotyping via Allelic Discrimination Assays 
Cancers are complex genetic diseases and are characterised by the outgrowth of selected 
clones of cells which possess selective growth advantages via multiple epigenetic and 
genetic alterations (Kotnis et al., 2005).  These sequential and cumulative genetic 
alterations lead to self-sufficiency in growth signals, insensitivity to growth-control 
signals, infinite replicative potential, evasion of apoptosis, sustained angiogenesis, as 
well as invasion and metastasis (Hanahan and Weinberg, 2000; Nakao et al., 2012).  
Consequently, these hallmark characteristics confer the clones with the ability to 
proliferate, expand and grow, which ultimately result in neoplastic progression (Abdel-
Rahman and El-Zein, 2000; Goode et al., 2002).  Therefore, the potential cancer 
susceptibility gene candidates comprise of xenobiotic metabolism, methylation, DNA 
repair, microenvironmental modifier, antitumour immune response, cell cycle check 
point and tumour suppressor genes, as well as oncogenes (Houlston and Peto, 2004; 
Houlston and Tomlinson, 2001; Kotnis et al., 2005). 
According to their biological roles, the potential cancer susceptibility genes are mainly 
those categorised as ‘gatekeepers’, ‘caretakers’ and ‘landscapers’ (Kinzler and 
Vogelstein, 1998).  The ‘caretaker’ genes are responsible in safeguarding and 
maintaining the integrity of the human genome, i.e., DNA repair genes and xenobiotic 
metabolizing enzymes-encoding genes.  Thus, the loss of the function of these 
‘caretaker’ genes will lead to hypermutability of the genome (Baak et al., 2003; Kinzler 
and Vogelstein, 1998; Kotnis et al., 2005).  Since our body cells are constantly exposed 
to various carcinogens from both the microenvironment (e.g., hydroxyl radicals and 
superoxide anions) and macroenvironment (e.g., viruses, chemical carcinogens and 
radiation), the ‘gatekeeper’ genes will come into action by prohibiting cellular 
Chapter Two – Literature Review 
35 
 
proliferation or inducing apoptosis, if the damaged DNA is not efficiently repaired.  
Both oncogenes and tumour suppressor genes are grouped under this category.  In fact, 
a defect in ‘gatekeeper’ genes is considered rate-limiting in tumourigenesis, as it allows 
the genetic errors to pass on to new daughter cells.  Therefore, it is predicted that any 
mutation or polymorphism that disrupts the biological roles of these genes will lead to 
the accumulation of genetic lesions and result in subsequent malignant transformation.  
On the other hand, the ‘landscaper’ hypothesis proposes that the disruption of the 
microenvironment (i.e., altered stroma) is also important in promoting neoplastic 
transformation, especially of epithelial malignancies (Barcellos-Hoff, 2001; Kinzler and 
Vogelstein, 1998; Wilson and Bohr, 2007).   
In general, cancers can be classified into hereditary and sporadic types.  The hereditary 
cancers are featured by germline mutations in high-penetrance genes, more often than 
not, the tumour suppressor genes and proto-oncogenes, e.g., BRCA1 and BRCA2 (breast 
and ovarian cancers), and APC (CRC) (Kotnis et al., 2005).  On the other hand, 
numerous somatic mutations and / or polymorphisms in low-penetrance genes, as well 
as environmental risk factors are the facet of non-hereditary, sporadic cancers (Houlston 
and Peto, 2004; Imyanitov et al., 2004).  Typically, the development of sporadic cancers 
can be elucidated with a polygenic model – a large number of alleles with each 
confering a small genotypic risk, combine either additively or multiplicatively in 
determining the individual susceptibility to cancer.  These gene-gene interactions, in 
conjunction with their interaction with endogenous and exogenous carcinogens, will 
ultimately contribute to the initiation and progression of sporadic cancers (Houlston and 
Peto, 2004).  Hereditary cancers only constitute to less than 5 % of all cancer cases, 
whilst a vast majority of human cancers arise sporadically without obvious Mendelian-
inheritance patterns.  Hence, the searching and identification of prospective low-
penetrance variants are of great significance owing to their high frequency in the 
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populations (high population attributable risk) and contribution in a high proportion of 
cancer cases (Kotnis et al., 2005). 
Of all CRC incidences, approximately 5 – 10 % are contributed by defined CRC-
predisposing hereditary syndromes (i.e., FAP and HNPCC syndromes), whereby 
germline mutations of high-penetrance genes are thought to underlie the CRC 
predisposition (Soreide et al., 2009).  This fact is prominently exemplified by 
established inherited mutations in the APC and DNA mismatch repair genes (e.g., 
MLH1, MSH2, MSH6 genes) in FAP and HNPCC syndromes, respectively (Kemp et al., 
2004).  These rare, high-penetrance mutations exhibit only a small contribution to the 
overall disease burden owing to their low allelic frequencies.  In typical, their 
identification can be performed through linkage analysis and positional cloning as they 
tend to result in multiple-cases families (Kotnis et al., 2005).  On the other hand, a large 
proportion of CRC incidences (88 – 94 %) are evolved sporadically without observable 
Mendelian-inheritance pattern, and are not attributed to those recognisable highly-
penetrant genetic variants (Houlston and Tomlinson, 2000; Soreide et al., 2009).  This 
polygenic, sporadic CRC is multifactorial where both ‘nature’ and ‘nurture’ underlie its 
occurrence.  It is proposed that the accumulation of multiple low-penetrance variants, 
accompanied by the gene-gene interactions, as well as their interactions with 
environmental and behavioral risk factors, deciphers the development of sporadic CRC 
(Caldecott et al., 1994; de la Chapelle, 2004; Kotnis et al., 2005).  In reality, each of 
these low-penetrance variants confers only a modest individual risk to CRC, but the risk 
is increased substantially through associated gene-gene and gene-environment 
interactions.   
According to Fearon and Vogelstein (1990), multiple genetic alterations that occur 
chronologically over years to decades, underlie the classical, multistep adenoma-
carcinoma sequence in CRC tumourigenesis (Figure 2.10) (Jelonek et al., 2010).
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Figure 2.10: The Vogelstein model of adenoma-carcinoma sequence, as well as genomic instability pathways involved in CRC tumourigenesis 
(Adapted from Fearon and Vogelstein, 1990; Souglakos, 2007; Worthley et al., 2007). 
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However, the rate of random mutational events alone is found to be insufficient to 
explicate the genetic abnormalities in cancer genome.  Thus, it is proposed that the 
tumour-specific patterns of genomic imbalances, which confer either the “suppressor” 
or “mutator” phenotype to cancer cells, are acquired early in the tumourigenesis of most 
human solid tumours including CRC (Loeb, 2001; Loeb et al., 2003; Ried et al., 1999).  
As exemplified by the molecular basis of CRC carcinogenesis, the genomic instability 
of the cancer genome can be elucidated via two prominent pathways, i.e., chromosomal 
instability (CIN) (suppressor) and microsatellite instability (MSI) (mutator) pathways 
(Deschoolmeester et al., 2010; Jass, 2007; Soreide, 2007; Soreide et al., 2006) (Figure 
2.10).  The CIN pathway, which lies beneath 85 % of sporadic CRC cases, is 
characterised by mutations of certain oncogenes, e.g., ras, myc and p53 genes.  It also 
involves the altered functions of genes that engage in mitotic-spindle checkpoint and 
sister-chromatids separation pathways, which eventually lead to the gaining or losing of 
whole or parts of the chromosomes during cell division.  Generally, the structural and 
numerical changes of chromosomes such as aneuploidy, allelic losses, translocations 
and loss of heterozygosity (LOH), are the hallmark of CIN tumours (Chen et al., 2012; 
Fortini and Dogliotti, 2007; Jallepalli and Lengauer, 2001; Leslie et al., 2003; Lindblom, 
2001; Liu et al., 2011).   
The remaining sporadic CRC cases are accounted for by the MSI pathway.  The 
inactivation of DNA mismatch repair genes through either frameshift mutations or base-
pair substitutions, ultimately leads to genomic instability (Aquilina et al., 1994; Soreide 
et al., 2006).  These two distinct pathways are characterised by diverse genetic 
alterations that render the development of CRC, different anatomical distribution of 
CRC tumours, distinctive pathological and clinical features, varying response to drug 
treatment, as well as different prognosis of CRC patients (Popat et al., 2005; Soreide et 
al., 2006; Thibodeau et al., 1993; Walther et al., 2009; Walther et al., 2008).     
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Recently, a third pathway involving epigenetic changes was proposed to underlie CRC 
carcinogenesis (Figure 2.10).  This pathway greatly differs from both classical CIN and 
MSI pathways as the chromosome anomalies and alterations at nucleotide levels are 
uncommon (Feinberg et al., 2006; Grady, 2005).  There is hypermethylation and 
hypomethylation at CpG islands, which eventually leads to the silencing of genes and 
increased in genes transcription, respectively (Wong et al., 2007).  These aberrant DNA 
methylation and altered histone modification patterns confer a CpG Island Methylator 
Phenotype (CIMP) to the cancer cells, in which the clinical, pathological and molecular 
features are distinctive from those CIN and MSI tumours (Lin et al., 2004; Toyota et al., 
1999; Van Rijnsoever et al., 2003).  On the whole, these three pathways are acquired 
early in CRC tumourigenesis and act as a pre-requisite for further accumulation of 
numerous genetic and epigenetic abnormalities, which then confer survival benefits to 
cancer clones, contribute to the neoplastic phenotypes and facilitate tumour progression 
(Habermann et al., 2006).   
CRC is considered as a common and lethal cancer, but the reality is, it is curable and 
preventable if early stage CRC or preneoplastic lesions are detected (Cincin et al., 2012).  
In fact, the slow progression rate of CRC carcinogenesis provides a great opportunity 
for effective screening of early stage CRC tumours or adenomas to reduce both the 
incidence and mortality rates (Winawer, 2007; Winawer et al., 1997).  There is a wide 
range of methods available for population screening.  Nevertheless, each of the methods 
has their own strengths and shortcomings, and none of the test is superior over another.  
Although colonoscopy remains the “gold standard” in CRC screening and detection to 
date, this method is time-consuming, costly, invasive and sometimes, accompanied with 
a risk of perforation as well as major bleeding.  Moreover, the need for prior vigorous 
bowel preparation will also cause discomfort and inconvenience to the patients (Cincin 
et al., 2012; Rabeneck et al., 2008; Winawer, 2007).  As for other methods, the 
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unsatisfactory false positive and false negative rates, limited sensitivity and specificity 
to certain morphologies and sizes of adenomas, low patient compliance, risk of 
morbidity, radioactive exposure risk, as well as the need for expertise personnel are the 
main drawbacks (Cincin et al., 2012; Gatto et al., 2003; Imperiale et al., 2004; Rockey 
et al., 2005; Toma et al., 2008; Winawer, 2007).  
Indeed, an ideal method for population screening should be simple, cost-effective, 
highly sensitive and specific, as well as widely-accepted by the public (Winawer, 2007).  
Yet, the clinically accessible CRC screening methods at present are subjected to various 
limitations (Cunningham et al., 2010).  Thus, it is of utmost importance to effectively 
risk-stratify the average-risk population in order to avoid unnecessary hassle through an 
array of screening and detection procedures, as the CRC population screening is mainly 
targeted on asymptomatic (potentially healthy) individuals (Winawer, 2007).  Since 
CRC is a genetically heterogenous disease where a large proportion of the CRC cases 
exhibit different inherited individual susceptibility conferred by multiple common, low-
penetrance variants, the screening of specific genetic fingerprints can potentially be 
applied as the foremost step in CRC screening programme for the risk-stratification 
purpose (Kemp et al., 2004).  
Numerous association studies (case vs control studies) have been performed in order to 
identify low penetrance CRC susceptibility variants.  It is anticipated that the 
identification of these low penetrance CRC susceptibility genes will open up 
possibilities for individual cancer risk assessment which in turn permit targeted 
screening, as well as individualised preventive measures or therapies in a foreseeable 
future (Kemp et al., 2004).  Generally, the potential CRC susceptibility candidate genes 
may be those of functionally relevance to the initiation, progression, transformation and 
metastasis of CRC neoplasms, as depicted in Figure 2.11. 
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Figure 2.11: Relevant functions of potential low-penetrance susceptibility genes pertaining to CRC carcinogenesis.   
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Theoretically, 99.9 % of the human genome is identical in all human beings, and the 
inter-individual variation is accounted by only 0.1 % difference of the genome, 
notwithstanding the presence of great phenotypic differences among individuals 
(Imyanitov et al., 2004; Venter et al., 2001).  The naturally occurring genetic variations 
in the DNA sequence, i.e., single nucleotide polymorphisms (SNPs), insertion / deletion 
polymorphisms, minisatellite and microsatellite polymorphisms, confer genomic 
variability in human.  These genetic polymorphisms are differed from mutations in 
which it occurs in the ‘normal healthy’ population at a frequency of at least 1 % 
(Balasubramanian et al., 2002).  In early 2005, an estimated 10 million SNPs were 
identified and listed in the NCBI public database, of which 3 – 5 million contribute to 
the inter-individual differences among humans (Altshuler and Clark, 2005; Shastry, 
2002).  A SNP is a single base substitution occurring ubiquitously within both the 
coding and regulatory regions in DNA strands, which will regulate the expression of 
gene or alter the functions of the encoded gene products (Xue et al., 2011).  In reality, 
only < 1 % of the SNPs occurs within gene-encoding exons, while the remaining of 
them affects the regions that command the expression of genes.  Although these low-
penetrance functional polymorphisms do not result in discernible phenotypes as those 
disease-causing mutations, it has been demonstrated to be responsible for the inter-
individual differences in disease predisposition, disease severity and outcome, as well as 
response to drug / treatment (Hemminki and Shields, 2002; Jiang et al., 2010; Yeatman, 
2003).  Furthermore, these functional polymorphisms will also impact the gene-gene 
and gene-environment interactions, which may in turn, increase or decrease the risk of 
developing diseases, i.e., cancers.  Over past decades, tremendous efforts were focused 
on single nucleotide polymorphisms (SNPs) as the low penetrance variants in 
determining individual cancer risk (Hemminki and Shields, 2002; Jiang et al., 2010; 
Yeatman, 2003).     
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2.3.2 Part B: Differential Transcriptome Analysis; and Part C: Differential 
Proteome Analysis via A Bottom-Up Proteomics Approach 
Notwithstanding continuous improvement via the refinement of staging criteria and 
stage subdivision over the years, several limitations in the TNM Staging System still 
exist.  Though this system is equipped with comprehensive definitions and uniform 
rules of application, yet the evaluation of anatomical pathology is greatly dependent on 
the expertise of pathologist and subjected to inter-observer variations (Puppa et al., 
2010).  Furthermore, the increased complexity of different subcategories within a cancer 
stage in its latest version has made the interpretation and stratification of CRC tumours 
more arduous and challenging (Doyle and Bateman, 2012; Jessup et al., 2011).  The 
type, quality and quantity of post-operative resection specimens provided for 
pathological assessment will also significantly influence the accuracy and reliability of 
this system (Treanor and Quirke, 2007).  For example, the number of positive lymph 
nodes is essential in nodal stratification, i.e., in distinguishing between pN1 (3 or less) 
and pN2 (more than 3) CRC tumours.  This is, however, largely dependent on the total 
number of lymph nodes harvested for pathological evaluation.  It was proposed later, a 
standard of 12 lymph nodes to be retrieved for pathological examination in order to 
avoid under-staging of nodal involvement (Jass et al., 2008; Sobin and Greene, 2001).  
Kotake and co-workers have recently demonstrated the number of retrieved lymph 
nodes as an important prognostic factor for Stage II and III CRC (Kotake et al., 2012).  
Hence, the accuracy and reliability of TNM Staging System is, in a greater part, relied 
on the expertise of surgeons and pathologists.         
Although the major background genetic alterations underlying the classical adenoma-
carcinoma sequence in CRC oncogenesis have been established decades ago, the 
inadequacy in elucidating the heterogeneity in disease manifestation and severity, as 
well as patients prognosis, response to treatment regime and recurrence risk, still exists 
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in actual clinical settings.  Notably, the molecular and clinical heterogeneity of CRC 
neoplasms are not merely contributed by these genetic variations alone, but also the 
disparity in ensuing transcription of mRNAs and translation of proteins.  The effects of 
cancer-causing genetic abnormalities are further tangled via their transcription and 
translation into a variety of functional proteins, which then pilot the initiation and 
progression of neoplasms.  The disease phenotypes of CRC, as with other cancers, are 
contributed by defective gene products or altered regulation in the gene expression 
levels.  Hence, molecular profiling, where the activity of genes and proteins is studied, 
has become an interesting avenue of research in medical oncology to provide insights 
into the pathogenesis, diagnosis, screening, prognostication and therapeutic targets of 
CRC at molecular level (Gerling et al., 2003; Liotta and Petricoin, 2000; Nannini et al., 
2009; Soreide et al., 2009). 
In this post-genomic era, vast endeavours are focused in transcriptomic and proteomic 
profiling of the CRC adenocarcinomas in an attempt to discern disease-specific 
alterations (molecular markers / targets), which can be potentially applied to improve 
the management and surveillance of CRC patients in future (Figure 2.12) (Nannini et al., 
2009; Nowsheen et al., 2012).  Undoubtedly, the integration of gene expression and 
proteomic profiling of individual patients, into existing clinical, imaging and 
microscopic examinations, is postulated to increase the reliability in CRC detection, 
diagnosis, classification and prognostication, as well as recurrence risk prediction, 
treatment regime selection and monitoring of response to therapy among CRC patients 
(Golub et al., 1999; Nowsheen et al., 2012; Wadlow and Ramaswamy, 2005).    
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Figure 2.12: Potential clinical applications of molecular profiling in the management and surveillance of CRC patients. 
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In light of the completion of the Human Genome Project, approximately 35, 000 genes 
are predicted to be present within the human genome.  But the fact is, only 1.1 % of 
human genome is comprised of protein-coding exons, while another 24 % are intronic 
regions and the remaining 75 % are intergenic DNA sequences with unknown function 
in RNA transcription and protein translation (Ewing and Green, 2000; Roest Crollius et 
al., 2000; Soreide et al., 2009; Venter et al., 2001).  Therefore, only a small proportion 
of the human genome (< 5 %) is transcribed into RNA molecules and constitutes the 
transcriptome of a given cell (Frith et al., 2005).   
The term “transcriptome” denotes to a population of transcribed genes or a set of 
mRNAs being transcribed by a genome.  This includes both unspliced and spliced gene 
products that code for proteins.  On the other hand, transcriptomic profiling involves the 
investigation on global transcriptional activity, and the expression of all encoding genes 
(Graveley, 2001; Sperling, 2001).  In reality, it is not uncommon that not every gene is 
transcriptionally active in all cell types at all time.  It was demonstrated that different 
cell types possess different compositions of transcriptome, and the gene expression 
patterns of a given cell / tissue is differed between its healthy and diseased states.  Thus, 
it is of great significance to analyse the transcriptomic pattern in providing insights into 
the pathogenesis and development of diseases, as certain alternative splicing events only 
occur in a specific tissue at a specific time under certain physiological / diseased 
conditions (Habermann et al., 2008; Soreide et al., 2009; Su et al., 2002).   
“Proteome” refers to a complete set of proteins encoded by a genome or the entirety of 
proteins expressed by a genome.  In general, proteomic research involves extensive 
studies on the protein abundance, post-translational polypeptides modifications, protein-
protein interactions, as well as functional and dynamic processes within cells / tissues 
(Gossage et al., 2012; Habermann et al., 2008).  Physiologically, the alternative splicing 
of pre-mRNAs and RNA editing processes result in multiple protein-encoding 
Chapter Two – Literature Review 
47 
 
transcripts (mRNA variants) and subsequently, a plethora of proteins and their isoforms 
which vary in characteristics and functions (Graveley, 2001; Tyers and Mann, 2003).  
Since human proteins are composed of 20 amino acids and possess a three-dimensional 
functional structure, the complexity of the human proteome is augmented and cannot be 
predicted simply by the blueprints of genetic sequences (Yeatman, 2003).  Moreover, 
the great diversity of the human proteome is further enhanced by a wide range of post-
translational modifications, i.e., phosphorylation, acetylation, glycosylation, prenylation, 
myristoylation, disulfides formation, side chain oxidation, N- and C-terminal sequence 
truncations, etc. (Kalia and Gupta, 2005; Khidekel and Hsieh-Wilson, 2004; Nedelkov, 
2008).   
In comparison to the human genome, the human proteome is in a fluidic state and more 
dynamic as the expression of proteins is greatly influenced by the types of cell / tissue, 
cellular processes, environmental signals, etc. (Nedelkov, 2008).  The expression levels 
of proteins are regulated at transcriptional, translational and post-translational levels, i.e., 
dependent on transcription rates, nuclear export and localisation of mRNAs, stability of 
transcripts, as well as translational control and regulation of proteins degradation 
(Belasco and Brawerman, 1993; Fleck and Nielsen, 2004; Kirschner, 1999; Sonenberg 
et al., 2000).  Therefore, a multitude of proteomes with different protein compositions 
and levels is postulated within a cell or within specific cells / tissues of an organism at 
different intervals of various developmental stages / disease conditions (Werner, 2004).  
In summary, proteomic profiling involves the study of the structure, function and 
expression of all proteins within a cell or tissue as a function of time, age, biological 
state and external factors (Gossage et al., 2012; Jiang et al., 2010a).   
During a diseased state, both macro- and micro-environmental factors exert impacts on 
the pathogenesis by altering gene products or their expression levels.  Inevitably, the 
transcriptomic and proteomic profiles of the affected cells / tissues are altered and differ 
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from their normal states (Gerling et al., 2003).  The CIN pathway, which is 
characterised by nuclear DNA aneuploidy, underlies the genomic imbalances in most of 
the sporadic CRC cases.  The impact of chromosomal aneuploidy on downstream 
cellular transcription level has been proven in several studies (Habermann et al., 2008; 
Mao et al., 2003; Phillips et al., 2001; Ried et al., 2012; Upender et al., 2004).  
Undoubtedly, the alteration in copy number of the whole chromosome will lead to an 
overall increased in the average expression of genes that reside on that particular 
chromosome.  Furthermore, the expression of a substantial number of genes located on 
other diploid chromosomes is also significantly altered in a stochastic manner 
(FitzPatrick et al., 2002; Habermann et al., 2006; Phillips et al., 2001).  On the other 
hand, epigenetic abnormalities in CRC tumours also lead to changes in the chromatin 
architecture, which subsequently alter the accessibility of genes for transcription and 
affect subsequent expression of genes (Hendrich and Bird, 2000; Klochendler-Yeivin 
and Yaniv, 2001).  The effects of these transcriptional dysregulation are further 
augmented at the protein level by post-translational modifications (Habermann et al., 
2006).  The presence of SNPs will also result in different amino acid compositions 
within the polypeptide sequences and in turn, affect the folding, processing and function 
of the final protein molecules (Nedelkov, 2008).  Furthermore, deletions or substitutions 
of base pair(s) may produce premature stop codon(s) and as a consequence, the altered 
gene is only partially transcribed and the downstream production of the functional 
protein is then affected (Baak et al., 2003).     
In the aforementioned multistep model of CRC tumourigenesis, different genetic and 
epigenetic alterations are acquired at different stages of cancer progression, as some of 
them occur early for tumour initiation, while others are involved in the later 
progression-related events.  The chromosomal aberrations, accompanied by these 
sequentially acquired genetic alterations, have resulted in global transcriptional 
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dysregulation, which gives a distinctive transcriptome and proteome composition in 
CRC tumours of different stages.  Hence, it is postulated that different transcriptomic 
and proteomic patterns at different stages of CRC progression, beginning from the pre-
malignant lesions to invasive tumours, are potentially useful to aid in tumour 
classification (Baak et al., 2003; Graveley, 2001; Kalia and Gupta, 2005).  In the near 
future, a paradigm shift in clinical cancer management is envisioned owing to more 
extensive cancer research at the genomic, transcriptomic and proteomic levels. 
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2.4 Objectives of Study 
In present study, we aimed to characterise the primary sporadic CRC tumours of our 
local Malaysian CRC patients from the perspective of genomics, transcriptomics and 
proteomics with specific objectives as follows: 
2.4.1 Part A: SNPs Genotyping via Allelic Discrimination Assays 
i) To investigate the potential association of the NOD2/CARD15, XRCC1, EGF 
and VEGF genes, as well as the common GWAS-identified CRC-associated 
variants, to sporadic CRC susceptibility in the Malaysian CRC patients. 
ii) To determine the distribution patterns of the NOD2/CARD15, XRCC1, EGF and 
VEGF genetic variants, as well as the common GWAS-identified CRC-
associated variants in the Malaysian population.  
2.4.2 Part B: Differential Transcriptome Analysis 
i) To identify differentially expressed genes in primary CRC tumours specific to 
the Malaysian sporadic CRC patients. 
ii) To characterise distinctive gene expression signatures for the early- and 
advanced stage sporadic CRC specific to the Malaysian CRC patients. 
iii) To complement current growing list of potential molecular candidates that could 
be applied to improve the screening, diagnosis and patients’ management of 
CRC in future.   
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2.4.3 Part C: Differential Proteome Analysis via A Bottom-Up Proteomics 
Approach 
i) To identify the CRC tumour-specific differentially expressed proteins in the 
Malaysian sporadic CRC patients. 
ii) To characterise the stage-specific differentially expressed proteins in each 
different stage of sporadic CRC progression of the Malaysian CRC patients. 
iii) To serve as a starting point for the development of custom-fit screening, 
diagnostic or treatment scheme to improve the management of our local 
Malaysian CRC patients.  
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3.1 Part A: SNPs Genotyping via Allelic Discrimination Assays  
3.1.1 Materials 
3.1.1.1 Commercialised Reagents, Instruments and Softwares 
Item Manufacturer 
Reagent 
Sucrose AMRESCO (United States) 
Triton X-100 Merck (Germany) 
Magnesium chloride hexahydrate (MgCl2.6H2O) AMRESCO (United States) 
Tris-Hydrochloride (Tris-HCl) AMRESCO (United States) 
Ethylenediaminetetraacetic acid (EDTA) AMRESCO (United States) 
Sodium dodecyl sulfate (SDS) Bio-Rad Laboratories (United States) 
Proteinase K Promega (United States) 
Premixed Phenol / Chloroform / Isoamyl alcohol (25:24:1) 
solution (~ pH 8.0) 
AMRESCO (United States) 
Sodium chloride (NaCl) AMRESCO (United States) 
Sodium acetate (NaOAc) AMRESCO (United States) 
Glacial Acetic acid Merck (Germany) 
Absolute ethanol VWR International (United States) 
Tris-EDTA (TE) Buffer Promega (United States) 
Pre-designed TaqMan SNP Genotyping Assays for Human Applied Biosystems (United States) 
Custom TaqMan SNP Genotyping Assays Applied Biosystems (United States) 
TaqMan GTXpress Master Mix Applied Biosystems (United States) 
Instrument 
Implen NanoPhotometer Implen (Germany) 
Applied Biosystems 7500 Fast Real-Time PCR System 
- Applied Biosystems 7500 software ver. 2.0.5 
Applied Biosystems (United States) 
Software 
TaqMan Genotyper software ver. 1.0.1  Applied Biosystems (United States) 
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3.1.1.2 Miscellaneous Materials 
Other required solutions were prepared accordingly, as follows: 
i) 1X Cell Lysis Buffer 
The 10X Cell Lysis Buffer stock solution was prepared by adding 548 g of Sucrose, 50 
ml of Triton X-100, 25 ml of 1 M MgCl2.6H2O and 60 ml of 1 M Tris-HCl (pH 7.5), 
into ddH2O to a final volume of 1 L.  The stock solution was stored at 4 
0
C and diluted 
to 1X working solution immediately before use.    
ii) 5X Proteinase K Buffer 
A 750 μl of 5 M NaCl was added to 2.4 ml of 0.5 M EDTA (pH 8.0), and topped up 
with ddH2O to a total volume of 10 ml.  The prepared solution was then filtered with 
0.45 μm syringe filter before aliquoting into 1 ml working solution.  All the aliquots 
were stored at -20 
0
C until further use.  
iii) 20 % (w/v) SDS 
The 20 % (w/v) SDS solution was prepared by dissolving 200 g of SDS in 1 L ddH2O.  
The prepared solution was filtered via membrane filtration. 
iv) 10 mg/ml Proteinase K 
The 10 mg/ml Proteinase K solution was freshly prepared by dissolving 10 mg of 
Proteinase K in 1 ml ddH2O. 
v) 6 M saturated NaCl 
A 35.06 g of NaCl was dissolved slowly in 100 ml of ddH2O and followed by 
autoclaving at 121 
0
C for 15 min.  The prepared solution was then kept at room 
temperature. 
Chapter Three – Methodology 
56 
 
vi) 2 M NaOAc (pH 5.6) 
A 16.41 g of NaOAc was dissolved in 100 ml of ddH2O to form a 2 M NaOAc solution.  
The pH was then adjusted to 5.6 with Glacial Acetic acid.  Finally, the prepared solution 
was autoclaved at 121 
0
C for 15 min, and stored at room temperature. 
vii) 70 % (v/v) ethanol 
A 100 ml of 70 % (v/v) ethanol was prepared by adding 70 ml of absolute ethanol with 
30 ml of ddH2O. 
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3.1.2 Methods 
3.1.2.1 Sample Recruiting Criteria 
The recruited cases were newly-diagnosed sporadic CRC patients from both University 
Malaya Medical Centre (UMMC) in Kuala Lumpur, and Queen Elizabeth Hospital in 
Sabah, Malaysia.  The patients were aged between 40 – 90 years and manifested 
different stages of disease progression, ranging from CRC Stage I to Stage IV.  The 
confirmed diagnosis and accurate staging of CRC patients were based on their 
histopathological reports, CT scanning images and serum CEA levels, as well as 
morphological evaluations during surgical resection.  All CRC cases were ruled out 
from any hereditary CRC syndrome, cancer history or family history of CRC.  
Concurrently, age-matched healthy controls, who were CRC-free at the time of 
sampling, were also randomly recruited for this study.           
3.1.2.2 Blood Specimen Collection 
Ethical approval was obtained from the Medical Ethics Committee of UMMC (Ref. No.: 
654.1) and the collection of blood samples was carried out in both institutions with 
written informed consent from all volunteers.  In total, 130 CRC patient and 212 normal 
healthy control blood samples were collected.  The blood specimens were collected in 3 
ml Vacutainer Blood Collection Tubes with spray-coated Potassium-EDTA (K2EDTA) 
(Becton, Dickinson and Company, United States).  The whole blood samples were then 
stored at -20 
0
C for further application.    
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3.1.2.3 Genomic DNA Isolation 
The extraction of human genomic DNA from blood samples was performed via a 
conventional phenol-chloroform DNA extraction method.  This is a liquid-liquid 
extraction method, where a mixture of biomolecules is separated based on their different 
solubility in two different immiscible liquids.  Through this method, DNA molecules 
are solubilised in the upper hydrophilic layer, and the lipids dissolved in the bottom 
hydrophobic organic phase; while the proteins and carbohydrates precipitate at the 
interface between the two phases.  Typically, a premixed solution containing phenol, 
chloroform and isoamyl alcohol is used.  The mixture of phenol and chloroform is more 
efficient in protein denaturation, whereas the addition of isoamyl alcohol is to prevent 
foaming (Tan and Yiap, 2009).  In our current study, both the concentration and purity 
of the extracted genomic DNA were determined via the Implen NanoPhotometer with 
ultra-low volume of samples, e.g., 0.7 – 10 μl, when compared to common 
spectrophotometers (Implen, Germany).   
3.1.2.3(a) Phenol-Chloroform DNA Extraction 
Genomic DNA was isolated from blood samples via an in-house phenol-chloroform 
DNA extraction protocol.  First, 6 ml of whole blood was added with 40 ml of 1X Cell 
Lysis Buffer and vortexed for 1 min.  The mixture was centrifuged at 3, 850 x g for 10 
min at 10 
0
C and the resulted supernatant was discarded.  Next, the pellet was 
resuspended in another 20 ml of 1X Cell Lysis Buffer and followed by centrifugation at 
3, 850 x g for 10 min at 10 
0
C.  The supernatant was discarded while the pellet was left 
to dry for 1 min.  Subsequently, 160 μl of 5X Proteinase K Buffer, 40 μl of 20 % (w/v) 
SDS, 40 μl of 10 mg/ml Proteinase K and 200 μl of ddH2O were added to the pellet.  
The mixture was vortexed briefly and incubated overnight at 37 
0
C. 
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On the second day, 800 μl of premixed Phenol / Chloroform / Isoamyl alcohol (25:24:1) 
solution (~ pH 8.0) was added.  The tube was shaken gently until the mixture became 
homogenous, and centrifuged later at 16, 060 x g at 10 
0
C for 15 min to allow a biphasic 
emulsion.  Subsequently, the upper clear, hydrophilic aqueous layer was transferred to a 
new 1.5 ml microcentrifuge tube, and 200 μl of 6 M saturated NaCl, 40 μl 2 M NaOAc 
of pH 5.6 and 900 μl of chilled absolute ethanol were added.  The mixture was then 
incubated overnight at -70 
0
C for DNA precipitation.  On the third day, the supernatant 
was discarded and the pellet was rinsed with 1 ml of 70 % (v/v) ethanol to remove the 
excess salt after centrifugation at 16, 060 x g for 5 min at 4 
0
C.  The tube was 
centrifuged again at similar conditions and the ethanol supernatant was discarded.  
Finally, the resulting DNA pellet was air-dried, resuspended in 100 μl of TE Buffer and 
stored at -70 
0
C. 
3.1.2.3(b) DNA Concentration and Purity Assessment 
In general, the concentration and purity of DNA can be assessed by applying a 
spectrophotometric method owing to its maximum absorbance at wavelength within the 
ultraviolet range of 260 nm.  According to the Beer-Lambert Law, a reading of 1.0 at 
260 nm corresponds to 50 μg/ml of double-stranded DNA (dsDNA) in 1 cm of 
pathlength.   
dsDNA concentration (μg/ml) = A260  x  50 μg/ml  x  dilution factor 
The A260 reading in conjunction with the measurement of absorbance at wavelengths 
of 280 nm and 230 nm were used to determine the DNA purity.  The A260/A280 ratio 
of less than 1.8 indicates protein contamination in the DNA sample because the 
aromatic ring structures on the amino acids absorb at a wavelength of 280 nm.  The 
ratio of A260/A230 is, on the other hand, another indicator for DNA purity.  Certain 
organic compounds such as carbohydrates, EDTA, phenol, as well as salts, absorb at a 
Chapter Three – Methodology 
60 
 
wavelength of 230 nm.  Hence, the lower the A260/A230 ratio, the more organic 
contaminants and salts carryover in the DNA sample (Sambrook and Russell, 2001).  In 
our study, only DNA samples with good purity (A260/A280 ratio of 1.8 – 2.0; and 
A260/A230 ratio of 2.0 – 2.2) were subjected for subsequent SNP genotyping.   
3.1.2.4 Genotyping via TaqMan 5’ Nuclease Assays 
A total of 15 SNPs were genotyped using Applied Biosystems TaqMan SNP 
Genotyping Assays (Applied Biosystems, United States) via the Applied Biosystems 
7500 Fast Real-Time PCR System.  The Applied Biosystems 7500 software ver. 2.0.5 
was used to monitor and execute the PCR reactions, whilst the TaqMan Genotyper 
software ver. 1.0.1 was employed for genotyping data analysis.    
3.1.2.4(a) qPCR 
Of the 15 SNPs, 13 were genotyped with Pre-designed TaqMan SNP Genotyping 
Assays for Human, while the remaining 2 with Custom TaqMan SNP Genotyping 
Assays.  The Assays ID, PCR primers and TaqMan MGB probes sequences are listed in 
Table 3.1.   
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Table 3.1: Assays ID, PCR primers and TaqMan MGB probes sequences used for the 
genotyping of 15 SNPs. 
 
Gene 
SNP 
Variant 
Nucleotide 
Substitution 
Assay ID /  
Primers and Probes Sequence 
Pre-designed TaqMan SNP Genotyping Assay 
 
NOD2/ 
CARD15 
Gly908Arg G>C C_11717466_20  
([V]: Allele C; [F]: Allele G) 
Pro268Ser C>T C_11717470_20 
([V]: Allele C; [F]: Allele T) 
Arg702Trp C>T C_11717468_20 
([V]: Allele C; [F]: Allele T) 
Chr. 11q23.1 rs3802842 C>A C_27503482_10 
([V]: Allele A; [F]: Allele C) 
Chr. 18q21.1 rs4939827 T>C C_27913406_10 
([V]: Allele C; [F]: Allele T) 
Chr. 8q24.21 rs6983267 G>T C_29086771_20 
([V]: Allele G; [F]: Allele T) 
Chr. 15q13.3 rs4779584 C>T C_28019826_10 
([V]: Allele C; [F]: Allele T) 
Chr. 8q23.3 rs16892766 A>C C_32670283_10 
([V]: Allele A; [F]: Allele C) 
EGF rs4444903 G>A C_27031637_10 
([V]: Allele A; [F]: Allele G) 
VEGF rs3025039 C>T C_16198794_10 
([V]: Allele C; [F]: Allele T) 
 
XRCC1 
rs1799782 C>T C_11463404_10 
([V]: Allele T; [F]: Allele C) 
rs25487 G>A C_622564_10 
([V]: Allele G; [F]: Allele A) 
rs25489 G>A C_622570_10 
([V]: Allele G; [F]: Allele A) 
Custom TaqMan SNP Genotyping Assay 
 
 
 
NOD2/ 
CARD15 
 
JW1 
 
C>T 
Primer (F): 5’- TGG AGT AAG GAA AAA   
                         AGA  CCA TTG GAT T-3’ 
Primer (R): 5’- GAG GAC AAG GGA CAT TTC  
                          CAA GT-3’ 
VIC-Probe: 5’- CAG AAA GAC TCG AGT  
                          GTC-3’ 
6-FAM-Probe: 5’- CAG AAA GAC TCA AGT  
                            GTC-3’ 
 
3020insC 
 
Wild-type / 
insC 
Primer (F): 5’- GTC CAA TAA CTG CAT CAC  
                         CTA CCT-3’ 
Primer (R): 5’- ACT TCC AGG ATG GTG TCA  
                          TTC C-3’ 
VIC-Probe: 5’- CCT GCA GGC CCT TG-3’ 
6-FAM-Probe: 5’- CTG CAG GCC CCT TG-3’ 
  *[V] = VIC-Probe, [F] = 6-FAM-Probe 
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Typically, each of these pre-formulated single-tube SNP Genotyping Assays comprised 
of a pair of unlabelled PCR primers and two allele-specific TaqMan MGB probes in a 
40X stock concentration (Table 3.2).  These made-to-order TaqMan SNP Genotyping 
Assays were specifically designed for universal thermal cycling conditions, in 
conjunction with Applied Biosystems TaqMan Genotyping Master Mix (Applied 
Biosystems, United States) for highly accurate, reproducible and reliable genotyping 
results. 
 
Table 3.2: Constituents of TaqMan SNP Genotyping Assay. 
Component Concentration 
Forward Primer 36 μM 
Reverse Primer 36 μM 
6-FAM dye-labelled TaqMan MGB Probe  8 μM  
VIC dye-labelled TaqMan MGB Probe 8 μM  
  
 
We used both TaqMan GTXpress Master Mix and Applied Biosystems 7500 Fast Real-
Time PCR System for fast SNP genotyping.  The total PCR reaction time is halved, 
when compared to typical standard genotyping protocols, as illustrated in Table 3.3.  
The fast PCR reactions for all 15 SNPs were performed using the same universal 
thermal cycling conditions (Table 3.3) with universal reaction components 
concentration (Table 3.4), as specified by the manufacturer. 
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Table 3.3: Universal thermal cycling protocol for fast genotyping on Applied 
Biosystems 7500 Fast Real-Time PCR System. 
Stage Step Temperature Time 
Holding DNA Polymerase Activation 95 
0
C 20 sec 
Cycling 
(40 cycles) 
Denaturation 95 
0
C 3 sec 
Annealing / Extension 60 
0
C 30 sec 
            
Table 3.4: PCR reaction components for fast genotyping. 
Reaction Component   Volume (μl) 
2X TaqMan GTXpress Master Mix 5.0 
20X TaqMan SNP Genotyping Assay 0.5 
20 ng/μl DNA Template 1.0 
ddH2O 3.5 
Total Volume 10.0 
 
3.1.2.4(b) Genotyping Data Analysis 
Following qPCR, the raw genotyping data obtained were analysed via TaqMan 
Genotyper software ver. 1.0.1.  The data files of different qPCR runs of each 15 SNPs 
were imported, compiled and analysed together under 15 different SNP studies created 
within the software.  Subsequently, all data points were called into different genotypes 
with the software algorithm through a ‘Autocalling’ method, and displayed as scatter 
plots for visualisation.  The genotype calls were reviewed carefully for confirmation and 
sometimes, ‘Manual Calling’ was performed if any of the calls were incorrect.         
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3.1.2.5 Statistical Analysis 
Both genotype and allele frequencies of the 15 SNPs were calculated for all the CRC 
patients and healthy controls.  The observed genotype frequencies were then verified for 
concordance to Hardy-Weinberg Equilibrium (HWE) by calculating the expected 
frequencies and significance testing with the Pearson’s Chi-squared (χ2) test.  The 
significance of observed differences in genotype and allele frequencies between CRC 
patients and healthy controls was assessed with the Fisher’s Exact Test, where a p value 
of less than 0.05 is considered significant.  In addition, the odds ratio (OR) was also 
determined with 95 % confidence interval (CI) (Xue et al., 2011).       
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3.2 Part B: Differential Transcriptome Analysis 
3.2.1 Materials 
3.2.1.1 Commercialised Reagents and Kits  
Chemical / Reagent / Kit Manufacturer 
Section 3.2.2.2 – Tissue Specimen Collection 
 RNAlater RNA Stabilization Reagent 
 
QIAGEN (Germany) 
Section 3.2.2.3 – Total RNA Isolation 
 RNeasy Plus Mini Kit 
 Absolute ethanol 
 40 U/μl ScriptGuard RNase Inhibitor 
 RNA 6000 Nano Kit for Eukaryote Total RNA 
 
QIAGEN (Germany) 
VWR International (United States) 
Epicentre Biotechnologies (United States) 
Agilent Technologies (United States) 
Section 3.2.2.4 – DEGs Identification 
 GeneFishing DEG 101 & 102 Premix Kit  
       (ACP1 – 20) 
 5X RT Buffer 
 200 U/μl M-MLV Reverse Transcriptase 
 Agarose 
 10X Tris-Borate-EDTA (TBE) Buffer 
 Ethidium bromide 
 PureLink Quick Gel Extraction Kit 
 TOPO TA Cloning Kit for Sequencing 
 Difco Lysogeny Broth (LB) Agar, Lennox  
 
 Ampicillin  
 Difco LB Broth, Lennox 
 
 10X Taq Buffer with Potassium chloride (KCl) 
 25 mM Magnesium chloride (MgCl2) 
 
Seegene (Korea) 
 
Mbiotech (Korea) 
Mbiotech (Korea) 
Promega (United States) 
Invitrogen (United States) 
Promega (United States) 
Invitrogen (United States) 
Invitrogen (United States) 
Becton, Dickinson and Company  
(United States) 
Merck (Germany) 
Becton, Dickinson and Company  
(United States) 
Fermentas (Canada) 
Fermentas (Canada) 
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Chemical / Reagent / Kit Manufacturer 
 10 mM Deoxyribonucleotide triphosphate  
        (dNTP) mix 
 5 U/μl Taq DNA Polymerase (recombinant) 
 PureLink Quick Plasmid Miniprep Kit 
Fermentas (Canada) 
 
Fermentas (Canada) 
Invitrogen (United States) 
Section 3.2.2.5 – Confirmatory Test 
 0.5 μg/μl Oligo(dT)12-18 Primer 
 5X First Strand Buffer 
 40 U/μl RNaseOUT Recombinant RNase 
Inhibitor 
 200 U/μl M-MLV Reverse Transcriptase 
 Custom TaqMan Gene Expression Assays 
 TaqMan Gene Expression Master Mix 
 Pre-developed TaqMan Endogenous Control 
Assays 
 
Invitrogen (United States) 
Invitrogen (United States) 
Invitrogen (United States) 
 
Invitrogen (United States) 
Applied Biosystems (United States) 
Applied Biosystems (United States) 
Applied Biosystems (United States) 
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3.2.1.2 Instruments and Services 
Instrument / Service Manufacturer /  
Service Provider 
1.5 ml pellet pestle with cordless motor Kimble Chase (United States) 
Agilent 2100 Bioanalyzer 
- Agilent 2100 Expert software ver. B.02.07.SI532 
Agilent Technologies (United States) 
IKA MS 3 Chip Vortexer IKA (Germany) 
Eppendorf Mastercycler Gradient Thermal Cycler Eppendorf (Germany) 
Applied Biosystems 7500 Fast Real-Time PCR System 
- Applied Biosystems 7500 software ver. 2.0.5 
Applied Biosystems (United States) 
Single Pass DNA Sequencing Service 1st BASE Pte Ltd (Malaysia) 
 
3.2.1.3 Softwares 
Software Manufacturer 
BioEdit software ver. 7.0.9 Ibis Biosciences (United States) 
Basic Local Alignment Search Tool (BLAST) 
programme 
National Institutes of Health  
(United States) 
Integromics RealTime StatMiner software ver. 4.2.8 Integromics (Spain) 
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3.2.1.4 Miscellaneous Materials 
Other required materials were prepared accordingly, as follows:   
i) 70 % (v/v) ethanol 
A 100 ml of 70 % (v/v) ethanol solution was prepared by adding 70 ml of absolute 
ethanol with 30 ml of ddH2O. 
ii) 2 mM dNTP mix 
A 1 in 5 dilution was performed on commercially-available 10 mM dNTP mix to obtain 
a concentration of 2 mM.  
iii) 3 % (w/v) agarose gel 
Three grams of agarose powder was dissolved in 100 ml of 1X TBE Buffer.  The 
mixture was heated until it became homogenous.  
iv) LB plate containing 50 μg/ml Ampicillin 
A 35 g of LB Agar powder was dissolved in 1 L of ddH2O, and autoclaved at 121 
0
C for 
15 min.  The solution was allowed to cool down to 50 
0
C before the addition of 50 
μg/ml Ampicillin.  Subsequently, the Ampicillin-containing LB medium was poured 
onto Petri dishes and left to solidify at room temperature.  The prepared LB plates were 
kept at 4 
0
C.     
v) LB 
The LB was prepared by dissolving 20 g of commercialised LB Broth powder in 1 L of 
ddH2O, and followed by autoclaving at 121 
0
C for 15 min.  Next, 50 μg/ml of 
Ampicillin was added once it was cooled down.  The LB was then aliquoted into 20 ml 
each and stored at 4 
0
C.  
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3.2.2 Methods 
3.2.2.1 Patient Characteristics  
The recruited CRC patients were those who presented with newly-diagnosed disease in 
the absence of previous history of cancer or family history of CRC.  All volunteered 
patients were ruled out for possible hereditary CRC syndromes by gastroenterologists.  
In addition, the patients were not subjected to any chemo- or radiotherapy prior to tissue 
specimen collection.  Our cohort of samples consisted of CRC patients aged between 40 
– 86 years old.  These patients, who presented with early stage CRC of Dukes’ A and B, 
were included for the identification of DEGs.  As for the confirmatory test, the recruited 
CRC patient samples exhibited all stages of cancer progression, ranging from Dukes’ A 
– D (Stages I – IV).  The accurate diagnosis and staging of all CRC patients were 
performed by experienced surgeons and oncologists by taking into consideration the 
histopathological reports, CT scanning images, morphological evaluations during 
surgery and serum CEA levels.          
3.2.2.2 Tissue Specimen Collection 
The preliminary study of the identification of DEGs comprised of four paired colonic 
tissue specimens, whilst a total of 27 paired samples were included for subsequent 
confirmatory tests.  In the confirmatory tests, the paired samples were further stratified 
into early stage (Stages I and II) and late stage (Stages III and IV) CRC groups, with 13 
and 14 sample pairs, respectively.  All paired colonic samples were collected from 
voluntary CRC patients who underwent surgical resection in UMMC with written 
informed consent.  Ethical approval had been obtained from the Medical Ethics 
Committee, UMMC (Ref. No.: 654.1) prior to specimen collection.  Both CRC tumours 
and normal colonic mucosa specimens were obtained from volunteered CRC patients by 
experienced gastrointestinal surgeons during surgery.  The CRC specimens were 
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excised from the dissected tumours, whereas the paired normal tissues were obtained 
from macroscopically normal colonic mucosa, distal to the tumours.  All the tissue 
specimens were submerged completely in the RNAlater RNA Stabilization Reagent 
immediately after excision and incubated overnight at 4 
0
C for fully immersion.  
Subsequently, the tissues were stored at -80 
0
C for archival storage.  This reagent 
efficiently preserves the integrity of RNA and enables reliable gene expression analysis, 
without the need of inconvenient and equipment-intensive sample processing steps, 
such as snap-freezing in liquid nitrogen and immediate processing of harvested tissue 
samples.       
3.2.2.3 Total RNA Isolation  
3.2.2.3(a) RNA Extraction 
Total RNA was extracted from both CRC tumours and normal colonic tissues via 
commercially-available RNeasy Plus Mini Kits.  These column-based total RNA 
extraction kits are capable of isolating high yield of total RNA, with the enrichment of 
mRNAs since most rRNAs and tRNAs (< 200 nucleotides) were selectively excluded.  
Moreover, the specifically designed gDNA Eliminator spin column enables effective 
elimination of possible genomic DNA contamination.  Initially, 30 mg of RNAlater-
stabilised tissue was excised and homogenised in 600 μl of Buffer RLT Plus by using a 
disposable 1.5 ml pellet pestle with cordless motor.  The lysate was then centrifuged at 
17, 000 x g for 3 min, and the supernatant was transferred to the gDNA Eliminator spin 
column.  Next, the tube was centrifuged at 13, 800 x g for 30 sec.  The flow-through 
was added with 1 volume of 70 % (v/v) ethanol and mixed well.  Seven hundred 
microlitres of sample was then transferred to an RNeasy spin column, followed by 
centrifugation at 13, 800 x g for 15 sec.  Subsequently, 700 μl of Buffer RW1 was 
added to the column and centrifuged for 15 sec at 13, 800 x g.  The column was then 
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added with 500 μl of Buffer RPE and centrifuged at 13, 800 x g for a further 15 sec.  
Later, 500 μl of Buffer RPE was added again to the spin column and centrifuged at 13, 
800 x g for 2 min.  The tube was centrifuged at full speed for 1 min following the 
placement of RNeasy spin column in a new 2 ml collection tube.  Finally, the purified 
total RNA was eluted by adding 30 μl of RNase-free water and centrifuging for 1 min at 
13, 800 x g.  The extracted total RNA was stored at -80 
0
C following the addition of 1 
μl of 40 U/μl ScriptGuard RNase Inhibitor.           
3.2.2.3(b) RNA Concentration and Integrity Assessment 
The concentration and purity of isolated total RNA were subsequently ascertained via 
the Agilent 2100 Bioanalyzer in conjunction with RNA 6000 Nano Kit for Eukaryote 
Total RNA.  This assay was performed according to the manufacturer’s protocol as 
described herewith.  The Agilent 2100 Expert software ver. B.02.07.SI532 was utilised 
to conduct the measurement, as well as view and analyse the data obtained.  This Lab-
on-a-Chip technology is able to quantitate 25 – 500 ng/µl of total RNA and measure the 
RNA integrity by determining the RNA Integrity Number (RIN) value.  The RIN 
algorithm across a ten-point scale is used for unambiguous integrity assessment of RNA 
samples.  This is especially important for comparative analysis where the intactness of 
RNA across samples will greatly influence the results observed (Fleige and Pfaffl, 
2006).  For accurate analysis, the RNA samples with RIN value of 8.0 – 10.0 and rRNA 
ratio [28S/18S] of 1.5 – 2.5 were selected for subsequent experiments.      
3.2.2.3(b)(i) Set Up of Chip Priming Station and Bioanalyzer 
First, a new syringe was inserted into the clip, slid into the luer lock adapter and 
screwed tightly onto the chip priming station.  The base plate of the chip priming station 
was then lifted to position C, while the syringe clip was placed at the top position.  
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Subsequently, the chip selector within the Agilent 2100 Bioanalyzer was adjusted to 
position (1). 
3.2.2.3(b)(ii) Preparation of Gel and Gel-Dye Mix 
The RNA 6000 Nano Gel Matrix was pipetted into a spin filter and centrifuged at 1, 500 
x g for 10 min under room temperature.  The filtered gel was aliquoted into 0.5 ml 
RNase-free microfuge tubes.  On the other hand, the RNA 6000 Nano Dye Concentrate 
was allowed to equilibrate to room temperature for 30 min and vortexed for 10 sec.  
Next, 1 µl of dye was added into 65 µl of gel aliquot.  The solution was vortexed and 
centrifuged under room temperature at 13, 000 x g for 10 min. 
3.2.2.3(b)(iii) Loading of RNA 6000 Nano Chip 
Initially, a new RNA 6000 Nano Chip was placed on the chip priming station.  Nine 
microlitres of gel-dye mix was pipetted into well marked .  The priming station was 
closed with the plunger positioned at 1 ml.  Next, the plunger was pressed down until it 
was held by the clip.  The clip was then released after 30 sec and slowly pulled back to 
the position of 1 ml after 5 sec.  Another 9 µl of gel-dye mix was loaded into each of the 
two wells marked .  Following gel priming, the RNA 6000 Nano Marker, RNA 6000 
Nano Ladder and RNA samples were loaded into the chip.  The RNA 6000 Nano 
Marker was pipetted into all 12 sample wells and the well marked , with 5 µl each.  
One microlitre of heat-denatured RNA 6000 Nano Ladder was then pipetted into the 
well marked .  Subsequently, 1 µl of RNA sample was loaded into each sample well.  
Finally, the chip was vortexed horizontally at 2, 400 rpm for 1 min with the use of IKA 
MS 3 Chip Vortexer.  The chip was then placed in the Agilent 2100 Bioanalyzer for 
analysis.               
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3.2.2.4 DEGs Identification 
The characterisation and identification of DEGs in CRC tumours, compared to normal 
colonic mucosa, was performed via two-step ACP-based PCR with commercially-
available GeneFishing DEG 101 & 102 Premix Kit (ACP1 – 20).  This technology 
increases the specificity of primers annealing, and thus allows target-specific PCR 
amplification (Hwang et al., 2003).     
3.2.2.4(a) First-strand Complementary DNA (cDNA) Synthesis 
The isolated total RNA was subjected to reverse transcription for the synthesis of first-
strand cDNA.  This step was carried out according to the manufacturer’s protocol in the 
GeneFishing DEG 101 & 102 Premix Kit (ACP1 – 20), as follows: 3 µg of total RNA 
was added with 2 µl of 10 µM dT-ACP1 (Table 3.5) and RNase-free water to a final 
volume of 9.5 µl.  The reagents was mixed by tapping and incubated at 80 
0
C for 3 min.  
Next, the tube was chilled on ice for 2 min and spun down briefly.  The mixture was 
then added with 4 µl of 5X RT Buffer, 5 µl of 2 mM dNTP mix, 0.5 µl of 40 U/µl 
ScriptGuard RNase Inhibitor and 1 µl of 200 U/µl M-MLV Reverse Transcriptase.  The 
tube was incubated at 42 
0
C for 90 min, followed by 94 
0
C for 2 min and chilled on ice 
for another 2 min.  Finally, the tube was spun briefly before adding 70 µl of DNase-free 
water to dilute the synthesised first-strand cDNA.  The cDNA was stored at -20 
0
C until 
further application.       
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3.2.2.4(b) ACP-based GeneFishing PCR 
The characterisation of DEGs was carried out via ACP-based PCR with 20 arbitrary 
ACPs (ACP1 – 20), as listed in Table 3.5. 
Table 3.5: Arbitrary ACP1 – 20, dT-ACP1 and dT-ACP2 primers in GeneFishing DEG 
101 & 102 Premix Kit. 
Primer Sequence 
Arbitrary ACP1 5’-GTCTACCAGGCATTCGCTTCATXXXXXGCCATCGACC-3’ 
Arbitrary ACP2 5’-GTCTACCAGGCATTCGCTTCATXXXXXAGGCGATGCC-3’ 
Arbitrary ACP3 5’-GTCTACCAGGCATTCGCTTCATXXXXXCCGGAGGATG-3’ 
Arbitrary ACP4 5’-GTCTACCAGGCATTCGCTTCATXXXXXGCTGCTCGCG-3’ 
Arbitrary ACP5 5’-GTCTACCAGGCATTCGCTTCATXXXXXAGTGCGCTCG-3’ 
Arbitrary ACP6 5’-GTCTACCAGGCATTCGCTTCATXXXXXGGCCACATCG-3’ 
Arbitrary ACP7 5’-GTCTACCAGGCATTCGCTTCATXXXXXCTGCGGATCG-3’ 
Arbitrary ACP8 5’-GTCTACCAGGCATTCGCTTCATXXXXXGGTCACGGAG-3’ 
Arbitrary ACP9 5’-GTCTACCAGGCATTCGCTTCATXXXXXGATGCCGCTG-3’ 
Arbitrary ACP10 5’-GTCTACCAGGCATTCGCTTCATXXXXXTGGTCGTGCC-3’ 
Arbitrary ACP11 5’-GTCTACCAGGCATTCGCTTCATXXXXXCTGCAGGACC-3’ 
Arbitrary ACP12 5’-GTCTACCAGGCATTCGCTTCATXXXXXACCGTGGACG-3’ 
Arbitrary ACP13 5’-GTCTACCAGGCATTCGCTTCATXXXXXGCTTCACCGC-3’ 
Arbitrary ACP14 5’-GTCTACCAGGCATTCGCTTCATXXXXXGCAAGTCGGC-3’ 
Arbitrary ACP15 5’-GTCTACCAGGCATTCGCTTCATXXXXXCCACCGTGTG-3’ 
Arbitrary ACP16 5’-GTCTACCAGGCATTCGCTTCATXXXXXGTCGACGGTG-3’ 
Arbitrary ACP17 5’-GTCTACCAGGCATTCGCTTCATXXXXXCAAGCCCACG-3’ 
Arbitrary ACP18 5’-GTCTACCAGGCATTCGCTTCATXXXXXCGGAGCATCC-3’ 
Arbitrary ACP19 5’-GTCTACCAGGCATTCGCTTCATXXXXXCTCTGCGAGC-3’ 
Arbitrary ACP20 5’-GTCTACCAGGCATTCGCTTCATXXXXXGACGTTGGCG-3’ 
dT-ACP1 5’-CTGTGAATGCTGCGACTACGATXXXXX(T)18-3’ 
dT-ACP2 5’-CTGTGAATGCTGCGACTACGATXXXXX(T)15-3’ 
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First, all four cDNA samples within each CRC and normal control group were pooled 
together in equal amount.  The 20 µl reagent mixture containing 50 ng of diluted first-
strand cDNA, 2 µl of 5 µM arbitrary ACP, 1 µl of 10 µM dT-ACP2 (Table 3.5), 10 µl 
of 2X SeeAmp ACP Master Mix and ddH2O was prepared.  Subsequently, the two-step 
PCR amplification was commenced in accordance to the manufacturer’s protocol and 
thermal cycling conditions (Table 3.6) of the GeneFishing DEG 101 & 102 Premix Kit 
(ACP1 – 20), on an Eppendorf Mastercycler Gradient Thermal Cycler.  The second-
strand cDNA was synthesised briefly during the first-stage PCR, and amplified in the 
second-stage PCR.  Finally, the amplified products were visualised on 3 % (w/v) 
ethidium bromide-stained agarose gels.  The differentially expressed bands between 
CRC and normal control samples were observed by comparing the intensity of bands 
through visual inspection. 
 
Table 3.6: Thermal cycling conditions for the two-steps ACP-based PCR amplification. 
PCR Temperature Duration No. of Cycle(s) 
 
First-stage 
94 
0
C 
50 
0
C 
72 
0
C 
5 min 
3 min 
1 min 
 
1 
 
Second-stage 
94 
0
C 
65 
0
C 
72 
0
C 
40 sec 
40 sec 
40 sec 
 
40 
Final Extension Step 72 
0
C 5 min 1 
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3.2.2.4(c) Gel Extraction 
The observed differentially expressed bands were extracted from the agarose gel by 
using commercially-available PureLink Quick Gel Extraction Kit.  This gel extraction 
kit enables the purification of DNA fragments, ranging from 40 bp to 10 kb in size, 
from both low- and high-melting point agarose gels.  First, the area of gel containing the 
desired DNA fragment was cut with a clean blade and weighed.  The Gel Solubilization 
Buffer was then added depending on the weight of gel slice, with 60 μl for every 10 mg 
of gel.  Subsequently, the gel piece in buffer was incubated at 50 
0
C for 15 min, and 
followed by another 5 min after the gel slice had dissolved.  The tube was mixed every 
5 min during the incubation period to ensure complete gel dissolution.  The dissolved 
gel piece was then loaded into a Quick Gel Extraction Column and centrifuged at 13, 
000 x g for 1 min.  Next, the flow-through was discarded and 500 μl of Gel 
Solubilization Buffer was added to the column.  The tube was then incubated at room 
temperature for 1 min and centrifuged at 13, 000 x g for 1 min.  The flow-through was 
discarded prior to the addition of 700 μl Wash Buffer W9.  The flow-through was 
discarded after incubation at room temperature for 5 min and centrifugation at 13, 000 x 
g for 1 min.  Before the elution step, the tube was centrifuged for another 1 min at 13, 
000 x g to remove any residual Wash Buffer W9.  Lastly, the purified DNA was eluted 
from the silica membrane by adding 30 μl of 68 0C TE Buffer, followed by incubating 
at room temperature for 1 min and centrifuging at 13, 000 x g for 2 min.  The purified 
DNA was stored at -20 
0
C for successive applications.           
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3.2.2.4(d) Molecular Cloning Strategy 
The cloning of desired differentially expressed bands was performed by using the 
commercially-available TOPO TA Cloning Kit for Sequencing.  This kit contains the 
OneShot TOP10 Chemically Competent E. coli and pCR4-TOPO plasmid vector.  The 
pCR4-TOPO enables direct selection of successful recombinants without the need of 
blue / white screening.  The ligation of targeted DNA fragment would disrupt the 
expression of lacZα-ccdB gene fusion, which then permits the growth of positive 
recombinant clones only upon transformation into TOP10 cells.  First, 4 μl of purified 
DNA fragment was added with 1 μl of salt solution (1.2 M NaCl and 0.06 M MgCl2) 
and 1 μl of pCR4-TOPO vector.  The mixture was then mixed and incubated for 5 min 
at room temperature.  Next, 2 μl of this TOPO cloning reaction mixture was added into 
a vial of OneShot TOP10 Chemically Competent E. coli and mixed gently.  The tube 
was incubated on ice for 30 min, heat-shocked at 42 
0
C for 30 sec without shaking and 
again, transferred to ice immediately.  Subsequently, 250 μl of room temperature S.O.C. 
medium was added to the tube and shaken horizontally at 200 rpm for 1 hour at 37 
0
C.  
A 50 μl of transformation mixture was then spread on pre-warmed selective LB plate 
containing 50 μg/ml Ampicillin, and incubated overnight at 37 0C.  Finally, 10 of the 
resulting colonies were picked and diluted individually in 10 μl of ddH2O.  Successful 
transformation was then confirmed by PCR screening using both M13F(-20) and 
M13R-pUC(-26) primers, on Eppendorf Mastercycler Gradient Thermal Cycler.  The 
PCR reaction components and thermal cycling conditions are stated in Tables 3.7 and 
3.8, respectively.  
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Table 3.7: Reaction components for PCR screening of positive transformants. 
Reaction Component Volume (μl) 
Diluted E.coli Cells 1.0 
10X Taq Buffer with KCl  2.0 
25 mM MgCl2  0.6 
50 μM M13F(-20) Primer 0.15 
50 μM M13R-pUC(-26) Primer 0.15 
10 mM dNTP mix    0.15 
5 U/μl Taq DNA Polymerase (recombinant) 0.15 
ddH2O 15.8 
Total Volume 20.0 
 
 
Table 3.8: Thermal cycling conditions for PCR screening of successfully transformed 
clones. 
PCR Step Temperature Duration No. of Cycle(s) 
Initial Denaturation 94 
0
C 5 min 1 
Denaturation 
Annealing 
Extension 
94 
0
C 
60 
0
C 
72 
0
C 
30 sec 
30 sec 
30 sec 
 
30 
Final Extension 72 
0
C 7 min 1 
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3.2.2.4(e) Plasmid Preparation 
The plasmid DNA was isolated from three successfully transformed clones with the use 
of the PureLink Quick Plasmid Miniprep Kit.  This silica-based spin column 
minipreparation enables the isolation of high quality plasmid DNA from E. coli cells.  
The isolated plasmid DNA is free of RNA, proteins and salt, and hence suitable for 
downstream applications such as automated fluorescent DNA sequencing, manual DNA 
sequencing, PCR, restriction mapping, cloning and labeling.  The selected transformed 
clone was initially cultured overnight in 1 ml LB at 37 
0
C.  This overnight culture was 
pelleted by centrifuging at 1, 500 x g for 15 min and the culture medium was then 
thoroughly discarded.  Next, the pellet was resuspended completely in 250 μl of 
Resuspension Buffer (R3) with RNase A.  The tube was then gently mixed by inverting 
it five times following the addition of 250 μl Lysis Buffer (L7).  The mixture was 
incubated at room temperature for 5 min and 350 μl Precipitation Buffer (N4) was then 
added.  Again, the tube was mixed gently by inverting it another five times and 
centrifuged at 12, 000 x g for 10 min at room temperature.  The resulting supernatant 
was loaded into a Quick Plasmid Mini spin column and centrifuged at 12, 000 x g for 1 
min.  The flow-through was discarded and 500 μl of Wash Buffer W10 with ethanol 
was added to the spin column.  The tube was incubated for 1 min at room temperature 
and centrifuged at 12, 000 x g for 1 min.  Prior to the addition of 700 μl Wash Buffer 
W9 with ethanol, the flow-through from previous step was discarded.  The spin column 
was then centrifuged twice at 12, 000 x g for 1 min in order to completely remove any 
residual Wash Buffer W9.  Finally, the purified plasmid DNA was eluted by adding 75 
μl of 68 0C TE Buffer and incubated at room temperature for 1 min.  The column was 
centrifuged at 12, 000 x g for 2 min and the purified plasmid DNA was stored at -20 
0
C 
for further applications.                  
 
Chapter Three – Methodology 
80 
 
3.2.2.4(f) Automated DNA Sequencing 
Purified plasmid DNA was sequenced in order to characterise the inserted gene of 
interest.  The automated DNA sequencing by capillary electrophoresis was employed 
under the Single Pass DNA Sequencing Service provided by 1st BASE Pte Ltd, 
Malaysia.  In this procedure, the high capacity fluorescence-based cycle sequencing 
platform, Applied Biosystems 3730xl Genetic Analyzer (Applied Biosystems, United 
States), in parallel with the BigDye Terminators v3.1 Cycle Sequencing Kit (Applied 
Biosystems, United States) were used.  The Applied Biosystems automated DNA 
sequencing, which utilises the labeling of fluorescent dyes, is an extension and 
improvement of the Sanger dideoxy sequencing method.  The whole sequencing process 
comprises of template preparation, cycle sequencing, purification, capillary 
electrophoresis and data analysis.  In an attempt to obtain sequencing results of superior 
quality, the optimised protocols supplied by Applied Biosystems were employed 
throughout the five-step workflow.  The standard thermal cycling conditions for cycle 
sequencing are showed in Table 3.9, while Table 3.10 lists the reaction components.  
Subsequently, the extension products were purified with the Agencourt CleanSEQ 
System (Agencourt Bioscience, United States) prior to capillary electrophoresis.  
Finally, the data was analysed using the Sequencing Analysis Software available from 
Applied Biosystems (Applied Biosystems, United States).                
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Table 3.9: Thermal cycling conditions for BigDye Terminators v3.1 Cycle Sequencing 
Kit. 
Stage Step Temperature Duration 
1 Denaturation 96 
0
C 1 min 
 
2 
 
Amplification 
(25 cycles) 
96 
0
C 10 sec 
50 
0
C 5 sec 
60 
0
C 4 min 
3 Hold 4 
0
C Indefinite 
 
 
Table 3.10: Reaction components for cycle sequencing. 
Reagent Quantity 
Ready Reaction Mix 8.0 μl 
Template 200 – 500 ng 
Primer 3.2 pmol 
ddH2O Variable 
Total Volume 20.0 μl 
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3.2.2.4(g) Pairwise Alignment and Sequence Similarity Matching 
Following sequencing, the results obtained were subjected to pairwise alignment by 
using the BioEdit software ver. 7.0.9.  The consensus sequences for all the DEGs were 
matched for sequence similarity via the web-interface programme, BLAST.  This 
programme allows the comparison of the query DNA sequences with the nucleotide 
database provided by the National Center for Biotechnology Information (NCBI), under 
National Institutes of Health (NIH), United States.  Finally, the sequence similarity 
scores were assessed and the DEGs were identified.      
3.2.2.5 Confirmatory Test 
The observed differential expression patterns from preceding ACP-based PCRs were 
further confirmed with two-step RT-qPCRs on a larger sample set.  The relative 
expression of all the identified DEGs was obtained for each individual paired samples.  
In this set-up, a second, different experimental approach was used to assess the 
significance of the differential expression patterns demonstrated previously.          
3.2.2.5(a) Reverse Transcription 
The isolated total RNA was reverse transcribed to first-strand cDNA before RT-qPCR.  
First, a 9.5 μl mixture containing 3 μg of total RNA, 2 μl of 0.5 μg/μl Oligo(dT)12-18 
Primer and RNase-free water was incubated at 80 
0
C for 3 min.  The tube was then 
chilled on ice for another 2 min.  Next, 4 μl of 5X First Strand Buffer, 5 μl of 2 mM 
dNTP mix, 0.5 μl of 40 U/μl RNaseOUT Recombinant RNase Inhibitor and 1 μl of 200 
U/μl M-MLV Reverse Transcriptase were added.  The mixture was then incubated at 42 
0
C for 90 min, and subsequently heated at 94 
0
C for 2 min.  Finally, the tube was chilled 
on ice for 2 min and the resulting first-strand cDNA was diluted in 70 μl of DNase-free 
water.  All the cDNA samples were stored at -20 
0
C until further applications.           
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3.2.2.5(b) RT-qPCR 
The difference in gene expression level between both CRC tumour and normal colonic 
mucosa samples was determined via a relative quantification method.  In the current 
study, the Comparative CT (∆∆CT) experimental design was employed along with the 
TaqMan chemistry.  The RT-qPCR was performed with the Applied Biosystems 7500 
Fast Real-Time PCR System.  The Applied Biosystems 7500 software ver. 2.0.5 was 
used to design, set up and monitor the RT-qPCR experiment, as well as determine the 
fluorescence location and intensity of each reading.  Finally, the data collected was 
further analysed by using the Integromics RealTime StatMiner software ver. 4.2.8, 
which is specifically designed and compatible with all the Real-Time PCR Systems 
from Applied Biosystems. 
3.2.2.5(b)(i) Synthesis of Primers and TaqMan Probes 
The sequences obtained previously were used to customise the primers and 6-FAM dye-
labelled TaqMan MGB (minor groove binder) probes (Applied Biosystems, United 
States) for each characterised DEGs.  The Primer Express software ver. 3.0 (Applied 
Biosystems, United States) was used to design the appropriate primers and probes 
sequences, as listed in Tables 3.11 and 3.12.  These Custom TaqMan Gene Expression 
Assays were specifically synthesised by Applied Biosystems in accordance to the Rapid 
Assay Development Guidelines, for optimum performance with TaqMan Gene 
Expression Master Mix.  On the other hand, the Applied Biosystems Pre-developed 
TaqMan Endogenous Control Assays were also available for both reference genes used 
in this study, i.e., the beta-actin (ACTB) (Assay ID: Hs99999903_m1) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Assay ID: Hs99999905_m1).   
Each of the assays was formulated with two unlabelled primers of 18 μΜ each and a 5 
μΜ 6-FAM dye-labelled TaqMan MGB probe in a single tube of 20X stock 
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concentration.  The synthesis of primers and probes in referral to the Rapid Assay 
Development Guidelines allowed the standardisation of assay conditions (default 
concentration of primers and probe) and thermal cycling parameters for all the gene 
expression assays from Applied Biosystems.        
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Table 3.11: Oligonucleotides primers sequences in Custom TaqMan Gene Expression 
Assays for all the identified DEGs. 
DEG Primer Sequence 
DEG1 Primer (F): 5’-GGGCGTGTGCACAGAAG-3’ 
Primer (R): 5’-AAGTCCTCCTGAGTGACATGGA-3’ 
DEG2 Primer (F): 5’-GATGCTTACCGAATCCGGAGATC-3’ 
Primer (R): 5’-GCATTGCTCTCTCACTGTTGTTAG-3’ 
DEG3 Primer (F): 5’-CAACCGTCATTGGGTACAAAGG-3’ 
Primer (R): 5’-TGTAAGGGTCCAGCTGATCAAGA-3’ 
DEG4 Primer (F): 5’-CGGCCAGGAAACTTGAACTTG-3’ 
Primer (R): 5’-CCGAGCTGCAGAACAAGGA-3’ 
DEG5 Primer (F): 5’-CTGGTCGAATGAGGCACCTAAAA-3’ 
Primer (R): 5’-TGGGTTTAGGTGTTGTTCCTTCAC-3’ 
DEG6 Primer (F): 5’-AGATTAGCGGGATGAAAACGTCTT-3’ 
Primer (R): 5’-CGCCCAGATGCCGAGAAAA-3’ 
DEG7 Primer (F): 5’-GGTAGTGATGTGCAAGAGTCCAT-3’ 
Primer (R): 5’-CCGCAGCGAGGAGTTTCT-3’ 
DEG8 Primer (F): 5’-GAAGGAGACCATCAAAGGATTCCA-3’ 
Primer (R): 5’-GAAGGCCTGTTCTGGGAGATG-3’ 
DEG9 Primer (F): 5’-GGCAGGGTGGTCCTGAGA-3’ 
Primer (R): 5’-CCGCCATTGGCCTTAACTG-3’ 
DEG11 Primer (F): 5’-CAGGTTTCAGTGAAGCCATCTG-3’ 
Primer (R): 5’-GGGTTGGCATCTACGTGTGA-3’ 
DEG12 Primer (F): 5’-CCAGGTCAAACTTGTGGATCCT-3’ 
Primer (R): 5’-GCTTCAGTAAATCTCCACTCGATCT-3’ 
DEG14 Primer (F): 5’-CCCGCTCCTTATCTGCAAGTT-3’ 
Primer (R): 5’-TCAAGATGGACGTGCACATTACTC-3’ 
DEG15 Primer (F): 5’-CGGCCTCCAAGCTCTCT-3’ 
Primer (R): 5’-TGAGAACACGGGCAATGGATTT-3’ 
DEG16 Primer (F): 5’-GGACTCTTCTGCTAATCGATGAACA-3’ 
Primer (R): 5’-GCCTCAACTTCGTCTGGAGAAAA-3’ 
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Table 3.12: TaqMan MGB probes sequences in Custom TaqMan Gene Expression 
Assays for all the identified DEGs. 
 
DEG Probe Sequence 
DEG1 5’-CTCGCAGGGCATACAT-3’ 
DEG2 5’-CCTCTTCCTCTTCCTCCTCC-3’ 
DEG3 5’-ATGGCAAGAAAATCAC-3’ 
DEG4 5’-CAGGGCCTCAATCACA-3’ 
DEG5 5’-CATGCCTGAATCTGC-3’ 
DEG6 5’-CCCCGTGATTGTTTTC-3’ 
DEG7 5’-CATTGCTGGAAAACTG-3’ 
DEG8 5’-ATTCACCTGCCAAAATC-3’ 
DEG9 5’-CCTCTCTCCGCCCCGGACA-3’ 
DEG11 5’-CACCCAAGGGTAACAAC-3’ 
DEG12 5’-ATGGACAGGAAACCCAC-3’ 
DEG14 5’-CATGCAGTGAACAAGC-3’ 
DEG15 5’-CCGGACGACTCGGATCT-3’ 
DEG16 5’-CAGATGGACCAATAAGTCA-3’ 
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3.2.2.5(b)(ii) Determination of Amplification Efficiency of TaqMan Gene 
Expression Assays 
The amplification efficiency for both target and reference gene expression assays must 
be approximately equal in order to assure accurate relative quantification with ∆∆CT 
method.  Hence, it is essential to determine the PCR amplification efficiency for all the 
target and reference gene expression assays prior to the experiment.  In this current 
study, the efficiency value was measured by using the CT slope method with 2-log 
dilution series in 5 concentration points.  First, a 5-point series of 2-fold dilutions of 
cDNA template was prepared as shown in Table 3.13. 
 
Table 3.13: Five-point 2-fold dilution series for the CT slope method. 
Dilution cDNA Concentration (ng/μl) Final Volume (μl) 
1 150.0 10 
2 75.0 10 
3 37.5 10 
4 18.75 10 
5 9.375 10 
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Subsequently, the CT value for each dilution was measured for all the target and 
reference gene expression assays by preparing the reaction mixture as shown in Table 
3.14.  The PCR was carried out according to the universal thermal cycling conditions 
from Applied Biosystems (Table 3.15).  
 
Table 3.14: Reaction components for PCR amplification. 
Reaction Component Volume per tube (μl) 
2X TaqMan Gene Expression Master Mix 10.0 
20X TaqMan Gene Expression Assay 1.0 
cDNA Template  1.0 
ddH2O 8.0 
Total Volume 20.0 
 
 
Table 3.15: Universal thermal cycling conditions from Applied Biosystems. 
PCR Step Temperature Duration No. of Cycle(s) 
Holding 50 
0
C 2 min 1 
Holding 95 
0
C 10 min 1 
Melting 
Annealing / Extension 
95 
0
C 
60 
0
C 
15 sec 
1 min 
40 
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There were a total of three replicates for each dilution sample, as well as three tubes of 
‘No Template Control’ (NTC) in each CT slope analysis.  Finally, a standard curve of 
CT value against the quantity of cDNA template in nanograms was plotted.  The slope 
of the standard curve indicates the amplification efficiency of the assay tested, and the 
value of -3.32 corresponds to 100 % efficiency, is the most ideal.  In addition, the 
square of correlation coefficient (R
2
) value reflects the statistical significance of the 
linear relationship between two variables.  The R
2
 value ranges from 0 to 1, and a value 
closer to 1 is more desirable.  As for the amplification efficiency, a value of 100 % (+ 
10 %) is preferred for all the target and reference assays in order to obtain reliable 
relative quantification results (Life Technologies Corporation, 2012; Liu and Saint, 
2002).               
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3.2.2.5(b)(iii) ΔΔCT Experiment 
There were a total of 27 paired colonic tissue samples obtained for this experiment.  
Each of the CRC tumour and normal colonic mucosa specimens was subjected to PCR 
amplification for all the target and reference genes in separate reaction plates (Table 
3.16).  The PCR amplification was performed in triplicates for each gene expression 
assay and NTCs were also included.  Table 3.17 shows the singleplex reaction mixture 
for PCR amplification whilst the universal thermal cycling parameters are as previously 
described in Table 3.15.  Both ACTB and GAPDH genes were used as reference genes 
for normalisation in determining the ‘true’ expression level of target genes.   
  CT (Target gene) – CT (Reference gene) = ∆CT  
In current ∆∆CT method, the normal colonic tissue sample served as a calibrator.  The 
relative expression level of target genes in CRC tumour compared to normal colonic 
mucosa was determined by using the following formula (Livak and Schmittgen, 2001): 
  ∆CT (Sample) – ∆CT (Calibrator) = ∆∆CT 
 
As shown in formula, the positive value of ΔΔCT indicates the over-expression of target 
gene in CRC tumour, and vice-versa.  On the other hand, the TCΔΔ-2  value refers to the 
relative fold change in gene expression level between the CRC tumour and normal 
colonic samples.   
TCΔΔ-2= (RQ) Expressionin  Change Fold Relative
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Table 3.16: Plate layout for PCR amplification of all the target and reference genes for each individual sample. 
ACTB 
NTC 
ACTB 
NTC 
ACTB 
NTC 
GAPDH 
NTC 
GAPDH 
NTC 
GAPDH 
NTC 
ACTB 
sample 
ACTB 
sample 
ACTB 
sample 
GAPDH 
sample 
GAPDH 
sample 
GAPDH 
sample 
ARPC2 
NTC 
ARPC2 
NTC 
ARPC2 
NTC 
ATP5B 
NTC 
ATP5B 
NTC 
ATP5B 
NTC 
ARPC2 
sample 
ARPC2 
sample 
ARPC2 
sample 
ATP5B 
sample 
ATP5B 
sample 
ATP5B 
sample 
C6orf173 
NTC 
C6orf173 
NTC 
C6orf173 
NTC 
C11orf10 
NTC 
C11orf10 
NTC 
C11orf10 
NTC 
C6orf173 
sample 
C6orf173 
sample 
C6orf173 
sample 
C11orf10 
sample 
C11orf10 
sample 
C11orf10 
sample 
FAM96B 
NTC 
FAM96B 
NTC 
FAM96B 
NTC 
MRPL24 
NTC 
MRPL24 
NTC 
MRPL24 
NTC 
FAM96B 
sample 
FAM96B 
sample 
FAM96B 
sample 
MRPL24 
sample 
MRPL24 
sample 
MRPL24 
sample 
PSMC5 
NTC 
PSMC5 
NTC 
PSMC5 
NTC 
RPL10 
NTC 
RPL10 
NTC 
RPL10 
NTC 
PSMC5 
sample 
PSMC5 
sample 
PSMC5 
sample 
RPL10 
sample 
RPL10 
sample 
RPL10 
sample 
RPS23 
NTC 
RPS23 
NTC 
RPS23 
NTC 
RPL35 
NTC 
RPL35 
NTC 
RPL35 
NTC 
RPS23 
sample 
RPS23 
sample 
RPS23 
sample 
RPL35 
sample 
RPL35 
sample 
RPL35 
sample 
RPL37 
NTC 
RPL37 
NTC 
RPL37 
NTC 
SLC25A1 
NTC 
SLC25A1 
NTC 
SLC25A1 
NTC 
RPL37 
sample 
RPL37 
sample 
RPL37 
sample 
SLC25A1 
sample 
SLC25A1 
sample 
SLC25A1 
sample 
TIMP1 
NTC 
TIMP1 
NTC 
TIMP1 
NTC 
UQCRH 
NTC 
UQCRH 
NTC 
UQCRH 
NTC 
TIMP1 
sample 
TIMP1 
sample 
TIMP1 
sample 
UQCRH 
sample 
UQCRH 
sample 
UQCRH 
sample 
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Table 3.17: Singleplex reaction mixture for PCR amplification. 
Reaction Component Volume per well (μl) 
2X TaqMan Gene Expression Master Mix 5.0 
20X TaqMan Gene Expression Assay 0.5 
50 ng cDNA Template 1.0 
ddH2O 3.5 
Total Volume 10.0 
 
3.2.2.5(b)(iv) Data Interpretation and Statistical Analysis 
Initially, the raw CT data from all paired samples, both CRC tumours and normal 
colonic mucosa, were imported to the RealTime StatMiner software.  The selected 
reference genes, i.e., ACTB and GAPDH were validated by evaluating the stability of 
their expression across current sample cohorts in the given experimental design.  The 
NormFinder Algorithm method, which takes into consideration of both inter- and intra-
group variations in gene expression, was used.  These sources of variation are used to 
compute the stability score, where a lower value indicates a more stable gene expression 
within the experimental setting. 
Prior to the analysis, the samples were further stratified according to the cancer stages 
(early and advanced) and tumour sites (right and left) in order to give a better 
illustration on the differential ability of these DEGs.  The within-group correlation was 
determined by measuring the median absolute deviation (MAD) for all the samples 
within the same experimental group.  Biological samples which do not correlate well 
with other samples in the same group, were detected as group outliers and excluded 
from the Paired t-test analysis.  Table 3.18 shows the number of samples before and 
after the exclusion of group outliers in each experimental group. 
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Table 3.18: Stratification of samples for the analysis of RT-qPCR data. 
Stratification Criteria Number of Samples 
Initially Recruited After Exclusion 
Cancer Stage 
Early Stage (Stages I and II) 13 10 
Advanced Stage (Stages III and IV) 14 10 
Tumour Location 
 Right-sided 10 6 
 Left-sided 17 13 
 
In order to assess the statistical significance of the observed differential expression 
patterns across the current sample cohort, a Two-tailed Paired t-test was performed with 
the RealTime StatMiner software.  A p value of less than 0.05 indicates that the 
observed differential gene expression is statistically significant, which corresponds to a 
less than 5 % probability that the observation obtained is merely by chance.  The log10 
RQ bar charts were then plotted to illustrate both statistically significant and non-
significant DEGs between both CRC tumour (sample) and normal colonic mucosa 
(calibrator) groups.         
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3.3 Part C: Differential Proteome Analysis via A Bottom-Up Proteomics 
Approach 
3.3.1 Materials 
3.3.1.1 Commercialised Chemicals, Reagents and Kits 
Chemical / Reagent / Kit Manufacturer 
Section 3.3.2.2 – Tissue Specimen Collection 
 Allprotect Tissue Reagent 
 
QIAGEN (Germany) 
Section 3.3.2.3 – Total Protein Isolation 
 Total Protein Isolation Kit for  
       Two-Dimensional Difference Gel Electrophoresis 
 100X Halt Protease Inhibitor Cocktail 
 0.5 M EDTA (100X) 
 Ettan 2-D Quant Kit 
 
ITSI-Biosciences (United States) 
 
Thermo Scientific (United States) 
Thermo Scientific (United States) 
GE Healthcare (United Kingdom) 
Section 3.3.2.4 – Total Protein Separation via 2-D 
                             DIGE 
 CyDye DIGE Fluor Minimal Dye Labeling Kit 
 Ettan 2-D Clean-Up Kit 
 Urea 
 Thiourea 
 PlusOne 3-[(3-cholamidopropyl)dimethylammonio] 
-1-propanesulfonate (CHAPS) 
 Sodium hydroxide (NaOH) 
 N, N-Dimethylformamide (DMF) Anhydrous 
 L-Lysine monohydrochloride 
 Dithiothreitol (DTT) 
 IPG Buffer (pH 4 – 7)  
 Bromophenol Blue 
 PlusOne DryStrip Cover Fluid 
 30 % Acrylamide/Bis Solution 37.5:1 (2.6 % C) 
 
 
GE Healthcare (United Kingdom) 
GE Healthcare (United Kingdom) 
Nacalai Tesque (Japan) 
GE Healthcare (United Kingdom) 
GE Healthcare (United Kingdom) 
 
AMRESCO (United States) 
Sigma-Aldrich (United States) 
Sigma-Aldrich (United States) 
Fermentas (Canada) 
GE Healthcare (United Kingdom) 
Bio-Rad Laboratories (United States) 
GE Healthcare (United Kingdom) 
Bio-Rad Laboratories (United States) 
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Chemical / Reagent / Kit Manufacturer 
 Tris Base 
 
 SDS 
 Ammonium persulfate 
 Tetramethylethylenediamine (TEMED) 
 PlusOne 87 % (w/w) Glycerol 
 Iodoacetamide 
 PlusOne Glycine 
 Agarose 
 Absolute methanol 
 Glacial Acetic acid 
 Sodium thiosulfate 
 Silver nitrate 
 Formalin (37 % Formaldehyde in water) 
 Sodium carbonate 
PhytoTechnology Laboratories  
(United States) 
Bio-Rad Laboratories (United States) 
Bio-Rad Laboratories (United States) 
Sigma-Aldrich (United States) 
GE Healthcare (United Kingdom) 
GE Healthcare (United Kingdom) 
GE Healthcare (United Kingdom) 
Promega (United States) 
Merck (Germany) 
Merck (Germany) 
AMRESCO (United States) 
Sigma-Aldrich (United States) 
AMRESCO (United States) 
Merck (Germany) 
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3.3.1.2 Consumables and Equipments 
Consumable / Equipment Manufacturer 
1.5 ml pellet pestle with cordless motor Kimble Chase (United States) 
Implen NanoPhotometer Implen (Germany) 
Neutralit pH-indicator strip (non-bleeding; pH 5.0 – 10.0) Merck (Germany) 
Ettan IPGphor 3 Isoelectric Focusing (IEF) Unit 
- Ettan IPGphor 3 Control software ver. 1.2 
GE Healthcare (United Kingdom) 
Immobiline DryStrip Reswelling Tray GE Healthcare (United Kingdom) 
13 cm Immobiline DryStrip Gel of pH 4 – 7  GE Healthcare (United Kingdom) 
Ettan IPGphor Strip Holder GE Healthcare (United Kingdom) 
SE 600 Ruby Standard Dual Cooled Gel Electrophoresis 
Unit 
GE Healthcare (United Kingdom) 
MS Waver Shaker Major Science (United States) 
Electrophoresis Power Supply EPS 601 GE Healthcare (United Kingdom) 
Typhoon FLA 9000 Variable Mode Laser Scanner 
- Typhoon FLA 9000 Control software ver. 1.2 
GE Healthcare (United Kingdom) 
 
3.3.1.3 Software and Service 
Software /  
Service 
Manufacturer /  
Service Provider 
DeCyder 2D software ver. 7.0 GE Healthcare (United Kingdom) 
Liquid Chromatography-Tandem Mass Spectrometry  
(LC-MS/MS) Service 
Proteomics International Pty Ltd 
(Australia) 
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3.3.1.4 Miscellaneous Materials 
Other solutions were prepared accordingly, as follows: 
i) Thiourea Rehydration Solution 
The Thiourea Rehydration Solution was prepared by adding 5.25 g Urea, 1.9 g Thiourea, 
0.25 g CHAPS and ddH2O, to a total volume of 12.5 ml.  Next, 1 ml aliquots of this 
solution were stored at -20 
0
C until further use.  
ii) 50 mM NaOH 
The 50 mM NaOH solution was prepared by dissolving 20 mg NaOH in 10 ml ddH2O. 
iii) 10 mM L-Lysine monohydrochloride 
The solution was prepared by dissolving 19 mg of L-Lysine monohydrochloride in 10 
ml of ddH2O.  
iv) 1 % (w/v) Bromophenol Blue stock solution 
The 1 % (w/v) Bromophenol Blue stock solution was prepared by dissolving 0.1 g of 
Bromophenol Blue powder in 10 ml of ddH2O. 
v) 4X Resolving Gel Buffer 
First, 181.7 g of Tris Base was dissolved in 750 ml of ddH2O.  The pH was then 
adjusted to 8.8, and the solution was further topped up to 1 L with ddH2O.  The 
prepared solution was filtered via a 0.45 μm syringe filter and stored at 4 0C.  
vi) 10 % (w/v) SDS 
Five grams of SDS was dissolved in 50 ml ddH2O and followed by filtration with a 0.45 
μm syringe filter.  The prepared 10 % (w/v) SDS solution was stored at room 
temperature. 
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vii) 10 % (w/v) Ammonium persulfate 
The 10 % (w/v) Ammonium persulfate was freshly prepared before use, by dissolving 
15 mg Ammonium persulfate in 150 μl of ddH2O.   
viii) SDS Equilibration Buffer 
The SDS Equilibration Buffer was prepared by adding 144.2 g of Urea, 20 ml of 
solution (v), 138 ml of 87 % (w/w) Glycerol, 8 g of SDS, and topping up to a final 
volume of 400 ml with ddH2O.  
ix) 10 mg/ml DTT-containing SDS Equilibration Buffer 
This solution was prepared by adding 0.1 g of DTT into 10 ml of solution (viii). 
x) 25 mg/ml Iodoacetamide-containing SDS Equilibration Buffer 
This solution was prepared by adding 0.25 g of Iodoacetamide into 10 ml solution (viii). 
xi) 1X Laemmli SDS Electrophoresis Buffer 
The 1X Laemmli SDS Electrophoresis Buffer was prepared by dissolving 30.3 g of Tris 
Base, 144 g of Glycine and 10 g of SDS in 10 L ddH2O.  The prepared solution was 
then stored at 4 
0
C. 
xii) 0.5 % (w/v) agarose sealing solution 
A 0.5 g of agarose powder was dissolved in 100 ml ddH2O via heating to form the 0.5 % 
(w/v) agarose sealing solution.   
xiii) Fixing solution containing 50 % (v/v) methanol and 5 % (v/v) Acetic acid 
The 250 ml fixing solution was prepared by adding 125 ml of absolute methanol and 
12.5 ml of Glacial Acetic acid, to 112.5 ml ddH2O. 
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xiv) Sensitizing solution containing 0.02 % (w/v) Sodium thiosulfate 
This sensitizing solution was prepared by dissolving 0.05 g of Sodium thiosulfate in 250 
ml of ddH2O.  
xv) Staining solution containing 0.1 % (w/v) Silver nitrate 
A 0.25 g of Silver nitrate was dissolved in 250 ml ddH2O to form a 0.1 % (w/v) Silver 
nitrate staining solution. 
xvi) Developing solution containing 0.04 % (v/v) Formalin (37 % Formaldehyde in 
water) and 2 % (w/v) Sodium carbonate 
The developing solution was prepared by adding 100 μl of Formalin (37 % 
Formaldehyde in water ) and 5 g of Sodium carbonate into 250 ml ddH2O. 
xvii) 5 % (v/v) Acetic acid 
The 5 % (v/v) Acetic acid solution was prepared by adding 12.5 ml of Glacial Acetic 
acid into 250 ml ddH2O. 
xviii) 1 % (v/v) Acetic acid 
A 2.5 ml of Glacial Acetic acid was added to 250 ml ddH2O to form a 1 % (v/v) Acetic 
acid solution. 
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3.3.2 Methods 
3.3.2.1 Patient Characteristics 
In this study, the volunteered CRC patients were aged between 40 – 86 years old and 
grouped accordingly based on their cancer stage at the time of diagnosis, i.e., either 
Stages II, III or IV.  Both the diagnosis and staging of these patients were accurately 
performed by experienced surgeons and oncologists by taking into account 
histopathological reports, CT scanning images, morphological evaluations during 
surgery, as well as serum CEA levels.  All recruited patients were newly-diagnosed with 
the absence of previous history of cancer or family history of CRC.  They presented 
with sporadic CRC and the possibility for any hereditary CRC syndrome was ruled out 
by gastroenterologists.  In addition, those who have received chemo- or radiotherapies 
prior to surgical resection were also excluded from this study.      
3.3.2.2 Tissue Specimen Collection 
The collection of tissue specimens was performed in UMMC with the necessary ethical 
approval (Ref. No.: 654.1).  A total of 20 paired tissue samples were collected from 
volunteered CRC patients – 10 presented with Stage II CRC, and 5 with Stages III and 
IV each.  Both CRC and normal tissue specimens were obtained during surgical 
resection with written informed consent.  The CRC specimens were obtained from 
resected CRC tumours, whilst the paired normal tissue samples were excised from 
distally located, macroscopically normal colonic mucosa.  All tissue specimens were 
submerged in Allprotect Tissue Reagent immediately after excision and incubated 
overnight at 4 
0
C prior to storage at -80 
0
C for further applications.  This reagent allows 
the immediate processing of harvested human tissue samples for protein preservation in 
long-term archival storage without degradation.  Hence, the cellular proteins will remain 
intact without the need of traditional labour- and equipment-intensive methods.       
Chapter Three – Methodology 
101 
 
3.3.2.3 Total Protein Isolation 
3.3.2.3(a) Protein Extraction 
The commercially-available Total Protein Isolation Kit for Two-Dimensional 
Difference Gel Electrophoresis (ToPI-DIGE Kit) was used to isolate total proteins from 
the tissue specimens.  Both the buffer systems and operating procedures of this kit were 
optimised and validated to improve the chances for successful downstream 2-D DIGE 
application.  First, approximately 50 – 100 mg of fresh tissue was weighed and rinsed 
briefly with 5 – 10 ml of Buffer 1.  The tissue was then immediately transferred into 
iTube-A and a 3X volume of Buffer 2 was added.  Subsequently, the tissue was rapidly 
homogenised by using disposable 1.5 ml pellet pestle with cordless motor.  The sample 
tube has to be immersed in ice throughout the homogenisation process.  The 
homogenised tissue was incubated on ice for 30 min and vortexed for at least 3 times 
during the incubation.  Next, the tube was centrifuged under 4 
0
C at 15, 000 x g for 10 
min and the supernatant was transferred into iTube-B.  Finally, an appropriate volume 
of 100X Halt Protease Inhibitor Cocktail and 0.5 M EDTA (100X) were added 
accordingly to produce a 1X final concentration each.  This ready-to-use cocktail 
inhibits the activity of aspartic acid, cysteine and serine proteases, and thus minimises 
protein degradation.  Furthermore, the inclusion of EDTA also enables the inhibition of 
metalloproteases.  The isolated total proteins was then stored at -80 
0
C for downstream 
applications.               
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3.3.2.3(b) Protein Quantification 
The concentration of isolated total proteins was determined with the commercialised 
Ettan 2-D Quant Kit prior to 2-D DIGE analysis.  This kit was exclusively designed to 
quantitatively precipitate proteins while leaving out interfering substances in the 
solution and thus, allows accurate determination of protein concentration.  It differs 
from other common spectrophotometric methods in a way that the precipitated proteins 
will specifically bind to copper ions in the copper-containing solution, while the 
unbound copper is then measured with the use of a colorimetric agent.  The initial step 
involved the construction of a standard curve by using 2 mg/ml of Bovine Serum 
Albumin (BSA) as a standard solution.  A total of six standards were prepared 
accordingly, as shown in Table 3.19.  As for the protein samples to be assayed, 5 ul was 
needed for quantity measurement with this kit.  
 
Table 3.19: Preparation of BSA standards for the construction of standard curve. 
Tube No. 1 2 3 4 5 6 
2 mg/ml BSA standard solution (μl) 0 5 10 15 20 25 
Protein quantity (μg) 0 10 20 30 40 50 
 
 
First, 500 μl of Precipitant was added to all the standard and sample tubes.  The mixture 
was vortexed briefly and incubated at room temperature for 3 min.  Another 500 μl of 
Co-precipitant was then added to the mixture and vortexed briefly prior to 
centrifugation at > 10, 000 x g for 5 min.  At this step, the protein was sedimented out 
and the supernatant decanted.  The tube was centrifuged again with a brief pulse and the 
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remaining supernatant (if any) was discarded.  Subsequently, 100 μl of copper solution 
and 400 μl of ddH2O were added.  The mixture was vortexed briefly to dissolve the 
precipitated proteins.  Next, 1 ml of working colour reagent was added by introducing it 
as rapidly as possible and the tube was inverted several times for instantaneous mixing.  
Following incubation at room temperature for 20 min, the absorbance of each standard 
and sample was read at 480 nm with water as a reference.  A standard curve was 
constructed by plotting the absorbance value of the standards against the protein 
quantities, and finally the protein concentration of the samples was determined.  Both 
absorbance measurements and standard curve construction were performed on the 
Implen NanoPhotometer.                 
3.3.2.4 Total Protein Separation via 2-D DIGE 
The application of the 2-D DIGE utilises the Ettan DIGE System (GE Healthcare, 
United Kingdom), which comprises the CyDye
 
DIGE Fluor Minimal Dye Labeling Kit 
(i.e., Cy2, Cy3 and Cy5), the Typhoon
 
FLA 9000 Variable Mode Laser Scanner and the 
DeCyder 2D software ver. 7.0.  The specific experimental design and advanced 
statistical analysis within this system effectively minimise both system-related results 
and inherent biological variations, compared to classical 2-D GE.  Moreover, this Ettan 
DIGE System also allows the detection and quantification of differences in protein 
abundance between two different samples, as small as 10 %, with a statistical 
confidence of greater than 95 % (GE Healthcare Bio-Sciences AB, 2005).     
3.3.2.4(a) Sample Randomisation and Experimental Set Up 
In an attempt to eliminate possible bias from experimental conditions, sample handling 
and CyDyes labeling, all total protein samples for both CRC tumour and normal colonic 
mucosa groups were evenly distributed among different CyDye DIGE Fluor Minimal 
Dyes (i.e., Cy3 and Cy5) for labeling, as shown in Table 3.20. 
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Table 3.20: Randomisation of protein samples for CyDyes labeling. 
Cy3 Cy5 
Stage II CRC Group 
E1 (N) E6 (N) 
E2 (N) E7 (N) 
E3 (N) E8 (N) 
E4 (N) E9 (N) 
E5 (N) E10 (N) 
E6 (C)  E1 (C) 
E7 (C) E2 (C) 
E8 (C) E3 (C) 
E9 (C) E4 (C) 
E10 (C) E5 (C) 
Stage III CRC Group 
L1 (N) L4 (N) 
L2 (N) L5 (N) 
L3 (N) L1 (C) 
L4 (C)  L2 (C) 
L5 (C) L3 (C) 
Stage IV CRC Group 
L6 (N) L9 (N) 
L7 (N) L10 (N) 
L8 (N) L6 (C) 
L9 (C)  L7 (C) 
L10 (C) L8 (C) 
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In addition, each individual paired CRC tumour and normal colonic mucosa samples of 
the same patient were loaded in different gels in order to avoid potential systematic 
errors, as illustrated in Table 3.21.  An internal standard was also included in every gel 
to minimise gel-to-gel variation and thus, permit an accurate quantification of protein 
expression changes between both CRC tumour and normal colonic mucosa samples.  As 
a result, no gel replicate is required as the system-related result variations were kept to a 
minimum (GE Healthcare Bio-Sciences AB, 2005).   
A total of 100 μg each for all protein samples (both CRC tumour and normal colonic 
mucosa samples) in Stages II, III and IV CRC groups were pooled together to yield 
2000 μg, 1000 μg and 1000 μg internal standards, respectively.  Subsequently, 100 μg 
of each internal standard, Cy3-labelled and Cy5-labelled samples were loaded into each 
gel, according to the randomised design, as shown in Table 3.21.  The multiplexing of 
the two differently CyDye-labelled samples and an internal standard in one gel halved 
the total number of gels required, i.e., 10, 5 and 5 gels for Stages II, III and IV CRC 
groups respectively, when compared to conventional 2-D GE (Table 3.21).        
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Table 3.21: Randomisation of protein samples for gel loading. 
Gel Cy2 Cy3 Cy5 
Stage II CRC Group 
1  
 
 
 
 
100 μg internal standard 
100 μg E1 (N) 100 μg E3 (C) 
2 100 μg E2 (N) 100 μg E5 (C) 
3 100 μg E3 (N) 100 μg E1 (C) 
4 100 μg E4 (N) 100 μg E2 (C) 
5 100 μg E5 (N) 100 μg E4 (C) 
6 100 μg E6 (C) 100 μg E7 (N) 
7 100 μg E7 (C) 100 μg E10 (N)  
8 100 μg E8 (C) 100 μg E6 (N) 
9 100 μg E9 (C) 100 μg E8 (N) 
10 100 μg E10 (C) 100 μg E9 (N) 
Stage III CRC Group 
1  
 
100 μg internal standard 
100 μg L1 (N) 100 μg L2 (C) 
2 100 μg L2 (N) 100 μg L3 (C) 
3 100 μg L3 (N) 100 μg L1 (C) 
4 100 μg L4 (C) 100 μg L5 (N) 
5 100 μg L5 (C) 100 μg L4 (N) 
Stage IV CRC Group 
1  
 
100 μg internal standard 
100 μg L6 (N)  100 μg L7 (C)  
2 100 μg L7 (N) 100 μg L8 (C)  
3 100 μg L8 (N) 100 μg L6 (C) 
4 100 μg L9 (C) 100 μg L10 (N) 
5 100 μg L10 (C) 100 μg L9 (N) 
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3.3.2.4(b) Sample Preparation 
The quality of 2-D GE results is usually affected by the presence of non-protein 
impurities in the samples.  Excessive salts and buffers in protein samples can lead to 
high conductivity and thus, affect the first-dimension isoelectric focusing (IEF) results.  
In addition, the presence of other interfering substances such as charged detergents, 
lipids, phenolics and nucleic acids can also lead to poor 2-D GE results.  Hence, it is 
essential to prepare and process the total protein samples adequately prior to 2-D DIGE 
applications in order to ensure optimum results (GE Healthcare Bio-Sciences AB, 2005).  
On the other hand, the labeling of protein samples is sensitive to pH, where a lower pH 
than optimal will render an ineffective labeling.  Therefore, the adjustment of protein 
samples to the optimum pH, i.e., 8.5, is very important for the following successful 
CyDyes minimal labeling within the 2-D DIGE workflow (GE Healthcare Bio-Sciences 
AB, 2005).      
3.3.2.4(b)(i) Clean-Up of Protein Samples 
All total protein samples were cleaned-up with commercially-available Ettan 2-D 
Clean-Up Kits.  These kits are specifically designed to improve the quality of 2-D GE 
results by reducing streaking, background staining and other interfering contaminants in 
the protein samples.  They selectively precipitate proteins and leave interfering 
substances, i.e., detergents, salts, lipids, phenolics, nucleic acids and chaotropes, in 
solution. 
First, 300 μl of Precipitant was added to 100 μg of total protein, followed by vortexing 
and incubation on ice for 15 min.  Next, 300 μl of Co-precipitant was added to the 
mixture and vortexed briefly.  The tube was then centrifuged at 17, 000 x g for 5 min.  
The supernatant was decanted until no visible liquid remained in the tube.  
Subsequently, another 40 μl of Co-precipitant was layered on top of the pellet and 
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incubated on ice for 5 min.  The wash was discarded following centrifugation at 17, 000 
x g for 5 min.  Twenty-five microlitres of ddH2O was layered on top of the pellet and 
vortexed for 5 – 10 sec before 1 ml of pre-chilled Wash Buffer and 5 μl of Wash 
Additive were added to the tube.  The pellet was then fully dispersed and incubated 
overnight at -20 
0
C.  The next day, the tube was vortexed and centrifuged at 17, 000 x g 
for 5 min.  The supernatant was then discarded and the pellet was air-dried briefly.  The 
resulting protein pellet was then resuspended in an appropriate volume of Thiourea 
Rehydration Solution, vortexed for at least 30 sec and incubated at room temperature 
until full dissolution.  The cleaned protein sample was quantified again according to the 
protocol as in Section 3.3.2.3(b), and was stored at -80 
0
C until further analysis.            
3.3.2.4(b)(ii) pH Adjustment of Protein Samples 
Each protein sample (1 – 3 μl) was spotted on Neutralit pH-indicator strips (non-
bleeding; pH 5.0 – 10.0) for pH screening.  The desired optimal pH 8.5 was targeted for 
effective and specific CyDyes labeling.  Small volume aliquots of 50 mM NaOH were 
gradually added to the protein samples if needed.      
3.3.2.4(c) CyDye DIGE Fluor Minimal Dye Labeling 
The CyDye DIGE Fluor Minimal Dyes consist of three spectrally resolvable dyes, i.e., 
Cy2, Cy3 and Cy5, which are matched in mass and charge.  Each of these dyes adds 
450 Da to the protein mass when it couples to the protein by forming an amide linkage 
with the lysine residue.  Therefore, it allows the multiplexing of up to three samples in a 
gel without affecting the pattern visible on the second-dimension SDS-denaturing 
polyacrylamide gel.  Moreover, the specific dye:protein ratio used in minimal labeling 
also ensures that the dye only labels an approximate of 1 – 2 % of lysine residues, and 
thus each labelled protein carries only one dye label and is visualised as a single protein 
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spot on the SDS-denaturing polyacrylamide gel (GE Healthcare Bio-Sciences AB, 
2005).       
3.3.2.4(c)(i) Preparation of CyDye DIGE Fluor Dyes 
Initially, 5 μl of DMF was added to each tube of 5 nmol CyDye (Cy2, Cy3 and Cy5).  
The tubes were vortexed vigorously for 30 sec to dissolve the dyes.  This was followed 
by centrifugation at 12, 000 x g for 30 sec.  Next, 1 mM of each CyDye DIGE Fluor 
Minimal Dye stock solution was obtained, i.e., the Cy2, Cy3 and Cy5; giving an intense 
colour of yellow, red and blue, respectively.  The reconstituted dye stock solutions were 
stored at -20 
0
C and stable for up to 2 months in the dark.   
Prior to labeling, a 400 pmol/μl working dye solution for each CyDye was prepared.  
The dye stock solution was spun briefly before the addition of 1.5 volumes of DMF to 1 
volume of dye stock solution.  The resulting working dye solutions were stored at -20 
0
C in the dark and were only stable for up to 1 week.      
3.3.2.4(c)(ii) Minimal Labeling of Protein Samples 
A volume of protein sample equivalent to 100 μg was added with 1 μl of 400 pmol/μl 
working CyDye solution.  The internal standard was labelled with Cy2 while the CRC 
and normal protein samples were labelled with either Cy3 or Cy5, according to the 
experimental design in Table 3.20.  The tube was then mixed and centrifuged briefly 
prior to incubation on ice for 30 min in the dark.  Next, 1 μl of 10 mM L-Lysine 
monohydrochloride was added to stop the labeling reaction.  The tube was mixed, spun 
briefly and incubated on ice for 10 min in the dark.  Finally, the labelled internal 
standard and protein samples were processed immediately in first-dimension IEF.  
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3.3.2.4(d) First-Dimension IEF 
The first-dimension IEF of protein samples was performed with Immobiline DryStrip 
Gels (GE Healthcare, United Kingdom) on the Ettan IPGphor 3 IEF Unit.  The 
Immobiline DryStrip Gels are pre-cast polyacrylamide gels with pre-formed pH 
gradient on a plastic backing.  The stable and accurate immobilised pH gradient allows 
highly reproducible and reliable first-dimension IEF results for gel-to-gel comparison 
(GE Healthcare Bio-Sciences AB, 2005).  The Ettan IPGphor 3 IEF Unit is equipped 
with Ettan IPGphor 3 Control software ver. 1.2 for the monitoring and documentation of 
IEF process.      
3.3.2.4(d)(i) Rehydration of Immobiline DryStrip Gels and Samples Application 
via Rehydration Loading Protocol 
First, the Immobiline DryStrip Reswelling Tray was leveled until the bubble in the spirit 
level is centered by turning the leveling feet.  Twenty milligrams of DTT, 5 μl of IPG 
Buffer (pH 4 – 7) and 2 ul of 1 % (w/v) Bromophenol Blue stock solution were added to 
the 1 ml aliquot of Thiourea Rehydration Solution.  Subsequently, a 250 μl-mixture 
consisting of CyDye-labelled protein samples (i.e., internal standard, CRC and normal 
protein samples) and Thiourea Rehydration Solution was pipetted into the tray channel.  
The 13 cm Immobiline DryStrip Gel of pH 4 – 7 was then positioned into the tray 
channel with gel side down.  Finally, the strip was overlaid with PlusOne DryStrip 
Cover Fluid and left overnight at room temperature in the dark for rehydration and 
sample uptake.        
3.3.2.4(d)(ii) IEF of Protein Samples 
Following overnight rehydration and sample uptake, the Immobiline DryStrip Gel was 
transferred to the Ettan IPGphor Strip Holder.  The strip was positioned with gel side up 
and the acidic end (“+” end) was oriented towards the anodic end of the Ettan IPGphor 
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3 IEF Unit.  Next, two paper electrode wicks were damped with ddH2O and placed onto 
both acidic and basic ends of the strip.  The electrodes were clipped firmly onto the 
paper electrode wicks, where the metal of electrodes was in contact with the thermally 
conductive aluminium oxide ceramic of the strip holder.  Subsequently, the strip was 
overlaid with 108 ml of PlusOne DryStrip Cover Fluid until it was fully covered.  
Finally, the IEF process was started and monitored by Ettan IPGphor 3 Control software 
with the running conditions shown in Table 3.22.  The running conditions were set at 20 
0C, 50 μA per strip, while the time required for each step was modified accordingly for 
a more convenient overnight IEF run. 
Table 3.22: Running conditions for 13 cm Immobiline DryStrip Gels on the Ettan 
IPGphor 3 IEF Unit. 
Step Step Voltage 
Mode 
Voltage  
(V) 
Time  
(hr:min:sec) 
Volt-hours 
(kVh) 
1 Step and Hold 100 5:00:00 0.5 
2 Step and Hold 500 2:00:00 1.0 
3 Gradient 4000 1:42:00 6.8 
4 Gradient 8000 1:30:00 12.0 
5 Step and Hold 8000 5:37:30 – 6:15:00 45.0 – 50.0 
Total 15:49:30 – 16:27:00 65.3 – 70.3 
 
3.3.2.4(e) Second-Dimension Sodium Dodecyl Sulfate (SDS)-Polyacrylamide 
Gel Electrophoresis (PAGE) 
The second-dimension SDS-PAGE was performed subsequent to the first-dimension 
IEF of protein samples.  A vertical electrophoresis system, i.e., SE 600 Ruby Standard 
Dual Cooled Gel Electrophoresis Unit was used for this purpose.    
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3.3.2.4(e)(i) Preparation of Glass Sandwich 
Initially, the gel caster was adjusted until the bubble in the spirit level was centered.  
Next, two pieces of clean, unchipped and scratch-free, 18 x 16 cm low fluorescence 
glass plates were assembled together with a 2 cm wide x 1 mm thick spacer placed on 
each side of the edge.  The glass sandwich was secured with clamps on both sides by 
tightening the screws on the clamps.  Prior to the assembly of glass sandwich on casting 
cradle, the laminated gaskets were placed into the casting cradles with foam side down.  
The glass sandwich was then placed into the casting cradle with screw side facing out 
and sealed with a cam at each side.   
3.3.2.4(e)(ii) Preparation of SDS-Denaturing Polyacrylamide Resolving Gel 
The proteins were resolved in a 12.5 % SDS-denaturing polyacrylamide gel, which was 
prepared according to the gel recipe in Table 3.23.   
Table 3.23: Gel recipe for 12.5 % SDS-denaturing polyacrylamide resolving gel. 
Component Volume (ml) 
Monomer Solution [30 % Acrylamide/Bis Solution 37.5:1 (2.6 % C)] 10.43 
4X Resolving Gel Buffer 6.25 
10 % (w/v) SDS 0.25 
ddH2O 7.93 
10 % (w/v) Ammonium persulfate 0.125 
TEMED 0.015 
Total Volume 25.0 
  
The gel solution was mixed gently and filled into the gel cassette until 5 – 10 mm below 
the top of the upper plate edge.  Immediately, a thin layer of ddH2O was overlaid on top 
of the gel.  The gel was then allowed to polymerise for 1 hr.     
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3.3.2.4(e)(iii) Equilibration and Loading of Focused Immobiline DryStrip Gels 
The focused Immobiline DryStrip Gels must be equilibrated immediately prior to SDS-
PAGE.  First, the focused strip was transferred to a 25 x 200 mm screw-cap culture tube, 
with gel side up and the support film towards the wall of tube.  Next, 10 ml of 10 mg/ml 
DTT-containing SDS Equilibration Buffer was added to the tube.  The strip was 
allowed to equilibrate for 15 min in the dark with gentle agitation on MS Waver Shaker 
at 35 rpm.  The solution was then discarded and 10 ml of 25 mg/ml Iodoacetamide-
containing SDS Equilibration Buffer was added.  Similarly, the strip was also incubated 
in the dark with gentle agitation at 35 rpm for 15 min.   
Following this, the equilibration solution was discarded and the focused Immobiline 
DryStrip Gel was rinsed briefly with 1X Laemmli SDS Electrophoresis Buffer.  The 
strip was then slid carefully in between the glass sandwich until it came in contact with 
the surface of gel.  The focused strip was positioned with the acidic end (“+” end) on 
the right side of the gel.  Finally, the Immobiline DryStrip Gel was sealed in place with 
an aliquot of melted 0.5 % (w/v) agarose sealing solution on the upper surface of the 
SDS-denaturing polyacrylamide resolving gel.       
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3.3.2.4(e)(iv) Assembly of Electrophoretic Unit and Electrophoretic Run 
The lower buffer chamber of the SE 600 Ruby Standard Dual Cooled Gel 
Electrophoresis Unit was first filled with 3 L of 1X Laemmli SDS Electrophoresis 
Buffer.  The upper buffer chamber was turned upside down where the slotted gasket and 
acrylic buffer dam were fitted into both sandwich holder recesses.  The glass sandwich 
was then released from the caster by removing the cams and clamped in place to the 
upper buffer chamber.  Finally, the assembled upper buffer chamber with gel sandwich 
was fitted into the lower buffer chamber, and 500 ml of 1X Laemmli SDS 
Electrophoresis Buffer was filled into the upper buffer chamber.   
Upon final assembly of the electrophoretic unit, the electrophoresis was programmed 
via the Electrophoresis Power Supply EPS 601 and commenced in two steps with 
constant current.  The electrophoretic running conditions were: Step 1 – 10 mA per gel 
for 20 min; and Step 2 – 30 mA per gel for ~ 2 hr 40 min. 
3.3.2.4(f) Acquisition of Gel Images 
Once the electrophoresis was completed, the electrophoretic unit was unassembled and 
the clamps were unscrewed.  The glass sandwich was wiped with deionised water until 
the glass plates were clean and free from lint.  Subsequently, the glass sandwich was 
placed onto the low fluorescence glass plate stage and fixed in position by both front 
and rear glass holders at each side.  The stage was then placed into the image scanner 
and the gel was ready for scanning under a pixel size of 100 μm.  
The gel was scanned with Typhoon FLA 9000 Variable Mode Laser Scanner, which 
supports the Ettan DIGE System with its fluorescence imaging mode.  In this mode, the 
Cy2, Cy3 and Cy5 dyes were excited by blue (473 nm), green (532 nm) and red (635 
nm) laser, respectively.  Upon excitation, the emitted light was collected and 
transformed to an electrical signal by bialkali photomultiplier tube (PMT).  These 
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electrical signals were then converted for image display.  Table 3.24 shows the 
excitation and emission wavelengths for different CyDyes, as well as the types of 
emission filter and PMT voltages used for their detection.  The whole gel scanning 
process was monitored and controlled via Typhoon FLA 9000 Control software ver. 1.2.  
 
Table 3.24: Excitation and emission wavelengths, as well as emission filters and PMT 
voltages used for the detection of different CyDyes. 
CyDye Excitation 
Wavelength (nm) 
Emission Light 
Wavelength (nm) 
Emission 
Filter 
PMT Voltage 
(V) 
Cy2 489 506 LPB 490 - 630 
Cy3 550 570 LPG 560 - 700 
Cy5 649 670 LPR 655 - 780 
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3.3.2.4(g) Mass Spectrometry (MS)-Compatible Silver Staining 
All gels were post-stained with MS-compatible silver staining to facilitate ensuing spot 
picking and mass spectrometric analysis, as well as to ensure satisfactory peptide 
sequencing results (Shevchenko et al., 1996).  This modified protocol has excluded the 
treatment of gel with glutaraldehyde, which is a cross-linking and sensitising agent 
commonly used in silver staining procedure.  Subsequent to images acquisition, the 
glass plates were separated, while the gel was lifted gently and placed carefully into the 
staining tray.  First, the gel was fixed in a solution of 50 % (v/v) methanol and 5 % (v/v) 
acetic acid for 20 min.  It was then washed in deionised water for 10 min.  Next, the gel 
was sensitised with 0.02 % (w/v) sodium thiosulfate for 1 min and rinsed twice with 
deionised water for 1 min each.  This was followed by incubation in chilled 0.1 % (w/v) 
silver nitrate for 20 min at 4 
0
C.  The gel was then rinsed twice with deionised water for 
1 min each prior to the developing step.  The gel was developed in a solution of 0.04 % 
(v/v) formalin (37 % formaldehyde in water) and 2 % (w/v) sodium carbonate with 
intensive shaking.  In this step, the developer was replaced with a new portion once it 
turned yellowish.  Finally, the development was terminated by washing the gel with 5 % 
(v/v) acetic acid after the desired intensity of staining was achieved.  All silver stained 
gels were stored in 1 % (v/v) acetic acid at 4 
0
C for spot picking.            
3.3.2.4(h) Image and Data Analysis 
The specifically designed and integrated DeCyder 2D software ver. 7.0 in the Ettan 
DIGE System allows co-detection of multiplexed gel images with its novel algorithm, 
DeCyder Detection Algorithm 6.0.  It is an automated image analysis software suite for 
the execution of gel-to-gel matching, as well as spots detection, quantification and 
analysis with high confidence and accuracy.  The DeCyder 2D software ver. 7.0 consists 
of five modules, i.e., Image Loader, Differential In-Gel Analysis (DIA), Biological 
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Variation Analysis (BVA), Batch Processor and XML Toolbox.  However, only the first 
three modules were employed for the analysis of 2-D DIGE results in the current 
experimental settings. 
3.3.2.4(h)(i) Image Loader Module 
In the 2-D DIGE experiments, each gel consisted of three images, i.e., Cy2, Cy3 and 
Cy5.  The images were first edited in order to remove unwanted artifacts and gel edges.  
The editing and cropping of images from the same gel was performed simultaneously 
using a three-coloured gel overlay image within the Image Editor module.  Next, the 
edited gel image files were imported into DeCyder 2D Database through the Image 
Loader module, readily analysed with the DIA module.   
3.3.2.4(h)(ii) DIA Module 
Prior to the inter-gel analysis in BVA module, the imported images were processed via 
DIA interface for the co-detection and quantification of protein spots within each in-gel 
linked image set.  The co-migration of CyDyes produced a set of three co-run images 
for a gel (i.e., Cy2, Cy3 and Cy5 images), which were then merged together for triple 
detection and matching of protein spots via DeCyder Detection Algorithm 6.0.  In the 
DIA module, the abundance value of each protein spot was expressed as ratios and 
determined by directly comparison of corresponding spots within an in-gel set of 
images.  In the current experimental setting, the abundance values of the protein spots 
for a sample (i.e., CRC tumour or normal colonic mucosa) was quantified against the 
internal standard to permit accurate inter-gel protein spots comparison.  Finally, all 
generated spots data were utilised for subsequent inter-gel analysis in BVA module.       
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3.3.2.4(h)(iii) BVA Module 
Following spot detection and quantification, the generated DIA workspaces, along with 
all original scanned image files, were imported into BVA module for inter-gel analysis.  
The gel-to-gel matching of all protein spots was performed within this module and 
allows for quantitative comparison of the protein expression levels across all biological 
replicates.  Initially, one of the Cy2 images was selected as ‘Master’ image, which all 
the other images were matched for the identification of common protein spots across 
multiple gels.  Subsequently, the average ratio of each protein spot, which indicates the 
difference in its expression level between the CRC tumour and normal colonic mucosa 
groups, was calculated.  The Two-tailed Paired t-test with False Discovery Rate (FDR) 
correction was performed to statistically assess the significance in protein expression 
changes between the CRC tumour and normal colonic mucosa samples within each 
stage of the CRC group.  A p value of less than 0.05 indicates that the observed 
difference in protein abundance is statistically significant, where only less than 5 % of 
the probability is merely due to stochastic events.    
3.3.2.5 Protein Identification via Liquid Chromatography-Tandem Mass 
Spectrometry (LC-MS/MS) 
The desired protein spots (where the different protein expression levels were 
statistically significant between the CRC tumour and normal colonic mucosa samples in 
each stage of the CRC group) were excised from the polyacrylamide gels and pooled for 
subsequent LC-MS/MS analysis.  These dried MS-compatible silver stained gel bands 
were sent to Proteomics International Pty Ltd in Australia for LC-MS/MS and MS/MS 
data analysis.     
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3.3.2.5(a) Mass Spectrometry (MS) 
In our current study, the MS analysis was performed on the UltiMate 3000 Nano HPLC 
System (Dionex, United States) interfaced with a 4000 Q TRAP Hybrid Triple 
Quadrupole / Linear Ion Trap Mass Spectrometer (Applied Biosystems, United States) 
which is coupled to a NanoSpray source. 
3.3.2.5(a)(i) De-staining Step  
Prior to trypsin digestion, the silver stained proteins were de-stained with chemical 
reducers in order to remove the silver, as described previously in Gharahdaghi et al., 
1999 (Gharahdaghi et al., 1999).  Initially, two stock solutions of 30 mM potassium 
ferricyanide and 100 mM sodium thiosulfate were prepared.  Next, the working solution 
which consisted of a 1:1 ratio of these stock solutions was prepared freshly before each 
de-staining process.  A 30 – 50 μl of working solution was added until the gel band is 
fully covered, and the tube was vortexed occasionally.  The gel band was then rinsed 
with deionised water for a few times to stop the reaction once the brownish colour of 
the gel band disappeared.  Subsequently, 200 mM of ammonium bicarbonate was added 
to cover the gel band and left at room temperature for 20 min.  The solution was then 
discarded and the gel band was cut into smaller pieces.  The gel pieces were washed 
with deionised water and dehydrated repeatedly with the changing of acetonitrile (ACN) 
solution until they turned opaque white.  Finally, the gel pieces were dried for 30 min in 
a vacuum centrifuge.  
3.3.2.5(a)(ii) Trypsin Digestion and Peptide Extraction  
The protein samples were digested with trypsin and the resulting peptides were 
extracted according to standard techniques, as previously described in Bringans et al., 
2008 (Bringans et al., 2008).  Ten microlitres of trypsin digest solution (which consisted 
of 12.5 μg/ml of trypsin in 25 mM of ammonium bicarbonate) was added to dried gel 
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pieces and incubated overnight at 37 
0
C.  Next, the digested peptides were extracted 
twice with the addition of 10 – 20 μl ACN containing 1 % trifluoroacetic acid (TFA) 
solution and incubated at room temperature for 20 min.  The pooled extracts were then 
dried and stored at -20 
0
C for further analysis via LC-MS/MS.  
3.3.2.5(a)(iii) LC-MS/MS   
The dried peptide extracts were resuspended in 50 μl of 2 % ACN consisting 0.05 % 
TFA solution.  Ten microlitres of tryptic peptides were then loaded onto the Acclaim 
PepMap100 C18 Nanocolumn (3 μm, 100 Å, 75 μm i.d. x 15 cm) (Dionex, United 
States).  Subsequently, the peptides were eluted over 60 min through the column with a 
linear gradient of 10 – 40 % ACN consisting 0.1 % formic acid at a flow-rate of 300 
nl/min, into the mass spectrometer via a PicoTip emitter.  The mass spectrometer was 
operated with the ion source temperature of 150 
0
C and the spray voltage of 2650 V 
(Ravenscroft et al., 2008). 
3.3.2.5(b) Peptide Matching and Database Searching 
All fragment ions data were imported into Mascot software ver. 2.3.02 (Matrix Science, 
United Kingdom) for peptide matching and database searching.  The MS/MS Ions 
Search was performed with the following searching parameters against Homo sapiens 
entries in the LudwigNR database (Aug 2012; 281, 382 sequences): peptide mass 
tolerance was +1.2 Da, fragment mass tolerance was +0.6 Da, trypsin specificity was 
applied to a maximum of one missed cleavage, and the monoisotopic mass value was 
reported.  In addition, there was no fixed modification being applied, but the oxidation 
of methionines was set as variable modification. 
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4.1 Part A: SNPs Genotyping via Allelic Discrimination Assays 
4.1.1 Genotyping of the NOD2/CARD15 Variants 
The genotyping of the NOD2/CARD15 variants was performed via real-time PCR with 
TaqMan chemistry.  Figure 4.1 illustrates the allelic discrimination plots that summarise 
the genetic distribution of each NOD2/CARD15 variant in both CRC patient and healthy 
control groups.  The Arg702Trp, Gly908Arg and 3020insC variants appear 
monomorphic (homozygous wild-type) in our Malaysian population, as depicted in 
Figures 4.1 (a), (b) and (c) respectively.  On the other hand, the mutation-positive 
heterozygotes were reported in addition to the homozygous wild-type for both 
Pro268Ser and JW1 variants [Figures 4.1 (d) and (e)].   
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(a) Arg702Trp 
 
 
 
 
 
Figure 4.1: Allelic discrimination plots for genetic distribution of the NOD2/CARD15 
variants. 
 
CRC Group 
Control Group 
        Homozygous C 
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(b) Gly908Arg 
 
 
 
 
 
Figure 4.1, continued. 
 
 
CRC Group 
Control Group 
        Homozygous G 
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(c) 3020insC 
 
  
 
 
 
Figure 4.1, continued. 
 
 
CRC Group 
Control Group 
        Homozygous wild-type 
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(d) Pro268Ser 
 
 
 
 
 
 
Figure 4.1, continued. 
 
 
 
CRC Group 
Control Group 
        Homozygous C            Heterozygous C/T        
Chapter Four – Results 
 
127 
 
(e) JW1 
 
 
 
 
 
 
Figure 4.1, continued. 
 
 
 
CRC Group 
Control Group 
        Homozygous C            Heterozygous C/T        
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Tables 4.1 and 4.2 summarise the respective genotype and allele frequencies of the 
Arg702Trp, Gly908Arg, 3020insC, Pro268Ser and JW1 variants in each CRC patient 
and healthy control group.  The observed genotype frequencies in the control group fit 
the HWE model for all the NOD2/CARD15 variants studied (p > 0.05) (Table 4.1).  
With regards to our Malaysian population, the mutant alleles of these NOD2/CARD15 
variants were either absent or present in an extremely low frequency (< 2.0 %) (Table 
4.2).  The rare variant (allele T) of the Pro268Ser and JW1 was scored as heterozygotes 
with a frequency of only 3.5 % and 0.6 %, respectively.  On the other hand, the Fisher’s 
Exact
 
Test had revealed that none of the NOD2/CARD15 variants was significantly 
associated to the development of CRC in Malaysian patients (p > 0.05) (Tables 4.1 and 
4.2).    
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Table 4.1: Genotype frequencies with HWE testing, p value and OR with 95 % CI for 
all NOD2/CARD15 variants in each CRC patient and healthy control group. 
  
 
 
 
 
 
 
NOD2/ 
CARD15 
Variant 
 
 
Genotype 
 
Genotype Frequency 
(%) 
 
 
Fisher’s 
p value 
 
 
OR  
(95 % CI) 
 
HWE 
(Control) 
p value CRC 
Patient 
 
Control 
 
Arg702Trp 
 
C/C 
C/T 
T/T 
130 (100) 
0 (0) 
0 (0) 
212 (100) 
0 (0) 
0 (0) 
 
1.0000 
 
- 
 
- 
 
Gly908Arg 
G/G 
G/C 
C/C 
130 (100) 
0 (0) 
0 (0) 
212 (100) 
0 (0) 
0 (0) 
 
1.0000 
 
- 
 
- 
 
 
3020insC 
 
-/- 
-/+ 
+/+ 
130 (100) 
0 (0) 
0 (0) 
212 (100) 
0 (0) 
0 (0) 
 
1.0000 
 
- 
 
- 
 
 
Pro268Ser 
 
C/C 
 
C/T 
 
T/T 
126 (96.9) 
 
4 (3.1) 
 
0 (0) 
204 (96.2) 
 
8 (3.8) 
 
0 (0) 
 
 
1.0000 
 
1.2353  
(0.3645-4.1868) 
0.8095  
(0.2388-2.7437) 
- 
 
 
0.7795 
 
JW1 
 
C/C 
 
C/T 
 
T/T 
129 (99.2) 
 
1 (0.8) 
 
0 (0) 
211 (99.5) 
 
1 (0.5) 
 
0 (0) 
 
 
1.0000 
 
0.6114  
(0.0379-9.8597) 
1.6357  
(0.1014-26.3784) 
- 
 
 
0.9725 
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Table 4.2: Allele frequencies, p value and OR with 95 % CI for all NOD2/CARD15 
variants in each CRC patient and healthy control group. 
 
 
 
 
NOD2/CARD15 
Variant 
 
Allele 
Allele Frequency (%)  
Fisher’s 
p value 
 
OR  
(95 % CI) 
CRC 
Patient 
 
Control 
Arg702Trp C 
T 
260 (100) 
0 (0) 
424 (100) 
0 (0) 
1.0000 
 
- 
 
Gly908Arg G 
C 
260 (100) 
0 (0) 
424 (100) 
0 (0) 
1.0000 
 
- 
 
3020insC - 
+ 
260 (100) 
0 (0) 
424 (100) 
0 (0) 
1.0000 - 
 
Pro268Ser 
C 
 
T 
256 (98.5) 
 
4 (1.5) 
416 (98.1) 
 
8 (1.9) 
 
1.0000 
1.2308  
(0.3669-4.1286) 
0.8125  
(0.2422-2.7255) 
 
JW1 
 
C 
 
T 
259 (99.6) 
 
1 (0.4) 
423 (99.8) 
 
1 (0.2) 
 
1.0000 
0.6123  
(0.0381-9.8318) 
1.6332  
(0.1017-26.2250) 
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4.1.2 Genotyping of the Common GWAS-identified CRC-associated Variants 
Figure 4.2 depicts the distribution of the common GWAS-identified CRC-associated 
variants in the Malaysian population, i.e., the rs6983267, rs4939827, rs4779584, 
rs16892766 and rs3802842.  All the three genotypes of these biallelic polymorphisms 
were scored in both CRC patient and healthy control groups [Figures 4.2 (a), (b), (c) 
and (e)], with the exclusion of the rs16892766 [Figure 4.2 (d)]. 
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(a) rs6983267 
 
     
 
 
 
Figure 4.2: Allelic discrimination plots for genetic distribution of the common GWAS-
identified CRC-associated variants. 
 
CRC Group 
Control Group 
        Homozygous G            Heterozygous G/T            Homozygous T 
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(b) rs4939827 
 
 
 
 
 
Figure 4.2, continued. 
 
 
CRC Group 
Control Group 
        Homozygous C            Heterozygous T/C            Homozygous T 
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(c) rs4779584 
 
 
 
 
 
Figure 4.2, continued. 
 
 
CRC Group 
Control Group 
        Homozygous C            Heterozygous C/T            Homozygous T 
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(d) rs16892766 
 
 
 
 
 
Figure 4.2, continued. 
 
 
CRC Group 
Control Group 
        Homozygous A            Heterozygous A/C        
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(e) rs3802842 
 
 
 
 
 
Figure 4.2, continued. 
 
 
CRC Group 
Control Group 
        Homozygous A            Heterozygous C/A            Homozygous C 
Chapter Four – Results 
 
137 
 
Tables 4.3 and 4.4 show the genotype and allele frequencies of these common variants 
in the CRC patient and healthy control groups, respectively.  The genotype frequencies 
of rs4939827, rs4779584, rs16892766 and rs3802842 SNPs in healthy control group fit 
the HWE (p > 0.05), but those of rs6983267 did not (p < 0.05) (Table 4.3).  As shown in 
Table 4.3, the genotype frequencies of rs6983267, rs4779584, rs16892766 and 
rs3802842 did not differ significantly between the CRC patient and healthy control 
groups (p > 0.05).  However, the common variant rs4939827 was inversely correlated to 
CRC susceptibility with an OR of 0.5936 (p < 0.05; 95 % CI = 0.3803-0.9267) (Table 
4.3).  Hence, we suggest that the allele C might confer a protective effect on the genetic 
predisposition of CRC in our Malaysian population (Table 4.4).   
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Table 4.3: Genotype frequencies with HWE testing, p value and OR with 95 % CI for 
all common GWAS-identified CRC-associated variants in each CRC patient 
and healthy control group. 
     
*
p < 0.05 – statistically significant 
 
 
SNP 
 
 
Genotype 
 
Genotype Frequency 
(%) 
 
 
Fisher’s 
p value 
 
 
OR  
(95 % CI) 
 
HWE 
(Control) 
p value CRC 
Patient 
 
Control 
 
 
rs6983267 
 
 
G/G 
 
G/T 
 
T/T 
29 (22.3) 
 
58 (44.6) 
 
43 (33.1) 
43 (20.3) 
 
87 (41.0) 
 
82 (38.7) 
0.6831 
 
0.5733 
 
0.3548 
1.1285  
(0.6632-1.9202) 
1.1574  
(0.7447-1.7989) 
0.7836  
(0.4956-1.2389) 
 
 
0.0284 
 
 
rs4939827 
T/T 
 
T/C 
 
C/C 
18 (13.8) 
 
63 (48.5) 
 
49 (37.7) 
22 (10.4) 
 
83 (39.1) 
 
107 (50.5) 
0.3867 
 
0.0930 
 
0.0253
*
 
1.3880  
(0.7136-2.6996) 
1.4614  
(0.9404-2.2712) 
0.5936  
(0.3803-0.9267) 
 
 
0.3293 
 
 
rs4779584 
C/C 
 
C/T 
 
T/T 
7 (5.4) 
 
44 (33.8) 
 
79 (60.8) 
8 (3.8) 
 
73 (34.4) 
 
131 (61.8) 
0.5881 
 
1.0000 
 
0.9090 
1.4512  
(0.5136-4.1008) 
0.9742  
(0.6146-1.5443) 
0.9578  
(0.6119-1.4991) 
 
 
0.5787 
 
 
rs16892766 
A/A 
 
A/C 
 
C/C 
129 (99.2) 
 
1 (0.8) 
 
0 (0) 
211 (99.5) 
 
1 (0.5) 
 
0 (0) 
1.0000 
 
1.0000 
 
1.0000 
0.6114  
(0.0379-9.8597) 
1.6357  
(0.1014-26.3784) 
- 
 
 
0.9725 
 
 
rs3802842 
C/C 
 
C/A 
 
A/A 
20 (15.4) 
 
62 (47.7) 
 
48 (36.9) 
29 (13.7) 
 
98 (46.2) 
 
85 (40.1) 
0.7508 
 
0.8238 
 
0.5701 
1.1473  
(0.6192-2.1260) 
1.0606  
(0.6848-1.6426) 
0.8746  
(0.5578-1.3714) 
 
 
0.9290 
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Table 4.4: Allele frequencies, p value and OR with 95 % CI for all common GWAS-
identified CRC-associated variants in each CRC patient and healthy control 
group. 
     *p < 0.05 – statistically significant                    
 
 
SNP 
 
Allele 
Allele Frequency (%) Fisher’s 
p value  
OR 
(95 % CI) CRC Patient Control 
 
rs6983267 
 
G 
 
T 
116 (44.6) 
 
144 (55.4) 
173 (40.8) 
 
251 (59.2) 
 
0.3394 
1.1688  
(0.8556-1.5966) 
0.8556  
(0.6263-1.1688) 
 
rs4939827 
T 
 
C 
99 (38.1) 
 
161 (61.9) 
127 (30.0) 
 
297 (70.0) 
 
0.0298
* 
1.4380  
(1.0386-1.9909) 
0.6954  
(0.5023-0.9628) 
 
rs4779584 
C 
 
T 
58 (22.3) 
 
202 (77.7) 
89 (21.0) 
 
335 (79.0) 
 
0.7019 
1.0808  
(0.7435-1.5709) 
0.9253  
(0.6366-1.3449) 
 
rs16892766 
A 
 
C 
259 (99.6) 
 
1 (0.4) 
423 (99.8) 
 
1 (0.2) 
 
1.0000 
0.6123  
(0.0381-9.8318) 
1.6332  
(0.1017-26.2250) 
 
rs3802842 
C 
 
A 
102 (39.2) 
 
158 (60.8) 
156 (36.8) 
 
268 (63.2) 
 
0.5695 
1.1091  
(0.8072-1.5238) 
0.9017  
(0.6562-1.2389) 
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4.1.3 Genotyping of the Low-penetrance Genes 
4.1.3.1 XRCC1 Variants 
All three genotypes of the biallelic polymorphisms, XRCC1 rs25487 and rs1799782 
were scored in our Malaysian population, as illustrated in Figures 4.3 (a) and (c).  
Meanwhile, the genotyping on the XRCC1 rs25489 variant revealed the common 
presence of homozygous G and heterozygous genotypes in both CRC patient and 
healthy control groups.  The homozygote A of the rs25489 variant is relatively rare, 
where only one individual presented with this genotype in our control group [Figure 4.3 
(b)]. 
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a) rs25487 
 
 
 
 
 
Figure 4.3: Allelic discrimination plots for genetic distribution of the XRCC1 variants. 
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Control Group 
        Homozygous G            Heterozygous G/A            Homozygous A 
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b) rs25489 
 
 
 
 
 
Figure 4.3, continued. 
 
CRC Group 
Control Group 
        Homozygous G            Heterozygous G/A            Homozygous A 
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c) rs1799782 
 
 
 
 
 
Figure 4.3, continued. 
CRC Group 
Control Group 
        Homozygous T            Heterozygous C/T            Homozygous C 
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As shown in Table 4.5, the observed genotype frequencies in our control group were 
within the probability limits for HWE (p > 0.05).  The homozygous genotypes for the 
minor alleles of all three XRCC1 SNPs were in very low frequencies, i.e., less than 10.0 % 
in our population.  The homozygotes A (minor allele carriers) for the XRCC1 variant 
rs25489 was only 0.5 % among the healthy controls and completely absent among the 
CRC patients (Table 4.5).  Further statistical analysis with Fisher’s Exact Test failed to 
establish any significant association between the studied XRCC1 genetic variants and 
CRC susceptibility in our Malaysian cohort (p > 0.05) (Tables 4.5 and 4.6).   
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Table 4.5: Genotype frequencies with HWE testing, p value and OR with 95 % CI for 
all XRCC1 variants in each CRC patient and healthy control group. 
 
  
 
 
 
 
 
 
SNP 
 
Genotype 
Genotype Frequency 
(%) 
 
Fisher’s 
p value 
 
OR  
(95 % CI) 
 
HWE 
(Control) 
p value 
CRC 
Patient 
 
Control 
 
 
rs25487 
 
 
G/G 
 
G/A 
 
A/A 
65 (50.0) 
 
53 (40.8) 
 
12 (9.2) 
109 (51.4) 
 
84 (39.6) 
 
19 (9.0) 
0.8243 
 
0.9095 
 
1.0000 
0.9450  
(0.6106-1.4625) 
1.0489  
(0.6721-1.6369) 
1.0330  
(0.4840-2.2048) 
 
 
0.6275 
 
 
 
rs25489 
G/G 
 
G/A 
 
A/A 
105 (80.8) 
 
25 (19.2) 
 
0 (0) 
170 (80.2) 
 
41 (19.3) 
 
1 (0.5) 
1.0000 
 
1.0000 
 
1.0000 
1.0376  
(0.5977-1.8015) 
0.9930  
(0.5709-1.7273) 
- 
 
 
0.3737 
 
 
 
rs1799782 
C/C 
 
C/T 
 
T/T 
65 (50.0) 
 
56 (43.1) 
 
9 (6.9) 
103 (48.6) 
 
94 (44.3) 
 
15 (7.1) 
0.8243 
 
0.8235 
 
1.0000 
1.0583  
(0.6838-1.6378) 
0.9500  
(0.6116-1.4756) 
0.9769  
(0.4147-2.3012) 
 
 
0.2985 
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Table 4.6: Allele frequencies, p value and OR with 95 % CI for all XRCC1 variants in 
each CRC patient and healthy control group. 
 
SNP 
 
Allele 
Allele Frequency (%) Fisher’s 
p value  
OR 
(95 % CI) CRC Patient Control 
 
rs25487 
 
G 
 
A 
183 (70.4) 
 
77 (29.6) 
302 (71.2) 
 
122 (28.8) 
 
0.8624 
0.9601  
(0.6839-1.3479) 
1.0416  
(0.7419-1.4623) 
 
rs25489 
G 
 
A 
235 (90.4) 
 
25 (9.6) 
381 (89.9) 
 
43 (10.1) 
 
0.8956 
1.0609  
(0.6313-1.7828) 
0.9426  
(0.5609-1.5840) 
 
rs1799782 
C 
 
T 
186 (71.5) 
 
74 (28.5) 
300 (70.8) 
 
124 (29.2) 
 
0.8623 
1.0389  
(0.7387-1.4612) 
0.9625  
(0.6843-1.3538) 
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4.1.3.2 EGF +61 A>G (rs4444903) 
All three genotypes, i.e., homozygous G, heterozygous and homozygous A, of the EGF 
+61 A>G polymorphism were scored in our Malaysian population (Figure 4.4).  The 
homozygous G was the most frequent genotype reported among the CRC patients 
(48.4 %), while the heterozygotes were the most common in the control group (49.1 %).  
On the other hand, the homozygous A was the least frequent genotype in both study 
groups.  The observed genotype frequencies of the EGF +61 A>G variant in the control 
group did not fit the HWE model (p < 0.05) (Table 4.7).  As calculated via the Fisher’s 
Exact Test, both genotype and allele frequencies of the EGF +61 A>G polymorphism 
did not differ significantly between CRC patient and healthy control groups (p > 0.05) 
(Table 4.7).       
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Figure 4.4: Allelic discrimination plots for genetic distribution of the EGF +61 A>G 
polymorphism. 
CRC Group 
Control Group 
        Homozygous A            Heterozygous G/A            Homozygous G 
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Table 4.7: Genotype frequencies with HWE testing, allele frequencies, p value and OR 
with 95 % CI of the EGF +61 A>G variant in each CRC patient and healthy 
control group. 
 
 
 
 
 
 
 
 
 
 
 
Genotype / 
Allele 
Genotype /  
Allele Frequency (%) 
 
Fisher’s 
p value 
 
OR  
(95 % CI) 
 
HWE 
(Control) 
p value 
CRC 
Patient 
 
Control 
Genotype 
G/G 
 
G/A 
 
A/A 
 
63 (48.4) 
 
53 (40.8) 
 
14 (10.8) 
 
95 (44.8) 
 
104 (49.1) 
 
13 (6.1) 
 
0.5765 
 
0.1471 
 
0.1486 
 
1.1581  
(0.7475-1.7940) 
0.7148  
(0.4597-1.1115) 
1.8475  
(0.8394-4.0662) 
 
 
 
0.0252 
 
Allele 
G 
 
A 
 
179 (68.8) 
 
81 (31.2) 
 
294 (69.3) 
 
130 (30.7) 
 
 
0.9321 
 
 
0.9772  
(0.6997-1.3645) 
1.0234  
(0.7328-1.4291) 
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4.1.3.3 VEGF +936 C>T (rs3025039) 
Figure 4.5 illustrates the genetic distribution of the VEGF +936 C>T polymorphism in 
both CRC patient and healthy control groups.  All three genotypes of this biallelic 
polymorphism were scored in our healthy control group, but the homozygous of the 
minor allele T was not reported among CRC patients (Figure 4.5).  Overall, the 
homozygous C genotype was the most common in our Malaysian population and the 
observed genotype frequencies for the control group were in HWE (p > 0.05) (Table 
4.8).  As summarised in Table 4.8, none of the genotypes or alleles of the VEGF +936 
C>T polymorphism was significantly associated to disease susceptibility in Malaysian 
CRC patients (p > 0.05).  
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Figure 4.5: Allelic discrimination plots for genetic distribution of the VEGF +936 C>T 
polymorphism. 
 
CRC Group 
Control Group 
        Homozygous C            Heterozygous C/T            Homozygous T 
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Table 4.8: Genotype frequencies with HWE testing, allele frequencies, p value and OR 
with 95 % CI of the VEGF +936 C>T polymorphism in each CRC patient 
and healthy control group. 
 
 
 
  
 
 
 
 
Genotype / 
Allele 
Genotype /  
Allele Frequency (%) 
 
Fisher’s 
p value 
 
OR  
(95 % CI) 
 
HWE 
(Control) 
p value 
CRC 
Patient 
 
Control 
Genotype 
C/C 
 
C/T 
 
T/T 
 
99 (76.2) 
 
31 (23.8) 
 
0 (0) 
 
151 (71.2) 
 
57 (26.9) 
 
4 (1.9) 
 
0.3794 
 
0.6106 
 
0.3018 
 
1.2901  
(0.7816-2.1295) 
0.8515  
(0.5139-1.4108) 
- 
 
 
0.6032 
 
Allele 
C 
 
T 
 
229 (88.1) 
 
31 (11.9) 
 
359 (84.7) 
 
65 (15.3) 
 
 
0.2567 
 
1.3375  
(0.8454-2.1162) 
0.7477  
(0.4726-1.1829) 
 
 
 
Chapter Four – Results 
 
153 
 
4.2 Part B: Differential Transcriptome Analysis 
4.2.1 RNA Concentration and Integrity Assessment 
The concentration and integrity of isolated total RNA were assessed by using the 
Agilent 2100 Bioanalyzer.  In the current study, total RNA samples with RIN value of 
8.0 and above were selected for the differential expression analysis.  Figures 4.6 (a), (b) 
and (c) are the examples of electropherogram for total RNA samples with RIN value of 
8.0, 9.0 and 10.0, respectively. 
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(a) Total RNA sample with RIN = 8.0 [Sample T1 (C)] 
 
(b) Total RNA sample with RIN = 9.0 [Sample T7 (N)] 
 
(c)  Total RNA sample with RIN = 10.0 [Sample T2 (N)]   
 
Figure 4.6: Electropherogram obtained from the Agilent 2100 Expert software.  The X-
axis represents the time in sec [s], while Y-axis, the fluorescence unit [FU]. 
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4.2.2 DEGs Identification 
4.2.2.1 Characterisation of Differential Banding Patterns 
The identification of DEGs in CRC tumours was performed via a two-step ACP-based 
PCR.  The resulting amplified products were visualised on 3 % (w/v) ethidium bromide-
stained agarose gels, and a total of 13 differentially expressed bands were observed, as 
shown in Figure 4.7.  The bands with different intensities between CRC tumours and 
normal colonic mucosa might represent potential DEGs, and thus were selected for 
further analysis. 
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               A4 ACP Primer   A6 ACP Primer          A9 ACP Primer 
                                                                          
    A10 ACP Primer     A13 ACP Primer 
                                                                                      
    A18 ACP Primer   A20 ACP Primer 
 
 
 
 
 
                                                                                      
Figure 4.7: Differential banding patterns on 3 % (w/v) ethidium bromide-stained 
agarose gels.  Lane N represents the normal colonic mucosa, while lane C, 
the CRC tumour. 
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4.2.2.2 Sequence Similarity Matching and Identification of DEGs 
Following sequencing, the genes of interest were identified through sequence similarity 
matching with the nucleotide database available from NCBI.  Each differentially 
expressed band corresponded to a gene identity, with the exception of bands A4.1, A9.2 
and A13.1 (Tables 4.9 and 4.10).  Tables 4.9 and 4.10 list out all the identified DEGs 
and their physiological importance, as well as sequence homology (%) and accession 
number of the BLAST results.  Among the 16 successfully identified DEGs, 13 of them 
were over-expressed (Table 4.9), while 3 were under-expressed in CRC tumours (Table 
4.10).    
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Table 4.9: Summary of BLAST results and description on the identified over-expressed DEGs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differentially 
Expressed 
Band 
 
Identity 
Sequence 
Homology 
(%) 
 
Accession Number 
(UniGene Number) 
 
Description 
A4.1 
(DEG1) 
Homo sapiens proteasome 26S subunit, 
ATPase, 5 (PSMC5), mRNA 
502/506 
(99%) 
NM_002805.4 
(Hs.79387) 
Involves in the ATP-dependent degradation of ubiquitinated 
proteins. 
A4.1 
(DEG2) 
Homo sapiens ubiquinol-cytochrome c 
reductase hinge protein (UQCRH), mRNA 
514/521 
(98%) 
NM_006004.2 
(Hs.481571) 
A component of the ubiquinol-cytochrome c reductase 
complex, which is part of the mitochondrial respiratory 
chain. 
A4.2 
(DEG3) 
Homo sapiens ribosomal protein S23 
(RPS23), mRNA 
551/551 
(100%) 
NM_001025.4 
(Hs.527193) 
A component of the 40S subunit of human ribosomes. 
A6.1 
(DEG4) 
Homo sapiens ribosomal protein L10 
(RPL10), transcript variant 1, mRNA 
554/557 
(99%) 
NM_006013.3 
(Hs.534404) 
A component of the 60S subunit of human ribosomes. 
 
A9.2 
(DEG6) 
 
Homo sapiens actin related protein 2/3 
complex, subunit 2, 34kDa (ARPC2), 
transcript variant 2, mRNA  
 
473/473 
(100%) 
 
NM_005731.2 
(Hs.529303) 
Involves in the regulation of actin polymerisation as an 
actin-binding component of the Arp2/3 complex, and 
mediates the formation of branched actin networks together 
with an activating nucleation-promoting factor (NPF). 
A9.2 
(DEG7) 
Homo sapiens TIMP metallopeptidase 
inhibitor 1 (TIMP1), mRNA 
503/511 
(98%) 
NM_003254.2 
(Hs.522632) 
Irreversibly inactivates the metalloproteinases by binding to 
their catalytic zinc cofactor. 
 
A10.1 
(DEG8) 
Homo sapiens ATP synthase, H+ 
transporting, mitochondrial F1 complex, 
beta polypeptide (ATP5B), nuclear gene 
encoding mitochondrial protein, mRNA 
 
917/919 
(99%) 
 
NM_001686.3 
(Hs.406510) 
A subunit of mitochondrial ATP synthase that catalyses the 
synthesis of ATP by utilizing an electrochemical gradient of 
protons across the inner membrane during oxidative 
phosphorylation. 
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Table 4.9, continued. 
  
 
Differentially 
Expressed 
Band 
 
Identity 
Sequence 
Homology 
(%) 
 
Accession Number 
(UniGene Number) 
 
Description 
A13.2 
(DEG11) 
Homo sapiens chromosome 11 open reading 
frame 10 (C11orf10), mRNA 
273/273 
(100%) 
NM_014206.3 
(Hs.437779) 
Unknown. 
 
A13.3 
(DEG12) 
Homo sapiens mitochondrial ribosomal 
protein L24 (MRPL24), nuclear gene 
encoding mitochondrial protein, transcript 
variant 2, mRNA 
 
408/411 
(99%) 
 
NM_024540.3 
(Hs.418233) 
Involves in protein synthesis within the mitochondrion. 
A13.4 
(DEG13) 
Homo sapiens similar to OK/SW-CL.16 
(LOC100288418) 
635/644 
(98%) 
XM_002342023.1 
(-) 
Unknown. 
A18.1 
(DEG14) 
Homo sapiens family with sequence 
similarity 96, member B (FAM96B), 
transcript variant 2, transcribed RNA 
486/487 
(99%) 
NR_024525.1 
(Hs.9825) 
Involves in chromosome segregation as part of the mitotic 
spindle-associated MMXD complex.  
A20.1 
(DEG15) 
Homo sapiens ribosomal protein L35 
(RPL35), mRNA 
440/446 
(99%) 
NM_007209.3 
(Hs.182825) 
A component of the 60S subunit of human ribosomes. 
A20.2 
(DEG16) 
Homo sapiens chromosome 6 open reading 
frame173 (C6orf173), mRNA 
551/554 
(99%) 
NM_001012507.2 
(Hs.486401) 
May be required for proper chromosome segregation during 
mitosis and involved with CENPT in the establishment of 
centromere chromatin structure. 
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Table 4.10: Summary of BLAST results and description on the identified under-expressed DEGs. 
Differentially 
Expressed 
Band 
 
Identity 
Sequence 
Homology 
(%) 
 
Accession Number 
(UniGene Number) 
 
Description 
A9.1 
(DEG5) 
Homo sapiens ribosomal protein L37 
(RPL37), mRNA 
284/284 
(100%) 
NM_000997.4 
(Hs.558601) 
A component of the 60S subunit of human ribosomes, and 
can bind to the 23S rRNA.  
 
A13.1 
(DEG9) 
 
Homo sapiens solute carrier family 25 
(mitochondrial carrier; citrate transporter), 
member 1 (SLC25A1), nuclear gene 
encoding mitochondrial protein, mRNA 
 
165/165 
(100%) 
 
NM_005984.2 
(Hs.111024) 
A mitochondrial tricarboxylate transporter which is 
responsible for the movement of citrate across the 
mitochondrial inner membrane. 
A13.1 
(DEG10) 
Homo sapiens similar to cytochrome c 
oxidase subunit II (LOC100288578), 
miscRNA 
141/146 
(97%) 
XR_078216.1 
(-) 
Unknown. 
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4.2.3 Confirmatory Test 
4.2.3.1 Assessment of Amplification Efficiency via CT Slope Method 
To ensure accuracy and reliability of the Comparative CT study, the PCR amplification 
efficiency for both reference and target gene assays must be approximately equal.  In 
our current study, an efficiency value of 90 – 110 % is acceptable.  Figure 4.8 illustrates 
the example of the standard curve for gene expression assay with an efficiency of 
100.6 %. 
 
Figure 4.8: Standard curve of the RPL10 gene expression assay. 
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4.2.3.2 Relative Quantification of DEGs Expression via Comparative CT (ΔΔCT) 
Experiment 
Following the commencement of PCR amplification for all the DEGs on paired tissue 
specimens, i.e., both CRC tumour and normal colonic mucosa, the relative 
quantification of their expression level was computed by using the afore-mentioned 
software.  The Applied Biosystems 7500 software ver. 2.0.5 was used to obtain the 
relative genes expression level between each individual paired sample.  The Integromics 
RealTime StatMiner software ver. 4.2.8 on the other hand, was employed to assess the 
stability of the chosen reference genes, quantify the relative expression level of the 
identified DEGs across all the sample pairs, and also determine the statistical 
significance of the observed differential expression patterns in current sample cohort.       
4.2.3.2(a) Computation of ΔCT, ΔΔCT and 
TCΔΔ-2 values 
Figure 4.9 shows the calculated ΔCT, ΔΔCT and 
TCΔΔ-2 values for one of the sample pairs 
using the Applied Biosystems 7500 software ver. 2.0.5.  These data were computed by 
using both ACTB and GAPDH as reference genes.  The relative expression, i.e., over- or 
under-expression, of the DEGs is illustrated in a bar chart of log10 RQ vs sample (Figure 
4.10).  
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Figure 4.9: Computed ΔCT, ΔΔCT and 
TCΔΔ-2 values for Paired Sample T19 (N) and (C). 
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Figure 4.10: Bar chart showing the relative expression of all DEGs for Paired Sample 
T19 (N) and (C). 
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4.2.3.2(b) Determination of Statistical Significance of the Observed Differential 
Expression Patterns. 
As stated previously, the raw CT data obtained for all paired samples were imported to 
the Integromics RealTime StatMiner software ver. 4.2.8, which executes the two-tailed 
paired t-test and computes the p value for each observed differential expression pattern.  
The statistical significance of the observed fold change in expression for all the reported 
DEGs were determined for each sample group, i.e., early stage CRC, advanced stage 
CRC, right-sided CRC tumours and left-sided CRC tumours.  In early stage CRC group, 
the RPL35, RPS23 and TIMP1 genes were significantly over-expressed (p < 0.05), 
while the ARPC2 gene was under-expressed (p < 0.05) (Table 4.11).  On the other hand, 
the C6orf173, RPL35, RPS23 and TIMP1 genes were reported to be significantly over-
expressed (p < 0.05) in advanced stage primary CRC tumours (Table 4.12).  Figures 
4.11 (a) and (b) illustrate the statistically significant and non-significant DEGs for both 
early- and advanced stage CRC groups, respectively. 
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Table 4.11: ΔCT mean, ΔΔCT, 
TCΔΔ-2 and p values for all the DEGs in early stage CRC 
group. 
       *p < 0.05 = statistically significant 
 
 
 
 
 
 
 
 
DEG 
ΔCT Mean 
(CRC) 
ΔCT Mean 
(Normal) ΔΔCT 
 
TCΔΔ
2
-
 log10 RQ p value 
ARPC2 2.6854 2.0664 0.6190 0.6511 -0.1864 0.0282
* 
ATP5B 1.5846 1.2702 0.3144 0.8042 -0.0946 0.3524 
C11orf10 3.2897 3.3639 -0.0742 1.0528 0.0223 0.8333 
C6orf173 6.1083 7.1943 -1.0860 2.1228 0.3269 0.0905 
FAM96B 3.5602 3.8955 -0.3353 1.2616 0.1009 0.2935 
MRPL24 4.9171 5.0839 -0.1668 1.1226 0.0502 0.3564 
PSMC5 3.8232 3.9617 -0.1385 1.1008 0.0417 0.6812 
RPL10 -0.7462 -0.4853 -0.2609 1.1982 0.0785 0.4001 
RPL35 -0.1926 0.6222 -0.8148 1.7591 0.2453 0.0024
* 
RPL37 -0.0059 -0.1539 0.1480 0.9025 -0.0446 0.8645 
RPS23 0.2176 0.7739 -0.5563 1.4705 0.1675 0.0310
* 
SLC25A1 3.7514 3.5430 0.2084 0.8655 -0.0627 0.5721 
TIMP1 2.9096 4.3059 -1.3963 2.6323 0.4203 0.0440
* 
UQCRH 2.0087 2.2216 -0.2129 1.1590 0.0641 0.4108 
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Table 4.12: ΔCT mean, ΔΔCT, 
TCΔΔ-2 and p values for all the DEGs in advanced stage 
CRC group. 
                   *p < 0.05 = statistically significant 
 
DEG 
ΔCT Mean 
(CRC) 
ΔCT Mean 
(Normal) ΔΔCT 
 
TCΔΔ
2
-
 log10 RQ p value 
ARPC2 2.7240 2.3300 0.3940 0.7610 -0.1186 0.2424 
ATP5B 1.9558 1.3838 0.5720 0.6727 -0.1722 0.1484 
C11orf10 3.3281 3.6709 -0.3428 1.2682 0.1032 0.3710 
C6orf173 5.9949 7.9087 -1.9138 3.7680 0.5761 0.0013
* 
FAM96B 3.5276 3.9920 -0.4644 1.3797 0.1398 0.2113 
MRPL24 4.9728 5.1467 -0.1739 1.1281 0.0523 0.7001 
PSMC5 3.7705 3.8455 -0.0750 1.0534 0.0226 0.8048 
RPL10 -1.1576 -0.5196 -0.6380 1.5562 0.1921 0.0950 
RPL35 0.1748 0.8769 -0.7021 1.6269 0.2114 0.0372
* 
RPL37 0.2184 0.7143 -0.4959 1.4102 0.1493 0.1537 
RPS23 0.0676 0.9431 -0.8755 1.8346 0.2635 0.0250
* 
SLC25A1 3.5565 3.4428 0.1137 0.9242 -0.0342 0.7991 
TIMP1 2.3330 3.8547 -1.5217 2.8713 0.4581 0.0062
* 
UQCRH 2.3375 2.4459 -0.1084 1.0780 0.0326 0.7808 
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(a) Early stage CRC 
 
 
 
 
 
 
Figure 4.11: Bar charts showing statistically significant and non-significant DEGs in 
early- and advanced stage CRC groups.  The X-axis represents the DEG, 
while Y-axis, the log10 RQ. 
X-axis: 
                                  ARPC2          RPL35          RPS23           TIMP1 
X-axis:                 C11ORF                FAM96B             Proteasome               RPL37                 UQCRH 
           
                          ATP5B                  C6ORF                MRPL24                 RPL10                   SLC25  
                                          
                                        
                          
 
 
Chapter Four – Results 
169 
 
(b) Advanced stage CRC 
 
 
 
 
 
 
Figure 4.11, continued. 
 
X-axis: 
                                  C6ORF          RPL35          RPS23           TIMP1 
X-axis:                   ATP5B                FAM96B             Proteasome               RPL37                 UQCRH 
           
                           ARPC2                 C11ORF               MRPL24                 RPL10                   SLC25  
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On the other hand, the stratification of samples according to the tumour site revealed 
different gene expression profiles.  For both right- and left-sided CRC tumours, three 
genes were reported to be significantly over-expressed (p < 0.05), i.e., C6orf173, RPL35 
and TIMP1 genes (Tables 4.13 and 4.14).  It is noted that the left-sided primary CRC 
tumours have an additional RPS23 gene which is over-expressed (p < 0.05), compared 
to its right-sided counterparts (Table 4.14).  Figures 4.12 (a) and (b) show the 
statistically significant and non-significant DEGs in both right- and left-sided primary 
CRC tumours, respectively.     
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Table 4.13: ΔCT mean, ΔΔCT, 
TCΔΔ-2 and p values for all the DEGs in right-sided CRC 
tumours. 
       *p < 0.05 = statistically significant 
 
 
 
 
 
 
 
 
DEG 
ΔCT Mean 
(CRC) 
ΔCT Mean 
(Normal) ΔΔCT 
 
TCΔΔ
2
-
 log10 RQ p value 
ARPC2 2.7905 2.0540 0.7365 0.6002 -0.2217 0.1234 
ATP5B 1.8011 1.2592 0.5419 0.6869 -0.1631 0.3267 
C11orf10 3.3613 3.5984 -0.2371 1.1786 0.0714 0.7056 
C6orf173 5.6993 7.8108 -2.1115 4.3214 0.6356 0.0222
* 
FAM96B 3.7004 3.8263 -0.1259 1.0912 0.0379 0.7562 
MRPL24 5.1103 5.2487 -0.1384 1.1007 0.0417 0.5558 
PSMC5 4.0208 3.9409 0.0799 0.9461 -0.0241 0.8673 
RPL10 -0.9872 -0.1565 -0.8307 1.7785 0.2501 0.1212 
RPL35 0.0551 0.9995 -0.9444 1.9244 0.2843 0.0463
* 
RPL37 -0.0984 0.8607 -0.9591 1.9441 0.2887 0.0756 
RPS23 0.2592 1.2111 -0.9519 1.9344 0.2865 0.0706 
SLC25A1 3.6657 3.5243 0.1414 0.9066 -0.0426 0.8234 
TIMP1 2.7847 4.5670 -1.7823 3.4397 0.5365 0.0028
* 
UQCRH 2.1359 2.5387 -0.4028 1.3221 0.1213 0.4135 
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Table 4.14: ΔCT mean, ΔΔCT, 
TCΔΔ-2 and p values for all the DEGs in left-sided CRC 
tumours. 
       *p < 0.05 = statistically significant 
 
 
 
 
 
 
 
 
DEG 
ΔCT Mean 
(CRC) 
ΔCT Mean 
(Normal) ΔΔCT 
 
TCΔΔ
2
-
 log10 RQ p value 
ARPC2 2.8380 2.4382 0.3998 0.7580 -0.1203 0.1223 
ATP5B 1.9302 1.6162 0.3140 0.8044 -0.0945 0.2882 
C11orf10 3.5019 3.6857 -0.1838 1.1359 0.0553 0.5246 
C6orf173 6.4111 7.6303 -1.2192 2.3282 0.3670 0.0208
* 
FAM96B 3.7068 4.1473 -0.4405 1.3571 0.1326 0.1499 
MRPL24 5.0577 5.1539 -0.0962 1.0690 0.0290 0.7758 
PSMC5 3.8735 4.1235 -0.2500 1.1892 0.0753 0.3475 
RPL10 -0.8851 -0.5358 -0.3493 1.2739 0.1051 0.2161 
RPL35 0.1602 0.7824 -0.6222 1.5392 0.1873 0.0089
* 
RPL37 0.4015 0.1894 0.2121 0.8633 -0.0638 0.7459 
RPS23 0.2246 0.8407 -0.6161 1.5327 0.1855 0.0228
* 
SLC25A1 3.7409 3.5992 0.1417 0.9065 -0.0426 0.6783 
TIMP1 2.6362 3.8726 -1.2364 2.3561 0.3722 0.0368
* 
UQCRH 2.4767 2.4948 -0.0181 1.0126 0.0054 0.9478 
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(a) Right-sided primary CRC tumours 
 
 
 
 
 
 
Figure 4.12: Bar charts showing statistically significant and non-significant DEGs in 
right- and left-sided CRC tumours.  The X-axis represents the DEG, while 
Y-axis, the log10 RQ. 
X-axis: 
                                 C6ORF          RPL35           TIMP1            
X-axis:                   ATP5B                FAM96B             Proteasome               RPL37                  SLC25 
           
                           ARPC2                 C11ORF               MRPL24                 RPL10                  RPS23                  UQCRH 
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(b)  Left-sided primary CRC tumours 
 
 
 
 
 
 
Figure 4.12, continued. 
 
X-axis: 
                                  C6ORF          RPL35          RPS23           TIMP1 
X-axis:                   ATP5B                FAM96B             Proteasome               RPL37                 UQCRH 
           
                           ARPC2                 C11ORF               MRPL24                 RPL10                   SLC25  
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4.3 Part C: Differential Proteome Analysis via A Bottom-Up Proteomics 
Approach 
4.3.1 Total Protein Separation via 2-D DIGE 
The isolated total proteins from the CRC tumours and normal colonic mucosa were 
labelled with CyDye DIGE Fluor Minimal Dyes (i.e., Cy3 and Cy5 dyes), according to 
the randomised experimental design shown in Section 3.3.2.4(a), Chapter 3.  On the 
other hand, the internal standard for each of the Stage II, III and IV CRC group was 
labelled with the Cy2 dye.  The two-dimensional separation of these total proteins was 
performed subsequently: first-dimension IEF on a 13 cm Immobiline DryStrip Gel of 
pH 4 – 7, and followed by second-dimension SDS-PAGE on 12.5 % SDS-denaturing 
polyacrylamide resolving gel.  Following 2-D GE, the Cy2, Cy3 and Cy5 channels were 
individually imaged with mutually exclusive excitation and emission wavelengths, as 
listed in Section 3.3.2.4(f), Chapter 3.  Figure 4.13 illustrates the representative CyDye 
images captured by the Typhoon FLA 9000 Variable Mode Laser Scanner. 
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Figure 4.13: Representative CyDye images of gel scanned at a 100 μm resolution.  The images of the protein sample labelled with Cy2, Cy3 and Cy5 
are represented by (a), (b) and (c), respectively.  
(b) (c) (a) 
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All scanned gel images were incorporated into the DeCyder 2D software ver. 7.0 for 
further analysis.  In the present study, we observe that the distribution of protein spots 
varies among the Stage II, III and IV CRC groups.  Figures 4.14 (a), (b) and (c) show 
the examples of 2-D DIGE spot map images of CRC tumour and paired normal colonic 
mucosa samples in Stage II, III and IV CRC Group, respectively.   
 
 
 
 
 
 
 
 
 
 
Chapter Four – Results 
 
178 
 
a) Stage II CRC Group 
                 
b) Stage III CRC Group 
                 
c) Stage IV CRC Group 
                 
 
Figure 4.14: Representative of 2-D DIGE spot map images of CRC tumour and paired 
normal colonic mucosa samples in each CRC Stage group (From left to 
right: pI 4 – 7). 
CRC Normal Colonic Mucosa 
CRC Normal Colonic Mucosa 
CRC Normal Colonic Mucosa 
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The quantitative comparison of the protein expression levels between the CRC tumours 
and normal colonic mucosa across all biological replicates of each CRC Stage group 
was conducted using the DeCyder 2D software ver. 7.0.  Under the DIA module, the 
intensity of every protein spot for each sample in all CRC Stage groups was quantified 
against their respective internal standard.  Gel-to-gel matching was then performed 
within each CRC Stage group via the BVA module.  Here, the differentially expressed 
protein spots were detected, and the average spot volume ratios calculated, to indicate 
the changes in abundance for individual proteins in primary CRC tumours when 
compared to their paired normal colonic mucosa.  Figure 4.15 illustrates an example of 
the abundance of a specific protein spot in 10 Stage II CRC tumours and their paired 
normal colonic mucosa samples.   
 
 
Figure 4.15: Protein abundance for Spot No. 547 in 10 Stage II primary CRC tumours 
and their corresponding paired normal colonic mucosa samples (Spot No. 
refers to the number assigned in Figure 4.16). 
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Subsequently, Two-tailed Paired t-tests were performed to assess the statistical 
significance of the observed differentially expressed protein spots.  The protein 
expression levels in both Stage III and IV CRC primary tumours were not significantly 
different from their paired normal colonic mucosa samples (p > 0.05) (Table 4.15).  
Following FDR correction, only the Stage II CRC Group reported with 46 statistically 
significant differentially expressed protein spots (out of 1356 protein spots detected) 
that were stably visualised on all 2-D DIGE spot map images of 10 parallel gels in the 
Stage II CRC Group (30 spot map images) (Table 4.15).  These protein spots of interest 
were reported with the average spot volume ratios of ≤ -2 or ≥ 2, and had a statistical 
variance within the 99 % confidence level (p < 0.01) (Table 4.15).  Here we had applied 
more stringent criteria in choosing the protein spots of interest for further analysis in 
order to minimise the effects of intrinsic variability associated with patient peculiarity 
and tissue heterogeneity.      
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Table 4.15: Number of differentially expressed protein spots in different stages of 
primary CRC tumours compared to their adjacent normal colonic mucosa, 
as analysed by the DeCyder 2D software ver. 7.0. 
 
CRC Stage Group Number of Protein 
Spots 
Stage II CRC Group 
- Total protein spots detected 
- Differentially expressed protein spots before FDR correction 
(p < 0.05; average ratio ≤ -2 or average ratio ≥ 2) 
- Differentially expressed protein spots after FDR correction   
(p < 0.05; average ratio ≤ -2 or average ratio ≥ 2) 
- Differentially expressed protein spots after FDR correction   
(p < 0.01; average ratio ≤ -2 or average ratio ≥ 2)  
 
1356 
139 
 
59 
 
46 
Stage III CRC Group 
- Total protein spots detected 
- Differentially expressed protein spots before FDR correction 
(p < 0.05; average ratio ≤ -2 or average ratio ≥ 2) 
- Differentially expressed protein spots after FDR correction   
(p < 0.05; average ratio ≤ -2 or average ratio ≥ 2) 
 
1488 
39 
 
0 
Stage IV CRC Group 
- Total protein spots detected 
- Differentially expressed protein spots before FDR correction 
(p < 0.05; average ratio ≤ -2 or average ratio ≥ 2) 
- Differentially expressed protein spots after FDR correction   
(p < 0.05; average ratio ≤ -2 or average ratio ≥ 2) 
 
1402 
15 
 
0 
Chapter Four – Results 
 
182 
 
In order to facilitate spot picking for subsequent LC-MS/MS analysis, all gels in Stage 
II CRC Group were post-stained with MS-compatible silver staining (Figure 4.16).  
Only protein spots that remained visible and appeared as individual spots on the silver-
stained gels were excised for protein identification.  The correct matching and 
localisation of the protein spots were performed by referring to their 3-D view for 
further confirmation (Figure 4.17).  After gel normalisation, background elimination, 
artifact removal and matching between the CyDye and silver-stained images, a total of 
20 protein spots with at least a significant two-fold difference in the expression levels 
were excised and sent for LC-MS/MS analysis (Figure 4.16).   
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Figure 4.16: Representative of gel images for Cy2-labelled internal control in Stage II CRC Group (a), and its corresponding post-silver-stained gel 
image indicating the protein spots of interest excised for LC-MS/MS analysis (b). 
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Figure 4.17: 3-D view for Spot. No. 547 (magenta-coloured) [Spot No. refers to the 
number assigned in Figure 4.16]. 
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Table 4.16 summarises all the 20 protein spots of interest, as well as their average spot 
volume ratios and statistical significance values.  A total of 13 protein spots appear to 
be more abundant in the Stage II primary CRC tumours, while seven others are more 
abundant in the normal colonic mucosa samples.  The calculated average spot volume 
ratios ranged from 3.68-fold decrease for Spot No. 1031 to 4.77-fold increase for Spot 
No. 1011 (Table 4.16). 
Table 4.16: The selected 20 protein spots of interest in Stage II CRC Group [Spot No. 
refers to the numbers assigned in Figure 4.16]. 
No. Spot No. Appearance Two-tailed Paired  
t-test (p value) 
Average Ratio 
1. 300 30 (30) 0.0076 2.49 
2. 306 30 (30) 0.0083 2.70 
3. 308 30 (30) 0.0034 3.28 
4. 326 30 (30) 0.0031 3.87 
5. 457 30 (30) 0.0034 -3.54 
6. 547 30 (30) 0.0039 -2.43 
7. 562 30 (30) 0.0057 -2.18 
8. 706 30 (30) 0.0039 2.36 
9. 730 30 (30) 0.0018 3.19 
10. 795 30 (30) 0.0052 2.28 
11. 877 30 (30) 0.0039 -2.05 
12. 943 30 (30) 0.0031 2.59 
13. 1010 30 (30) 0.00069 4.62 
14. 1011 30 (30) 0.00074 4.77 
15. 1031 30 (30) 0.0031 -3.68 
16. 1040 30 (30) 0.0053 -2.41 
17. 1055 30 (30) 0.0028 2.21 
18. 1095 30 (30) 0.00069 2.85 
19. 1146 30 (30) 0.0028 -2.46 
20. 1199 30 (30) 0.0080 2.18 
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4.3.2 Protein Identification via LC-MS/MS 
Following LC-MS/MS run, the MS/MS data was analysed and interpreted using the 
Mascot software ver. 2.3.02 and LudwigNR database (Aug 2012; 281, 382 sequences).  
In our study, the protein identity was determined by taking into account a few criteria.  
The first was the highest Protein Score and exponentially modified Protein Abundance 
Index (emPAI) value among the listed putatively identified proteins.  The second, at 
least two individual peptide matches with an Expect value of less than 0.05, and the Ions 
Score indicating extensive homology or identity (above the “threshold” score).  Peptide 
match with Ions Score above the “threshold” score is considered statistically significant 
(p < 0.05), as shown in Figure 4.18.  The “threshold” score varies with every search and 
represents a 5 % confidence threshold.  On the other hand, an Expect value of less than 
0.05 indicates a confident match where less than 5 % probability that the observed 
match would be found by chance.  Table 4.17 summarises the protein identities for all 
the 20 protein spots of interest in Stage II CRC Group.   
 
Figure 4.18: Histogram showing Ions Score distribution for peptide matches. 
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Table 4.17: Protein identities for all the 20 protein spots of interest excised for LC-
MS/MS analysis. 
Spot 
No.a 
Accession 
No.b 
Protein Identityc Protein 
Score 
No. of 
Matched 
Peptidesd 
Sequence 
Coverage 
(%) 
Molecular 
Weight 
(Da)e 
Calculated 
pIe 
Trend of 
changes in 
protein 
expressionf 
300 B3GQS7 Mitochondrial 
heat shock 60kD 
protein 1 variant 1  
105 5 (2) 16 60813 5.83 ↑ 
306 B3GQS7 Mitochondrial 
heat shock 60kD 
protein 1 variant 1   
914 27 (25) 44 60642 5.83 ↑ 
308 P10809 60kDa heat shock 
protein, 
mitochondrial   
1124 35 (34) 67 61016 5.70 ↑ 
326 B3GQS7 Mitochondrial 
heat shock 60kD 
protein 1 variant 1 
790 25 (23) 51 60642 5.83 ↑ 
457 P35900 Keratin, type I 
cytoskeletal 20 
762 28 (14) 74 48457 5.52 ↓ 
547 P68032 Actin, alpha 
cardiac muscle 1  
447 14 (8) 58 42334 5.23 ↓ 
562 P62736 Actin, aortic 
smooth muscle  
414 9 (8) 51 42381 5.23 ↓ 
706 P05388 60S acidic 
ribosomal protein 
P0  
95 4 (3) 30 34423 5.71 ↑ 
730 Q15181 Inorganic 
pyrophosphatase  
255 8 (7) 36 32639 5.54 ↑ 
795 O00299 Chloride 
intracellular 
channel protein 1  
149 7 (3) 54 27248 5.09 ↑ 
877 P04792 Heat shock 
protein beta-1  
127 4 (4) 56 22826 5.98 ↓ 
943 Q5W0H4 Tumour protein, 
translationally-
controlled 1  
249 9 (5) 52 21512 5.34 ↑ 
1010 P06748 Nucleophosmin  87 4 (2) 12 32555 4.64 ↑ 
1011 Q99627 COP9 
signalosome 
complex subunit 
8  
77 1 (1) 12 23211 5.25 ↑ 
1031 Q6IBG1 MYL9 protein  297 7 (7) 34 19836 4.94 ↓ 
1040 Q6IBG1 MYL9 protein 108 1 (1) 22 19894 4.94 ↓ 
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Table 4.17, continued. 
 
Spot 
No.a 
Accession 
No.b 
Protein Identityc Protein 
Score 
No. of 
Matched 
Peptidesd 
Sequence 
Coverage 
(%) 
Molecular 
Weight 
(Da)e 
Calculated 
pIe 
Trend of 
changes in 
protein 
expressionf 
1055 P15531 Nucleoside 
diphosphate 
kinase A  
82 2 (1) 60 17309 5.83 ↑ 
1095 B5BU83 Stathmin  229 6 (6) 38 17320 5.76 ↑ 
1146 G3V1V0 Myosin light 
polypeptide 6  
119 4 (3) 53 18311 4.68 ↓ 
1199 P06702 Protein S100-A9  62 3 (0) 52 13291 5.71 ↑ 
a Spot No. refers to the numbers assigned in Figure 4.16. 
b Accession No. provided in the LudwigNR database. 
c Chosen protein identity is of the Tax_Id = 9606 [Homo sapiens], and presented with the highest protein score and  
  emPAI value. 
d No. of matched peptides where Expect value < 0.05 and Ions Score indicates homology (No. of matched peptides where  
  Expect value < 0.05 and Ions Score indicates extensive homology or identity.   
e Theoretical value. 
f ↑ indicates over-expression, ↓ indicates under-expression.       
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5.1 Part A: SNPs Genotyping via Allelic Discrimination Assays 
Upon the completion of the Human Genome Project, our insight into human diseases 
has crossed the boundary of clinicopathological features, and deepened into a more 
complex molecular level (Caldecott, 2003; Venter et al., 2001).  Numerous endeavours 
were involved in studying the relationship between genetic variation and different 
aspects of diseases.  Genetic association studies were performed in an attempt to 
investigate the correlation between genetic variants and diseases, as well as identify 
potential disease susceptibility loci, especially in complex diseases, e.g., cancers 
(Lohmueller et al., 2003).  Of all, the case-control study is the most widely-used and 
simplest study design to determine the association between a genetic variant (exposure) 
and the disease risk (outcome).  It involves the direct comparison of allele / genotype 
frequency of the genetic polymorphism between cases (individuals diagnosed with 
disease) and controls (unaffected individuals) (Lewallen and Courtright, 1998; Lewis 
and Knight, 2012; Xue et al., 2011).  Generally, case-control studies are retrospective 
based and thus, are suitable for diseases with long latency periods, i.e., cancers.  Cohort 
studies on the other hand, are unfeasible (Schulz and Grimes, 2002). 
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5.1.1 Genotyping of the NOD2/CARD15 Variants 
Typically, the normal physiological inflammatory response is self-limiting, but in some 
circumstances, chronic inflammation will ensue if the initiating factors persist or the 
resolving mechanisms fail (Coussens and Werb, 2002; Macarthur et al., 2004).  As early 
as 1863, Virchow had hypothesised a correlation between inflammation and cancer.  
This hypothesis was proven later through our discovery of the inflammatory cells-rich 
microenvironment of the neoplasms, i.e., the presence of infiltrating leucocytes in both 
supporting stroma and malignant tissues (Balkwill and Mantovani, 2001).  In fact, the 
inflammatory-type response was found to be an early and persistent event that is 
responsible for cancer development and progression (de Visser et al., 2006).  The 
recruitment of various inflammatory cells (which subsequently produce a broad array of 
cytokines and chemokines) favours the growth and differentiation of tumour cells in 
early carcinogenesis.  Later in the neoplastic process, the inflammatory response and its 
byproducts also remodel the extracellular matrix, as well as promote angiogenesis and 
evade host defence mechanisms for the dissemination of tumour cells (Coussens and 
Werb, 2002; Jackson et al., 1997; Jaiswal et al., 2000; Nakajima et al., 1997; Orlando, 
2002).  The prominent examples for the connection between chronic inflammatory 
condition and human malignancy are: human papillomavirus infection and cervical 
cancer; hepatitis B infection and hepatocellular carcinoma; H. pylori-induced gastritis 
and gastric cancer; IBDs and colorectal cancer, and etc. (Parkin et al., 1999). 
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The insult of the epithelial barrier in the gastrointestinal system results in direct 
exposure of the intestinal microflora to host immune system.  Subsequently, the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity is triggered and 
pro-inflammatory molecules are released (Figure 5.1). 
 
 
Figure 5.1: The role of activated NF-κB in tumour growth and progression (Adapted 
from: Karin and Greten, 2005). 
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In the milieu of chronic inflammation, the disrupted mucosal barrier and concomitant 
immune hyperactivity are thought to model the permissive microenvironment for the 
neoplastic transformation of colonic epithelial cells.  On the other hand, the constitutive 
activation of NF-κB also confers survival to the transformed epithelial cells through 
activated Toll-like receptors (TLRs) in a cell-autonomous manner (Beutler, 2004; 
Cheon et al., 2002; Clevers, 2004; Seril et al., 2003) (Figure 5.1).  In brief, the NF-κB 
acts as an omnipresent transcription factor that regulates a wide assortment of genes 
involved in inflammation, apoptosis, cell proliferation, oncogenesis, etc. (Gupta et al., 
2010; Macarthur et al., 2004) (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Molecular targets of the activated NF-κB and their roles in carcinogenesis 
(Chart generated according to Baud and Karin, 2009). 
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Often, the histology of the CRC precursor lesions exhibits a certain degree of 
inflammatory features (Higaki et al., 1999).  Chronic inflammation paves the way for 
CRC oncogenesis by enhancing epithelial cells turnover, inducing DNA damage, 
facilitating genomic instability and stimulating persistent cell proliferation (Coussens 
and Werb, 2002).  In reality, an estimated 1 – 2 % of the total CRC incidences were 
developed on the background of chronic IBDs.  These IBD-related CRCs were reported 
in up to 15 % of the IBDs patients and attributed for nearly 1 in 6 deaths among them.  
Therefore, it is considered as a serious sequela in IBD patients despite its low 
proportion in the global CRC burden (Bernstein et al., 2001; Eaden et al., 2001; 
Munkholm, 2003).  Notably, the clinical features of this colitis-associated CRC are 
distinguishable from sporadic CRC, e.g., younger age at diagnosis, more proximal 
tumours and higher proportion of mucinous or signet ring cell adenocarcinoma.  In 
addition, it also follows a distinctive histological sequence, i.e., the inflammation-
dysplasia-carcinoma pathway, instead of the classical adenoma-carcinoma model of 
sporadic CRC.  Nonetheless, both disease entities share similarities in the molecular 
pathogenesis of CRC (Balkwill and Mantovani, 2001; Itzkowitz and Yio, 2004; Rhodes 
and Campbell, 2002; Seril et al., 2003; Xie and Itzkowitz, 2008). 
Owing to the pronounced relationship between IBDs and CRC, it was thus proposed 
that the predisposing genes of IBDs might also influence the risk of developing CRC.  
The NOD2/CARD15 gene is the most prominent and well-defined candidate in the 
genetic predisposition of IBDs (Hugot et al., 2001).  The NOD2/CARD15 gene is 
located on chromosome 16q12 and encodes for the NOD2 protein of 1040 amino acids, 
a member of the Apaf-1/Nod1 superfamily.  Structurally, the NOD2 protein is tripartite 
and consisted of two N-terminal caspase recruitment domains (CARDs), a central 
nucleotide-binding domain (NBD), and a C-terminal regulatory domain of ten tandem 
leucine-rich repeats (LRRs) (Ogura et al., 2001).  Generally, this intracellular protein is 
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mainly expressed in the monocytes, macrophages and granulocytes, as well as other cell 
types, e.g., Paneth cells and epithelial cells (Gutierrez et al., 2002; Ogura et al., 2003; 
Uehara et al., 2007).  Its expression in the intestinal epithelial cells plays an integral role 
in guarding against the luminal bacteria via mucosal innate immune response 
(Hisamatsu et al., 2003).  In innate immunity, the LRR domain of the NOD2 protein 
recognises its ligand, the muramyl-dipeptide (MDP) of the peptidoglycans in bacterial 
cell wall, and leads to the activation of NF-κB (Inohara and Nunez, 2001; Naohiro et al., 
2005; Ogura et al., 2001) (Figure 5.3). 
 
 
Figure 5.3: The recognisation of the MDP by NOD2 protein and downstream activation 
of the NF-κB in innate immunity (Adapted from: Shaw et al., 2011). 
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In our study, the mutant alleles of the Arg702Trp, Gly908Arg and 3020insC variants 
were absent among the Malaysians, while those of the Pro268Ser and JW1 variants 
were reported in low frequencies.  Remarkably, the observed genetic distribution 
patterns were similar to a previous study on CD and NOD2/CARD15 variants of the 
same cohort (Chua et al., 2009).  Earlier observations had revealed the existence of 
ethnic heterogeneity in the genetic distribution of the Arg702Trp, Gly908Arg and 
3020insC variants.  The mutant allele frequencies of these three major NOD2/CARD15 
variants were notably different between the Caucasians and Asians (Esters et al., 2004).  
For instance, the mutant alleles of these variants were scored among the Greeks, 
Hungarians, Poles, Germans and Finns, but not reported in the Japanese, Indian, 
Chinese and Korean populations (Alhopuro et al., 2004; Gao et al., 2005; Inoue et al., 
2002; Lakatos et al., 2007; Lee et al., 2005; Mockelmann et al., 2009; Papaconstantinou 
et al., 2005; Pugazhendhi et al., 2008; Szeliga et al., 2008).  Our findings were in 
concordance with other Asian cohorts as these three genetic variants were also absent in 
our Malaysian samples.    
Numerous studies were performed to unravel the association between NOD2/CARD15 
variants and CRC susceptibility.  Yet, the findings obtained thus far are still 
controversial.  Among them, the 3020insC variant is the most extensively studied owing 
to its functional relevance on the intact NOD2 protein.  It is proposed that this single 
base insertion results in a premature stop codon that truncates the LRR domain of the 
NOD2 protein (Ogura et al., 2001a).  As a consequence, the loss of NOD2 function will 
lead to an excessive NF-κB activation in the adaptive immune system, which might then 
initiate the inflammation-dysplasia-carcinoma process in the colorectal oncogenesis 
(Angeletti et al., 2009; Vermeire et al., 2002).  The correlation between the 3020insC 
variant and CRC susceptibility among patients older than 50 years has been replicated 
in several studies (Kurzawski et al., 2004; Lubinski et al., 2005; Suchy et al., 2008).  
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The same association, however, was not observed in Finnish, New Zealand, Hungarian, 
German and Polish CRC patient studies (Alhopuro et al., 2004; Lakatos et al., 2007; 
Mockelmann et al., 2009; Roberts et al., 2006; Szeliga et al., 2008). 
Our study demonstrated that both genotype and allele frequencies of the Arg702Trp, 
Gly908Arg, 3020insC, Pro268Ser and JW1 variants were not significantly different 
between CRC patients and healthy controls.  Hence, we failed to establish any 
relationship between NOD2/CARD15 variants and cancer susceptibility in our 
Malaysian CRC patients.  Likewise, the Arg702Trp and Gly908Arg variants were also 
not associated to CRC susceptibility among the Hungarians, Polish, Germans and Finns 
(Lakatos et al., 2007; Mockelmann et al., 2009; Szeliga et al., 2008; Tuupanen et al., 
2007).  On the contrary, Papaconstantinou and his group had successfully demonstrated 
the correlation between all three major NOD2/CARD15 variants and CRC risk in the 
Greek population (Papaconstantinou et al., 2005).  As for the Pro268Ser and JW1 
variants, the investigation into their relationship to the risk of getting CRC is relatively 
scarce compared to the other three major NOD2/CARD15 variants (Kutikhin, 2011; 
Tian et al., 2010).  Szeliga and his group had reported an increased risk of getting rectal 
cancer with the allele T of Pro268Ser in the Polish patients, but no association was 
observed among the New Zealanders (Roberts et al., 2006; Szeliga et al., 2008). 
On the whole, the great discrepancy in these association findings is mainly contributed 
by the ethnic heterogeneity in the genetic distribution of the NOD2/CARD15 variants.  
Typically, these variants are rare or completely absent in the northern European and 
Asian countries.  Hence, the rarity of these variants is thought to deter the assessment of 
their impacts on CRC risk in our population.  In addition, the presence of varying 
confounding factors in different population background might also, to a certain extent, 
lead to the conflicting results obtained (Tian et al., 2010). 
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5.1.2 Genotyping of the Common GWAS-identified CRC-associated Variants 
The first-degree relatives of CRC cases have a two-fold increased risk compared to the 
general average population (Butterworth et al., 2006).  Twin studies had revealed that 
the genetic components underlie the familial clustering of CRC, and contribute to about 
30 % of the total CRC burden (Lichtenstein et al., 2000).  In fact, familial risk in known 
hereditary CRC syndromes can be explained by rare, high-penetrance genetic variants, 
e.g., APC gene in FAP and DNA mismatch repair genes in HNPCC.  Nonetheless, these 
identified genetic variants confer risk to only < 5 % of the total CRC incidences, while 
other common, low-penetrance variants are postulated to be responsible for the 
remaining familial risk (Aaltonen et al., 2007).  The “common disease, common variant” 
paradigm in CRC carcinogenesis suggests that an appreciable amount of common 
genetic variants (minor allele frequency (MAF) > 0.05), each with minor effects on 
CRC risk, has constituted a significant fraction of the overall sporadic CRC burden 
(Tenesa and Dunlop, 2009).  Predominantly, the investigations on the genetic 
predisposition of CRC were based on the candidate gene approach in focusing on SNPs 
within the candidate genes or pathways that might be essential for CRC oncogenesis 
(Dong et al., 2008).  However, this method may be rather impractical because of the 
need to explore the millions of SNPs that are present in our human genome.   
With the advent in SNP genotyping approaches and platforms, GWAS had recently 
emerged as a high-throughput and robust method in identifying the common, low-
penetrance CRC susceptibility loci, as it allows scanning of the whole genome without 
prior knowledge on any candidate genes or pathways (Easton and Eeles, 2008).  To date, 
GWAS have successfully identified 14 novel independent CRC susceptibility loci 
mapped to chromosomal regions of 8q24, 8q23, 11q23, 15q13, 18q21, 10p14, 14q22, 
16q22, 19q13, 20p12, 1q41, 3q26, 12q13 and 20q13.  These common variants exert 
only a modest risk on the development and progression of CRC (OR < 1.2) (Broderick 
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et al., 2007; Houlston et al., 2010; Houlston et al., 2008; Jaeger et al., 2008; Tenesa et 
al., 2008; Tomlinson et al., 2008; Zanke et al., 2007).  Most of these regions were 
destitute of known coding sequences and transcriptional activities, and hence, their 
biological significance on CRC oncogenesis remains to be elucidated.  It was then 
postulated that these common variants might affect CRC tumourigenesis by interacting 
with other critical CRC-related genes / pathways (Goel and Boland, 2010; Hoskins et al., 
2012; Tokuoka et al., 2009).  
In the present study, we failed to demonstrate any association between loci 8q24, 8q23, 
11q23 and 15q13, and disease susceptibility in the Malaysian CRC patients.  However, 
the relationship between rs4939827 mapped to chromosome 18q21 and CRC risk was 
established herein.  The individuals with CC genotype might be protected from the 
development of CRC, with the reported p value of 0.0253 and OR of 0.5936 (95 % CI = 
0.3803-0.9267).  This observation was parallel to those previously reported where there 
was an inverse association between the allele C of rs4939827 and CRC (Broderick et al., 
2007; Slattery et al., 2010; von Holst et al., 2010).  On the other hand, the allele T was 
associated to an increased risk of CRC in other replication studies (Ho et al., 2011; 
Tenesa et al., 2008; Xiong et al., 2010).  The association between this common variant 
and CRC predisposition was not, however, reported in several other studies (Curtin et 
al., 2009; Li et al., 2011; Thompson et al., 2009).  Meanwhile, the observed frequencies 
for rs4939827 in our population were comparable to those among Han Chinese, where 
the major allele is allele C instead of allele T in the Western populations (Li et al., 2011; 
Xiong et al., 2010). 
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With the exception of rs6983267, the rs4939827 SNP was the most top-ranking CRC 
risk locus in previous GWAS (Broderick et al., 2007; Song et al., 2012).  This 
rs4939827 SNP was mapped to the LD block within the intron 3 of the mothers against 
decapentaplegic homolog 7 (SMAD7) gene, but its functional implications on SMAD7 
gene and CRC progression still remains elusive (Broderick et al., 2007; Tokuoka et al., 
2009).  SMAD7 is an intracellular antagonist that negatively regulates the transforming 
growth factor-beta (TGF-β) signaling cascade in human (Figure 5.4).  In oncogenesis, 
the TGF-β pathway exerts tumour suppressor effects at pre-neoplastic stage but displays 
its pro-oncogenic properties later in tumour development (Blobe et al., 2000; Glick, 
2004; Roberts and Wakefield, 2003; Siegel and Massague, 2003).  It was well-
established that the aberrant expression of SMAD7 is crucial in CRC progression owing 
to its roles in modulating both TGF-β and Wnt signaling pathways (Boulay et al., 2003; 
ten Dijke and Hill, 2004; Levy and Hill, 2006).  The SMAD7 overexpression is 
correlated to the perturbation of TGF-β-induced growth inhibition and apoptosis, which 
consequently favours the development and progression of CRC tumours (Broderick et 
al., 2007; ten Dijke and Hill, 2004; Mochizuki et al., 2004). 
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Figure 5.4: TGF-β signaling pathway and antagonistic role of SMAD7 (Adapted from: 
Yang, 2010). 
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The failure to replicate the associations between common variants rs6983267, 
rs4779584, rs16892766 and rs3802842, and CRC susceptibility in our present study 
may be due to the diverse allele frequencies of the variants, differences in CRC 
prevalence, other confounding risk factors for CRC, as well as different impacts of 
genetic variation on CRC risk under different population backgrounds (Ioannidis, 2007; 
Lubbe et al., 2012; Picelli et al., 2009).  On the other hand, the discrepancy in the 
direction of association for rs4939827 and CRC risk could be due to genetic 
heterogeneity and possible gene-environment interactions in different ethnicities / 
populations (Center et al., 2009; Jakobsson et al., 2008; Sebastiani et al., 2009). 
Owing to the relatively modest individual effects of these CRC risk loci, they are 
postulated to interact with other common alleles for a more profound impact on CRC 
susceptibility.  Thus, continuous efforts are needed to search for more CRC 
susceptibility loci as the multi-locus model holds promise for more effective risk 
prediction and stratification, e.g., 80 % accuracy in CRC risk prediction with a multi-
locus model of ~100 SNPs, in order to identify high-risk subgroups for regular 
colonoscopic surveillance (Tenesa and Dunlop, 2009). 
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5.1.3 Genotyping of the Low-penetrance Genes 
The genetic predisposition of non-hereditary sporadic CRC is attributed to the 
combination of a set of low-penetrance genes, which each confers a relatively small 
genotypic risk in modulating the individual’s susceptibility to CRC; as opposed to 
single gene mutation or a few high-penetrance genes (Houlston and Peto, 2004; 
Houlston and Tomlinson, 2000; Imyanitov et al., 2004; Kotnis et al., 2005; Pharoah et 
al., 2004).  According to Knudson, the heritable predisposition to cancer is 
unambiguous, while the interaction between the low-penetrance susceptibility variants 
and environmental risk factors is of relevance in triggering sporadic CRC (de la 
Chapelle, 2004; Knudson, 2002).  Since it has been proven that both nature and nurture 
underlie the cancer predisposition of an individual, growing attention has been devoted 
to investigate the cancer-genotype associations of low-penetrance genetic variants in 
many human malignancies. 
5.1.3.1 XRCC1 Variants 
Our body is constantly exposed to endogenous (e.g., methylation, hydroxylation and 
oxidation processes) and exogenous factors (e.g., ionizing radiation and environmental 
toxins) that induce damages to our genomic DNA.  The DNA repair machinery is 
targeted to correct any erroneous DNA lesion(s) in order to maintain the integrity and 
stability of the human genome (Fleck and Nielsen, 2004; Friedberg, 2008).  There are 
several important DNA repair pathways that function in rectifying different types of 
DNA damage, i.e., nucleotide excision repair (NER), mismatch repair (MMR), double-
strand break repair (DSBR) and base excision repair (BER) pathways (Naccarati et al., 
2007).  The BER pathway is responsible in repairing small DNA lesions, e.g., oxidised 
or reduced bases, and non-bulky adducts, resulting from oxidation, deamination, 
alkylation and methylation processes (Naccarati et al., 2007; Wilson and Bohr, 2007). 
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Since the maintenance of genome integrity is crucial for the general and specialised 
functions of cells, any anomaly in the DNA repair mechanisms or abnormality of the 
participating components can lead to deleterious consequences, e.g., cancers 
(Hoeijmakers, 2001; Kaina, 2003).  The inherited defects in the DNA repair pathways 
will modulate the individual’s DNA repair capacity, which might in turn determine the 
individual susceptibility to cancer development (Friedberg, 2003).  Numerous evidences 
have addressed the relevance of DNA repair capacity in triggering human malignancies 
(Tomlinson et al., 2012).  It has been reported the individuals with DNA repair capacity 
of about 65 – 80 % are more frequently associated to the cancer cohort in a general 
population (Grossman, 1997).   
Previous studies have also demonstrated that inter-individual polymorphic variations in 
the BER genes will confer inter-individual variation in DNA repair capacity.  This will 
hence affect inter-individual differences in cancer risk, prognosis, as well as response to 
cancer therapy (Berwick and Vineis, 2005; Gossage et al., 2012).  Hence, tremendous 
efforts have been focused on analyzing the influence of the low-penetrant BER gene, 
i.e., the X-ray repair cross complementation group 1 (XRCC1) gene, on DNA repair 
capacity and cancer predisposition.  The encoded XRCC1 protein (one of the accessory 
scaffold proteins), plays key mechanistic roles in the BER machinery through 
interactions with other BER components, e.g., DNA ligase III, DNA polymerase β, 
PARP, polynucleotide kinase and AP endonuclease I (Figure 5.5) (Caldecott et al., 1994; 
Fortini and Dogliotti, 2007; Gryk et al., 2002; Vidal et al., 2001; Whitehouse et al., 
2001).  Evidences have shown that XRCC1 deficiency will evoke mutagenesis and the 
embryonic knock-out of this protein is lethal (Thompson and West, 2000). 
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Figure 5.5: Role of XRCC1 in the BER pathway (Adapted from: Caldecott, 2003). 
 
Given these facts, the coding polymorphisms of the XRCC1 gene in exons 6, 9 and 10 
have been widely investigated in cancer research, i.e., Arg194Trp (rs1799782, C/T), 
Arg280His (rs25489, G/A) and Arg399Gln (rs25487, G/A), respectively (Mohrenweiser 
et al., 1989; Shen et al., 1998).  Among these three biologically plausible XRCC1 
variants, the Arg194Trp and Arg399Gln have been more extensively studied for their 
association to cancer susceptibility (Abdel-Rahman and El-Zein, 2000; Lunn et al., 
1999).  For the Arg194Trp variant, the 194Trp/Trp genotype was found to confer a 
perceptible increased risk of lung and gastric cancers, while Goode and his group had 
contradictorily reported a decreased risk of cancer with the 194Trp allele (Chen et al., 
Damaged DNA base 
is removed by DNA 
glycosylase, and 
displaced from the 
abasic site by APE1. 
APE1 recruits Polβ 
and cleaves the abasic 
site.  
Polβ inserts a single 
nucleotide and repairs 
the 5’-deoxyribose 
phosphate terminus 
created by APE1. 
 Results in a ligatable 
nick which is sealed 
by the recruitment of 
XRCC1-Lig3α. 
 
Chapter Five – Discussion 
206 
 
2012; Goode et al., 2002; Jiang et al., 2010; Wen et al., 2012).  Meanwhile, several 
other studies have failed to demonstrate any significant association between the codon 
194 polymorphism and CRC susceptibility in different populations (Gsur et al., 2011; 
Hong et al., 2005; Jiang et al., 2010a; Muniz-Mendoza et al., 2012; Pardini et al., 2008; 
Skjelbred et al., 2006; Sliwinski et al., 2008).  
Likewise, contradictory findings were also described for the relationship between the 
Arg399Gln variant and cancer susceptibility.  In gliomas, as well as colorectal, 
pancreatic and endometrial cancers, the increased risk of disease development was 
associated with carriers of the 399Gln allele (Abdel-Rahman et al., 2000; Cincin et al., 
2012; Hong et al., 2005; Jelonek et al., 2010; Nakao et al., 2012; Wang et al., 2012; 
Zeng et al., 2013).  Through a meta-analysis, it was shown that increased CRC risk was 
correlated with the Arg399Gln polymorphism in Asians, instead of Caucasians (Zeng et 
al., 2013).  Most the cancer studies however, failed to link the codon 399 polymorphism 
conferring susceptibility to CRC, as well as other cancer entities, i.e., gastric and liver 
cancers (Gsur et al., 2011; Li et al., 2013; Liu et al., 2011; Muniz-Mendoza et al., 2012; 
Nissar et al., 2013; Pardini et al., 2008; Sliwinski et al., 2008; Xue et al., 2011). 
To date, the 280His allele of the Arg280His variant has been significantly correlated to 
a higher risk of lung cancer, but not colorectal and gastric cancers (Hong et al., 2005; 
Ratnasinghe et al., 2001; Xue et al., 2011).  In our present case-control study, none of 
the XRCC1 genetic variants was significantly associated to CRC susceptibility in our 
Malaysian population.  This was further supported by a few recent meta-analyses 
showing that these three major XRCC1 coding polymorphisms do not confer genetic 
predisposition of CRC (Liu et al., 2013; Mao et al., 2013; Wang et al., 2010).  Thus far, 
the investigations on the relationship between the XRCC1 genetic variants and CRC 
susceptibility have been conflicting and inconclusive.  These discrepancies can be 
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unfolded by the variation in ethnic origins and confounding factors in different 
population backgrounds (Skjelbred et al., 2006). 
5.1.3.2 EGF +61 A>G (rs4444903) 
In humans, the EGF/EGFR (epidermal growth factor receptor) signaling cascade is 
involved in several crucial cellular processes, i.e., proliferation, migration, 
differentiation and apoptosis, via the activation of various transcription factors through 
intracellular mitogen-activated protein kinase (MAPK) and phosphatidyl inositol 3-
kinase- (PI3K-) protein kinase B (AKT) pathways.  Physiologically, the ligand binding 
of EGFR activates its intrinsic tyrosine kinase domains, which in turn leads to the 
autophosphorylation and activation of the downstream intracellular signal transduction 
pathways (Figure 5.6).  In view of its roles in key cellular events, the EGFR signaling 
pathway is tightly-regulated at the receptor level, as well as via both positive and 
negative feedback loops under normal circumstances (Citri and Yarden, 2006). 
Evidently, the deregulation of growth signaling is one of the hallmarks of cancer cells 
(Hanahan and Weinberg, 2000).  The aberrant regulation or any gene mutation, 
amplification and over-expression of any component within the EGFR cascade 
contributes to the malignant phenotypes of the tumour cells and leads to neoplastic 
transformation (Figure 5.6) (Citri and Yarden, 2006; Mitsudomi and Yatabe, 2010; 
Normanno et al., 2006).  During oncogenesis, the EGF/EGFR interaction is thought to 
act in both the autocrine and paracrine manner within the tumour microenvironment (De 
Luca et al., 2008).  In fact, the expression of EGFR is known to correlate with a variety 
of human malignancies, e.g., gliomas, cancers of the lung, colon, head and neck, 
pancreas, breast, etc. (Krasinskas, 2011). 
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Figure 5.6: EGF/EGFR signaling cascade and its roles in oncogenesis (Adapted from: 
Brambilla and Gazdar, 2009). 
 
Of all, the EGF is the most important natural ligand for EGFR and essential for the 
survival, proliferation, differentiation and tumourigenesis of the human epithelial cells 
(Groenen et al., 1994; Lanuti et al., 2008; Yarden and Schlessinger, 1987).  The EGF 
was first described by Cohen in 1962 but its ability to stimulate the growth of cultured 
cells was only discovered ten years later (Carpenter and Cohen, 1976; Cohen, 1962).  
The EGF gene is located on chromosome 4q25-27 and encodes for a 6 kDa protein of 
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53 amino acids.  This encoded product is a potent mitogenic peptide that exerts effects 
on the DNA synthesis and cell proliferation in epidermal tissues (Boguski and 
McCormick, 1993; Laurence and Gusterson, 1990; Salomon et al., 1995; Taylor et al., 
1972).  Since EGF is one of the key components in the EGFR signaling pathway, the 
genetic variants within the EGF gene are postulated to impact the susceptibility and 
severity of cancers, as well as the prognosis and response to treatment of the cancer 
patients. 
In our study, we focused on the only EGF SNP in which the functional impact had been 
described thus far, i.e., the EGF +61 A>G transition in the 5’-untranslated region.  This 
polymorphism has been shown to modulate the EGF gene transcription and 
consequently, alter the serum EGF level (Araújo et al., 2007).  For example, the 
homozygous A genotype was demonstrated with a significantly lower EGF level in 
cultured peripheral-blood mononuclear cells (Shahbazi et al., 2002).  Hence, this EGF 
variant in the promoter region may be responsible for inter-individual differences in 
cancer susceptibility and outcome.  The EGF +61 A>G polymorphism has been 
demonstrated to associate with either the disease susceptibility, severity, outcome or 
patients’ survival in gastric, cervical, lung, colorectal and esophageal cancers, as well as 
in melanomas and glioblastomas (Bhowmick et al., 2004; Jin et al., 2007; Kang et al., 
2007; Lanuti et al., 2008; Lim et al., 2005; Shahbazi et al., 2002; Spindler et al., 2007). 
A study in Caucasians had revealed a significant increased in CRC susceptibility among 
individuals carrying homozygous G genotypes (Wu et al., 2009).  In addition, the 
homozygosity of the allele G was also significantly correlated to the development of 
melanoma and gallbladder cancer (Shahbazi et al., 2002; Vishnoi et al., 2008).  
Evidences have shown that the minor allele G and its homozygous genotype are 
associated with a higher EGF production.  This higher serum level of EGF might then 
favour the development of cancer and increase the cancer risk (Araújo et al., 2007; 
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Bhowmick et al., 2004; Lanuti et al., 2008; Shahbazi et al., 2002).  Nevertheless, our 
current study did not show any significant difference in either the genotype distribution 
or allele frequencies of the EGF +61 A>G variant between CRC patients and healthy 
controls.  This is consistent with similar results in Chinese and Iranian CRC patients 
(Daraei et al., 2012; Yu and Weng, 2011).  To date, the research on the relationship 
between EGF +61 A>G polymorphism and CRC risk is still scarce.   
Through a meta-analysis on the association between EGF +61 A>G polymorphism and 
cancer risk, the carriage of allele A was proposed as a protective factor in cancer 
development.  Remarkably, this association is ethnic-specific, i.e., more pronounced 
among the Asians and Americans, compared to the Caucasians.  It is also cancer-
specific where similar associations were only reported in the gastric and esophageal 
cancers, hepatomas and gliomas, but not in other cancer entities (Xu et al., 2010).  In 
reality, the genetic distribution of the EGF +61 A>G polymorphism shows ethnic-
specificity in which the allele G is more frequent in Asians than Europeans.  The 
homozygous G genotype is relatively more common in non-Caucasians, i.e., Japanese 
(47.8 %), Han Chinese (47.6 %) and Korean (51.5 %) (Goto et al., 2005; Jin et al., 2007; 
Kang et al., 2007).  Likewise, G homozygotes were most commonly scored in our 
Malaysian samples.  Hence, the discrepancy in existing association findings might be 
attributed to the genetic diversity of the EGF +61 A>G in different ethnicities and 
diverse carcinogenic mechanisms of different cancer entities.  
5.1.3.3 VEGF +936 C>T (rs3025039) 
The generation of new blood vessels via either angiogenesis or vasculogenesis is one of 
the critical steps in neoplastic progression (Witsch et al., 2010).  Initially, the increased 
proliferation rate and evasion from apoptosis will lead to early hyperplastic growth.  
Subsequently, tumour vascularisation is crucial for the transition from the small 
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localised avascular masses to highly vascularised neoplastic outgrowth (Baeriswyl and 
Christofori, 2009).  New blood vessels are formed in order to supply metabolic demands, 
e.g., oxygen and nutrients, for tumour growth, as well as provide routes for further 
dissemination of tumour cells (Baeriswyl and Christofori, 2009; Ferrara and Davis-
Smyth, 1997).  In fact, both vasculogenesis and angiogenesis are essential in embryonic 
development, but remain quiescence most of the time later in adulthood.  Nonetheless, 
angiogenesis is retained and reactivated under certain circumstances, i.e., during wound 
healing, in the cycling ovary and placenta during pregnancy, as well as certain 
inflammatory and malignant disorders (Carmeliet, 2003).   
The angiogenic switch, which is elicited when the fine-tuned balance between various 
angiogenic promoters and inhibitors is tilted, is an intrinsic event within the tumour 
microenvironment.  The tilted equilibrium towards pro-angiogenic activities results in 
the migration and proliferation of endothelial cells, capillary morphogenesis, as well as 
increased vascular permeability (Bergers and Benjamin, 2003; Ribatti et al., 2007).  
Generally, the expression of pro-angiogenic factors is stimulated by hypoxia, reactive 
oxygen species, cellular acidosis, the activation of oncogenes and loss of function of 
tumour suppressor genes (Arbiser et al., 1997; North et al., 2005; Pugh and Ratcliffe, 
2003; Ravi et al., 2000).  Within the tumour microenvironment, both tumour cells and 
tumour-infiltrating inflammatory cells secrete and regulate the ultimate ratio of pro- and 
anti-angiogenic factors that favours the angiogenic process.  In a plethora of stromal 
cells, the tumour-associated macrophages (TAMs) are one of the central components in 
regulating angiogenesis through a paracrine fashion.  Initially, the tumour cells secrete 
chemo-attractants for the recruitment of TAMs into tumour microenvironment, while 
these TAMs are then in turn, responsible for tumour progression via the secretion of 
pro-angiogenic factors, including VEGF (Carmeliet and Jain, 2000; Pollard, 2004; 
Veikkola and Alitalo, 1999; Zumsteg and Christofori, 2009). 
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In the milieu of oncogenesis, the roles of growth factors are not merely related to clonal 
expansion, but are also in the invasion and metastasis of the neoplasms.  The VEGF, 
which binds to its bona fide vascular endothelial growth factor receptor (VEGFR) on 
the endothelial cells of blood vessels, is the most potent direct-acting pro-angiogenic 
factor in humans.  It is a pivotal driver in both physiological and pathological 
angiogenesis owing to its functional specificity on vascular endothelial cells (Figure 
5.7).   
 
 
Figure 5.7: VEGF signaling pathway (Adapted from: Li and Harris, 2009). 
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Evidences have shown that the VEGF is mitogenic to the endothelial cells and capable 
to increase vascular permeability (Alitalo et al., 2005; Connolly et al., 1989; Ferrara et 
al., 2003; Ferrara and Davis-Smyth, 1997).  The VEGF signaling exerts both autocrine 
and paracrine stimulatory effects on tumour-associated angiogenesis (Figure 5.8) 
(Lichtenberger et al., 2010; McMahon, 2000).  Hypoxia is the main stimulus for VEGF 
production and additionally, the overexpression of various oncogenes, e.g., Ras, is also 
responsible for the overexpression of VEGF in tumours of epithelial origin (Bergers and 
Benjamin, 2003; Minchenko et al., 1994; Shweiki et al., 1992). 
 
 
Figure 5.8: Autocrine and paracrine stimulation of VEGF on tumour angiogenesis 
(Adapted from: McMahon, 2000). 
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VEGF and its cognate receptor are well-recognised in the angiogenic process of solid 
tumours, i.e., breast, colon, bladder, gastric, lung and prostate cancers (Balbay et al., 
1999; Droller, 1998; Kitamura et al., 1998; Kurebayashi et al., 1999; Shaheen et al., 
1999; Toi et al., 2001).  Within the classical adenoma-carcinoma model of CRC, VEGF 
is thought to initiate and sustain angiogenesis throughout the neoplastic transformation 
as it is overexpressed in both adenomas and carcinomas (Hanrahan et al., 2003).  
Consistent with this notion, the VEGF overexpression is associated with increased 
tumour size, formation of metastasis, tumour vascularity, as well as poor prognosis in 
CRC patients (Baker et al., 2000; Guba et al., 2004; Hanrahan et al., 2003; Kang et al., 
1997; Maeda et al., 2000; Tokunaga et al., 1998).  Clinically, the anti-angiogenic 
treatment through the inhibition of VEGF signaling via VEGF antagonists has been 
proven to suppress the angiogenesis and growth of tumours in cancer management 
(Figure 5.9) (Ferrara, 2002; Jain, 2005). 
 
Figure 5.9: Examples of anti-angiogenic agent in cancer therapy (Adapted from: Chau 
and Figg, 2012). 
Binds to all isoforms 
of VEGF-A 
Targets all isoforms of 
VEGF-A, VEGF-B & PIGF  
Binds to the extracellular 
domain of VEGFR-2 
Binds to the extracellular 
domain of VEGFR-1 
Targets the intrinsic tyrosine 
kinase activity & inhibits     
ligand-dependent receptor     
auto-phosphorylation of VEGFRs  
Chapter Five – Discussion 
215 
 
The human VEGF gene, which consists of eight exons and seven introns, is located on 
chromosome 6p21.3.  An estimation of 30 SNPs have been described in previous 
published studies and among them, the functional SNP VEGF +936 C>T in the 3’-
untranslated region is of particular remark (Chae et al., 2006; Dassoulas et al., 2009; 
Vincenti et al., 1996; Watson et al., 2000; Xu et al., 2010a).  A significantly lower 
circulating VEGF plasma level was demonstrated with the VEGF +936 C>T transition 
owing to the loss of the potential binding site for transcription factor AP-4 (Renner et al., 
2000).  Hence, this functional relevance on VEGF production has driven interests in 
studying the relationship between this polymorphism and cancer susceptibility. 
Our results show that the VEGF +936 C>T variant is not associated with disease 
susceptibility in Malaysian CRC patients.  This observation is in parallel with those 
previously reported among the Caucasians and Greeks (Dassoulas et al., 2009; Hofmann 
et al., 2008; Wu et al., 2009).  However, the TT genotype of this functional 
polymorphism is correlated with other adverse clinicopathological features of CRC, i.e., 
more advanced stage and higher histologic grade of tumours, higher CA19-9 serum 
level, as well as distant metastasis (Chae et al., 2008).  Moreover, the TT genotype 
carriers have also reported worse overall survival rates among Greek and Korean CRC 
patients (Dassoulas et al., 2009; Kim et al., 2008).  As for other cancer entities, the 
allele T was associated with an increased risk of gastric and oral cancers, but an inverse 
association was reported for breast cancer (Bae et al., 2008; Kataoka et al., 2006; Krippl 
et al., 2003; Xu et al., 2010a; Yapijakis et al., 2007).  Other researchers were unable to 
demonstrate any relationship between the VEGF +936 C>T polymorphism and genetic 
predisposition of cancer (Balasubramanian et al., 2002; Lee et al., 2005a). 
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According to a recent meta-analysis, the allele T was proposed to exert an augmentative 
effect on cancer risk among the Asians and Europeans, but not in the Africans (Xu et al., 
2010a).  The great discrepancy in the impacts of VEGF genetic variants on cancers 
might be grounded on a few basis - first, the VEGF signaling pathway is a complex 
network that involves ‘cross-talk’ between various molecules, instead of the VEGF 
alone.  Second, the differences in genetic backgrounds, gene-environment interactions 
and confounding risk factors within different study populations might contribute to the 
contradictory findings.  Third, the studied SNP might be in linkage disequilibrium with 
other SNPs in the VEGF or other genes that are not yet identified (Hofmann et al., 2008; 
Jain et al., 2009). 
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5.2 Part B: Differential Transcriptome Analysis 
In the preliminary phase of the present study, a total of thirteen over-expressed and 
three under-expressed genes were successfully identified in CRC tumours, in 
comparison to normal colonic mucosa samples.  These observed differential expression 
patterns were further examined for their consistencies in another cohort of primary CRC 
tumours, which were stratified according to the CRC stage and tumour site, i.e., early- 
and advanced stage CRC groups; right- and left-sided CRC tumours.  Only four out of 
the sixteen DEGs reached statistical significance for each early- and advanced stage 
CRC group.  The early stage CRC tumours were characterised with the down-regulation 
of ARPC2, and up-regulation of RPL35, RPS23 and TIMP1.  On the other hand, the 
over-expressed C6orf173, RPL35, RPS23 and TIMP1 genes were features of advanced 
stage CRC neoplasms.  Based on the tumour site stratifications, the significant over-
expression of C6orf173, RPL35 and TIMP1 genes was reported in both right- and left-
sided primary CRC tumours, but with an addition of RPS23 gene in the left-sided 
neoplasms.  These distinctive patterns of mRNA expression levels reflect the molecular 
differences in tumour biology between different stages of CRC progression and between 
different sites of primary CRC tumours (Gervaz et al., 2001). 
In the following sections, we discuss the relevance of identified DEGs in the 
development and progression of CRC.  These identified small gene expression 
signatures comprise of genes that are statistically significant, as well as biologically 
related and clinically important to oncogenesis.    
5.2.1 RPL35 and RPS23 
Ribosome biogenesis is precisely coordinated with the cell cycle machinery under 
normal physiological condition (Pyronnet and Sonenberg, 2001).  Ribosome production 
and protein synthesis are proportionately associated with cellular growth and 
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proliferation as a response to the increased metabolic demands in the proliferating cells 
(Pyronnet and Sonenberg, 2001).  In ribosome biogenesis, the ribosomal proteins serve 
as RNA chaperones, guide the assembly of the ribosomal components, stabilise the 
domains within the rRNAs, as well as coordinate the interaction between different 
translational apparatuses, e.g., ribosome, mRNAs, initiation and elongation factors 
(Boisvert et al., 2007; Draper and Reynaldo, 1999; Maguire and Zimmermann, 2001; 
Ramakrishnan, 2002).  In addition to their roles in basic cellular machinery, human 
ribosomal proteins are also related to other extra-ribosomal functions, i.e., apoptosis 
(e.g., RPL23), transcription / translation (e.g., RPL26), mRNA processing (e.g., RPS13), 
DNA repair (e.g., RPS3), development (e.g., RPL11) and malignant transformation (e.g., 
RPS15a) (Dai et al., 2004; Gazda et al., 2008; Ko et al., 2008; Lian et al., 2004; 
Malygin et al., 2007; Takagi et al., 2005; Wool, 1996).  There is an approximate of 80 
ribosomal proteins and their encoding genes are mapped successfully in humans, each 
with only one functional gene code (Lai and Xu, 2007; Perry, 2005). 
As early as the 19
th
 century, cancer-associated abnormalities in nucleolar morphology 
have reliably featured malignant transformation.  The hypertrophic nucleolus and the 
deregulation of translational machinery are prominent within cancer cells (Gani, 1976).  
In oncogenesis, the aberrant regulation of ribosome biogenesis was thought to trigger 
and promote tumour growth and progression (Amsterdam et al., 2004; Ruggero and 
Pandolfi, 2003; Stewart and Denell, 1993; Watson et al., 1992).  It was proposed that 
the overall increase in translational capacity might result in the increased level of the 
functionally-important cancer-related proteins, which are normally expressed in low or 
moderate levels (Montanaro et al., 2008).  Another hypothesis awaiting to be proven 
suggests that altered ribosome biogenesis is merely a consequence of increased cellular 
proliferation rate during tumourigenesis (Lindstrom, 2009; Ruggero and Pandolfi, 2003). 
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Owing to their functional roles in ribosome biogenesis and other possible independent 
extra-ribosomal events, the deregulation of ribosomal protein biosynthesis in inherited 
genetic diseases and cancers, is theoretically not inconceivable (Jang et al., 2004; Lai 
and Xu, 2007; Lian et al., 2004; Marygold et al., 2005; Ruggero and Pandolfi, 2003).  
Since decades ago, the perturbation in the mRNA expression of ribosomal proteins was 
constantly demonstrated in several human malignancies, e.g., breast, prostate, uterine 
cervical, esophageal, liver and colorectal cancers (Cheng et al., 2002; Henry et al., 1993; 
Kim et al., 2004; Kitahara et al., 2001; Vaarala et al., 1998; Wang et al., 2001).  
Mounting evidences have shown that proto-oncogenes and tumour suppressor genes 
will exert a direct impact on ribosomal protein biosynthesis.  For instance, the proto-
oncogene MYC was reported to up-regulate the transcription of ribosomal proteins 
(Boon et al., 2001; Menssen and Hermeking, 2002).  The activation of the PI3K 
signaling cascade during carcinogenesis will also increase the translation of ribosomal 
proteins (Holland et al., 2004). 
As noted previously, the mRNA expression level of ribosomal proteins is greatly 
dependent on the types of cell, cell cycle progression and ambient conditions within the 
cellular microenvironment (Bortoluzzi et al., 2001).  Hence, the expression patterns of 
the ribosomal proteins mRNAs are tissue- and tumour-specific in both normal and 
pathological states (Barnard et al., 1992; Barnard et al., 1993; Bortoluzzi et al., 2001).  
The relationship between the aberrant expression of ribosomal proteins and CRC has 
been well-characterised in several studies.  For instance, the increased mRNA 
expression of ribosomal proteins S3, S5, S6, S8, S9, S10, S12, S29, L5, L18, L21, L27a, 
L28, L31 and L37 are associated with the initiation and proliferation of CRC neoplasms 
(Barnard et al., 1993; Chester et al., 1989; Frigerio et al., 1995; Kitahara et al., 2001; 
Pogue-Geile et al., 1991).  The mRNA expression of ribosomal proteins P0 and S19 
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have also been shown to correlate with CRC progression and metastasis (Barnard et al., 
1992; Kondoh et al., 1992). 
In the present study, we have added two ribosomal proteins, i.e., the RPL35 and RPS23, 
to this expanding list.  Both RPL35 and RPS23 were significantly over-expressed, and 
the fold change in the mRNA expression level was noted to be comparable between the 
early- and advanced stages of CRC.  This was in agreement with Barnard’s and 
Frigerio’s reports, where the observed mRNA over-expression of the ribosomal proteins 
was not related to the CRC stage (Barnard et al., 1993; Frigerio et al., 1995).  These 
findings appeared to be acceptable as the same ribosomal protein may play different 
roles in different stages of cancer progression.  Moreover, the possible contribution of 
their extra-ribosomal roles, which are still unknown to date, also cannot be excluded 
(Lai and Xu, 2007).  Ivanov and his groups had demonstrated a high affinity of RPS23 
to the pre-mRNA fragment of RPS26, but its functional consequence remains to be 
determined (Ivanov et al., 2002; Ivanov et al., 2004). 
From the aspect of tumour site, the mRNA of RPL35 was significantly over-expressed 
in both right- and left-sided primary CRC tumours.  On the other hand, the over-
expression of RPS23 mRNA was only reported in the latter group.  The fold change in 
mRNA expression of RPL35 was comparable between right- and left-sided CRC 
neoplasms and thus, was not reflective of the tumour site.  Presumably, the proliferation 
rate in CRC tumours is not much significantly different from normal colonic mucosa, 
which typically possesses a high basal turnover time.  Hence, more studies are 
warranted to investigate the true implications of the aberrant expression of human 
ribosomal proteins in the development and progression of CRC, instead of arbitrarily 
taking it as a mere consequence of increased proliferation in tumour cells (Hoffman and 
Post, 1967; Lai and Xu, 2007; Pogue-Geile et al., 1991). 
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5.2.2 TIMP1 
Our results showed that the tissue inhibitors of metalloproteinase 1 (TIMP1) was 
significantly over-expressed in CRC tumours, compared to normal colonic mucosa 
samples.  A comparable fold change in mRNA expression level was observed between 
early- and advanced stage CRC groups, as well as between right- and left-sided CRC 
tumours.  Our observation was in agreement with other reported findings, where TIMP1 
mRNA over-expression in CRC neoplasms was not uncommon (Baker et al., 2000a; 
Inagaki et al., 2010; Offenberg et al., 2008; Pesta et al., 2005).  In fact, there have been 
several researchers that have not observed any significant relationship between TIMP1 
mRNA expression levels and tumour sites / CRC stages (Inagaki et al., 2010; Pesta et 
al., 2007).  Likewise, the observed TIMP1 mRNA over-expression in our study was also 
not indicative of either the CRC stage or primary tumour site.  On the basis of evidences 
to date, this lack of significant correlation between mRNA expression level of TIMP1 
and CRC stage might be ascribed to its dual role in tumour development and 
progression (Egeblad and Werb, 2002; Herszenyi et al., 2012; Jiang et al., 2002). 
TIMP1 is one of the members in the TIMP family that reversibly inhibits and abolishes 
the proteolytic activities of proteolytic enzymes, the matrix metalloproteinases (MMPs).  
Typically, TIMP1 is an endogenous tissue-specific inhibitor for the MMP-1, MMP-3 
and MMP-9.  It binds to the N-terminal of the activated form of MMPs and 
subsequently, inhibits these enzymatically active proteinases in a 1:1 stoichiometric 
manner (Bode et al., 1994; Ennis and Matrisian, 1993; Lambert et al., 2004).  Under 
normal state, the finely-regulated MMP / TIMP balance is indispensable for the 
turnover and homeostasis of extracellular matrix (ECM), as well as several 
physiological processes in the human gut (Medina and Radomski, 2006; Sun, 2010).  
Therefore, the shifted MMP / TIMP equilibrium towards the preponderance of ECM 
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degradation is one of the crucial events in gastrointestinal malignancies (Herszenyi et al., 
2012; Herszenyi et al., 2012a). 
In the milieu of neoplasis, MMPs and TIMPs are produced and secreted by both the 
tumour and its surrounding stromal cells (Herszenyi et al., 2012; Hewitt et al., 1991; 
Newell et al., 1994; Tomita and Iwata, 1996).  MMPs are responsible in degrading the 
ECM and maintaining a favoured microenvironment for further growth, invasion and 
metastasis of primary tumours (Amalinei et al., 2010; Geho et al., 2005; Herszenyi et al., 
2012a; Herszényi et al., 2000).  In line with this, the over-expression of MMPs was 
correlated with tumour aggressiveness and prognosis in a variety of human 
malignancies, including CRC (Figueira et al., 2009; Gao et al., 2006; Giannopoulos et 
al., 2008; Groblewska et al., 2012; Hu et al., 2012; Liu et al., 2011a). 
Theoretically, the TIMP1 was simply thought as an intrinsic barrier to cancer 
progression owing to its direct roles in modulating MMPs activities and proteolysis of 
ECM components.  In fact, the elevated expression of TIMP1 through gene transfer had 
demonstrated a profound anti-tumour effect in various animal models (Brand, 2002; 
Elezkurtaj et al., 2004).  Previous studies however, had related the TIMP1 over-
expression with poorer prognosis and shorter disease-free survival in several carcinomas, 
e.g., gastric, lung, breast and colorectal cancers (Fong et al., 1996; Mimori et al., 1997; 
Ree et al., 1997; Zeng et al., 1995).  Initially, this increase in TIMP1 expression was 
hypothesised as a response to the increased MMPs activities rather than a cause in 
carcinogenesis (Egeblad and Werb, 2002; Inagaki et al., 2010; Joo et al., 2000; Kahlert 
et al., 2008; Schrohl et al., 2004).  It was only thereafter that the active tumour-
promoting roles of the TIMP1, i.e., stimulating cell proliferation, inhibiting apoptosis, 
regulating angiogenesis, as well as facilitating invasion and metastasis of tumour cells, 
were revealed through mounting evidences (Akahane et al., 2004; Bourboulia and 
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Stetler-Stevenson, 2010; Hornebeck et al., 2005; Liu et al., 2003; Mannello and 
Gazzanelli, 2001; Tsuchiya et al., 1993). 
In CRC carcinogenesis, these growth-stimulatory and metastasis-promoting effects of 
the TIMP1 are well-characterised.  A significantly higher expression of the TIMP1 
mRNA was associated with the presence of synchronous lymph nodes and distant 
metastasis in CRC patients.  Furthermore, the over-expression of TIMP1 mRNA was 
also reported in the metastatic liver foci of CRC (Asano et al., 2008; Sutnar et al., 2007; 
Zeng et al., 1995).  As observed in our present study, the TIMP1 mRNA over-
expression in both early- and advanced stages of CRC was not paradoxical, but in line 
with its pleiotropic effects in both MMP inhibitory and MMP-independent regulatory 
activities.  However, the actual clinical relevance of this over-expression of TIMP in 
CRC carcinogenesis remains to be clarified. 
5.2.3 ARPC2 
In the present study, the actin-related protein 2/3 complex, subunit 2 (ARPC2) gene is 
significantly under-expressed in early stage CRC primary tumours, but not in the 
advanced stage neoplasms.  This under-expression of ARPC2 gene however, did not 
reach statistical significance after stratifying our CRC patients according to tumour sites.  
Notably, this is the only under-expressed gene being observed in our sample cohort. 
The ARPC2 is one of the seven evolutionarily well-conserved subunits of the actin-
related protein 2/3 (Arp2/3) complex.  It serves as the structural core of the Arp2/3 
complex by forming a heterodimer with ARPC4 (Robinson et al., 2001).  On the other 
hand, the ARPC2 is also essential for side binding and branch formation because the 
heterodimer ARPC2/ARPC4 was predicted to contact substantially with the mother 
filaments during actin polymerisation (Bailly et al., 2001; Volkmann et al., 2001).  The 
Arp2/3 complex is the major actin nucleator in eukaryotes and plays a crucial role in 
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forming the branched-actin-filament network.  Following its binding to nucleation 
promoting factors, the activated Arp2/3 complex nucleates the formation of new 
filaments at a 70
0 
angle from existing filaments in a Y-branch configuration (Amann 
and Pollard, 2001; Mullins et al., 1998).   
Under normal physiological state, the organisation of actin cytoskeleton is important for 
cellular vesicle trafficking, cell motility, cell division, cell adhesion, phagocytosis, 
mechanical support for cells, etc. (Cao et al., 2010; Le Clainche and Carlier, 2008; 
Stossel et al., 2001).  Along with the degradation of ECM, the inactivation of cell-cell 
adhesion and remodeling of actin network are key drivers in tumour cells migration, 
leading to lethal metastatic disease in cancers (Iwaya et al., 2007; Rauhala et al., 2013).  
This aberrant regulation in tumour cell motility is the driver behind the cancer invasion 
and metastasis achieved through protrusive structures, e.g., lamellipodia, in which the 
Arp2/3 complex is localised within its leading edge (Bailly and Condeelis, 2002; 
Machesky, 2008; Machesky et al., 1997; Yamaguchi et al., 2005).   
In view of its critical roles in nucleation and branching of the actin network, the 
dysfunction of Arp2/3 complex was predicted to modulate the above-mentioned cellular 
processes, which in turn contributes to cancer development and progression (Otsubo et 
al., 2004; Wang et al., 2005).  In fact, the WAVE-Arp2/3 complex pathway, which is 
one of the downstream targets within the EGF signaling pathway (a fundamental 
pathway involved in oncogenesis), was up-regulated in several cancers (Otsubo et al., 
2004; Semba et al., 2006; Wang et al., 2004).  The altered mRNA and protein 
expression levels of the subunits of Arp2/3 complex were also reported in tumour 
tissues and invasive cells (Otsubo et al., 2004; Wang et al., 2005).  The over-expression 
of ARPC2 was reported in melanomas and acted as one of the discriminative markers in 
distinguishing melanomas from benign nevi (Kashani-Sabet et al., 2009).  
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However, Kaneda and his group had reported a significant decrease in mRNA 
expression of all the seven subunits of the Arp2/3 complex in human gastric cancer.  
These observed reductions in the expression level were particularly pronounced for 
ARPC2, ARPC4 and Arp2 (Kaneda et al., 2004).  Similarly, our present study on CRC 
also revealed a decreased mRNA expression level of the ARPC2.  Since the actin 
cytoskeleton is important in supporting and maintaining the cell shape, it was 
hypothesised that the under-expression of the Arp2/3 complex or its subunits might be 
responsible for the dysplastic cell morphology, a typical feature of cancer cells 
(Flanagan et al., 2001; Welch, 1999).  On the other hand, the decreased expression of 
the subunits of Arp2/3 complex might also affect the intracellular signal transductions 
that are regulated by the actin network (Kaneda et al., 2004; Stossel et al., 2001).  These 
hypotheses might then provide a different conceptual view on the implications of the 
aberration in Arp2/3 complex expression patterns in carcinogenesis. 
5.2.4 C6orf173 
The chromosome 6 open reading frame 173 (C6orf173) is more commonly known as 
the cancer-upregulated gene 2 (CUG2), and later renamed as centromere protein W 
(CENP-W) (Hori et al., 2008).  Given to its potent in vivo and in vitro transforming 
abilities, the CENP-W has been identified as a novel oncogene and is up-regulated in 
several human cancer tissues, i.e., ovary, liver, lung, breast, colon, rectum and stomach 
(Lee et al., 2007).  As implied by its name, the CENP-W is also one of the centromere-
associated network proteins – a crucial participant in both mitosis and meiosis (Hori et 
al., 2008; Kim et al., 2009; Perpelescu and Fukagawa, 2011). 
In mitosis, the proper chromosome segregation is important in maintaining the euploidy 
of daughter cells, as well as ensuring the accurate transmission of genetic materials and 
normal cell physiology.  The centromere is a specific chromosomal region where the 
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formation of kinetochore takes place for the attachment of spindle microtubules and 
subsequent segregation of sister chromatids to the opposite poles of the dividing cells 
(Kops et al., 2005; Mellone et al., 2006; Perpelescu and Fukagawa, 2011).  Thus, both 
centromere and kinetochore specifications are central for faithful chromosome 
segregation and of all the kinetochore proteins, the targeted deposition of histone H3 
variant CENP-A is the key determinant for centromere identity at the chromatin level 
(Cheeseman and Desai, 2008; Howman et al., 2000; Sullivan et al., 1994). 
The recently-identified novel CENP-W is one of the members of the constitutive 
centromere-associated network (CCAN), in which a group of kinetochore proteins are 
interdependent in propagating the centromere and assembling the kinetochore, with 
coordination of CENP-A (Hori et al., 2008; Liu et al., 2006; Okada et al., 2006; Okada 
et al., 2009).  The CENP-W is tightly associated with CENP-T to form a complex that 
functions upstream of other CCAN components and provides a platform for their 
assembly within the centromeric region (Okada et al., 2006).  This CENP-T / CENP-W 
complex possesses DNA-binding ability, and interacts directly with the nucleosomal 
DNA and canonical histone H3 for the formation of centromere chromatin structure 
(Hori et al., 2008). 
In line with the roles of CENP-T / CENP-W complex in mediating the centromeric 
chromatin and outer kinetochore components, as well as assembling the functional 
kinetochore in G2 phase, its aberrant expression was hypothesised to influence the 
mitotic process and implicate in oncogenesis (Hori et al., 2008; Kim et al., 2009; 
Perpelescu and Fukagawa, 2011; Prendergast et al., 2011).  Several CENPs were related 
to the promotion and progression of neoplasms, i.e., CENP-A and CENP-H in CRC; 
CENP-F in head and neck squamous cell carcinoma (de la Guardia et al., 2001; 
Tomonaga et al., 2005; Tomonaga et al., 2003).  Typically, the dysregulation of 
kinetochore proteins is associated with chromosome missegregation and aneuploidy, a 
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ubiquitous feature of solid tumours in human (Pihan and Doxsey, 1999; Yuen et al., 
2005).  Although the aneuploidy is closely-related to CIN in human malignancy, there 
has yet to be any evidence on the direct causative relationship between the impaired 
kinetochore assembly and CIN thus far (Orr-Weaver and Weinberg, 1998; Tomonaga et 
al., 2005).   
Our present study revealed that the C6orf173 (CENP-W) was over-expressed in both 
early- and advanced stage primary CRC tumours, but only reached statistical 
significance in the latter group.  This was supported by a report where a greater 
proportion of the advanced stage CRC neoplasms were found to be aneuploid and they 
tend to exhibit higher growth rate, as well as poorer survival than the diploid tumours 
(Chen et al., 2002; Saccani Jotti et al., 1995).  In order to ensure normal kinetochore 
assembly and proper spindle checkpoint signaling, the stoichiometric expression and 
dosage of the core kinetochore components are vital.  It was hence, proposed that any 
anomaly in the expression of the kinetochore components and their assembly might 
contribute to aneuploidy and CRC carcinogenesis (Tomonaga et al., 2005; Yuen et al., 
2005).   
Following the stratification of the sample cohort by tumour sites, the C6orf173 was 
significantly over-expressed in both right- and left-sided CRC neoplasms.  Notably, the 
observed fold change in the C6orf173 mRNA expression level was approximately 
double in the right-sided CRC tumours ( TCΔΔ-2 = 4.3214), compared to its left-sided 
counterparts ( TCΔΔ-2 = 2.3282).  In fact, previous studies had revealed the differences in 
the clinical and molecular features between right- and left-sided CRC tumours.  Most of 
the left-sided CRC tumours are aneuploid, highly-differentiated and follow the CIN 
pathway, while the right-sided neoplasms are mostly diploid, poorly-differentiated and 
follow the MSI pathway (Iacopetta, 2002; Soreide et al., 2009).  Hence, our observation 
in the right-sided CRC tumours might reveal a possible contribution of CENP-W in 
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other oncogenic activities on top of the aneuploidy.  A recent study by Chun and his 
team had demonstrated the localisation of CENP-W in various sub-nuclear 
compartments, e.g., nucleoli and nuclear matrix, rather on the centromere alone.  This 
provides an additional insight into the potential involvement of the CENP-W in other 
crucial nuclear activities or even carcinogenesis (Chun et al., 2011). 
In brief, our findings on the over-expression of C6orf173 in primary CRC tumours were 
in concordance with a few hypothesis and facts – first, the aberrant expression of 
kinetochore protein might associate with aneuploidy in CRC neoplasms.  Second, the 
aneuploidy is associated with advanced stage and poorly-differentiated tumours.  Third, 
there might be the presence of other hitherto unknown function(s) of CENP-W in 
oncogenesis.  Therefore, further functional studies on diploid cell lines and mouse 
models are in need to delineate the true impacts of mRNA over-expression of C6orf173 
on CRC carcinogenesis (Yuen et al., 2005). 
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5.3 Part C: Differential Proteome Analysis via A Bottom-Up Proteomics 
Approach 
Two-dimensional DIGE and LC-MS/MS were employed for the quantitative proteomic 
profiling of sporadic CRC tumours.  The recruited CRC tumour specimens were 
grouped according to their cancer stage in order to characterise the stage-specific CRC 
tumour-specific protein expression patterns.  Despite our attempts to investigate 
tumouric samples of all CRC stages, we failed to obtain the Stage I level samples.  As 
approximately 70 % of CRC cases are usually detected at advanced tumour stages 
(which often relate with poor patient prognosis), this could have possibly impeded the 
sample collection (O'Connell et al., 2004).  According to a demographic and anatomic 
survey conducted among Malaysian CRC patients, only 4.5 % of the patients were 
diagnosed with Dukes’ A CRC at the time of diagnosis (Goh et al., 2005).  Hence, our 
sample cohort only comprised of the primary CRC tumours of Stages II, III and IV. 
Through our comparative protein expression screening, only Stage II CRC tumours 
were reported with significant differentially expressed proteins.  However, the global 
protein abundance of the advanced stage CRC neoplasms, i.e., Stages III and IV, was 
not significantly different from their respective adjacent morphologically normal 
colonic mucosa.  These intriguing findings are not unexpected as the histologically 
normal colorectal mucosa adjacent to the advanced stage tumours might have 
experienced certain molecular changes to provide a conducive tumour 
microenvironment for the invasion and metastasis of primary tumours to distal sites 
(Brown et al., 1999; Hanrahan et al., 2003).  Alternatively, the proteins that exhibit 
significant changes in the expression level for advanced stage CRC tumours might not 
fall within the investigated pI range (pI 4 – 7).  Hence, further experimental attention 
with the use of different pH ranges or lengths of Immobiline DryStrip Gels is warranted.  
It would also be useful to further investigate the relative basal level of protein 
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abundance between the histologically normal colonic mucosa adjacent to early- and 
advanced stage CRC tumours.  
Our present study had revealed a total of 20 protein spots which exhibited significant 
changes in the protein abundance, and were consistently reported in all 10 CRC patients 
within the Stage II CRC Group [as shown in Table 4.16, Section 4.3, Chapter 4].  These 
spots displayed an average volume ratio ranging from -3.68 for Spot No. 1031 to 4.77 
for Spot No. 1011, and had a statistical variance within the 99 % confidence level (p < 
0.01).  Following mass spectrometric protein identification, we had successfully 
identified 16 unique proteins that were aberrantly regulated in the Stage II CRC tumours.  
Ten proteins were found to be over-expressed, while the remaining 6 were under-
expressed.  The details are shown in Tables 5.1 and 5.2.  In our current study, the Hsp60 
and LC20 proteins appeared in multiple protein spots upon 2-D DIGE separation [as 
shown in Table 4.17, Section 4.3, Chapter 4].  This observation may correspond to the 
post-translational modifications on the same proteins which may be responsible for the 
different molecular mechanisms related to CRC carcinogenesis (Friedman et al., 2004).   
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Table 5.1: Over-expressed proteins in primary Stage II CRC tumours compared to 
adjacent paired normal colonic mucosa. 
No. Over-expressed 
Protein 
Alternate Name* Molecular 
Function* 
Reported in CRC 
Studies** 
1. Mitochondrial heat shock 
60kD protein 1 variant 1 
Heat shock protein 60; 
Chaperonin; Hsp60 
Chaperone activity - Alfonso et al., 2005 
- Bi et al., 2006 
- Gourley et al., 2010 
- Krasnov et al., 2009 
- Lin et al., 2009 
- Muto et al., 2011 
- O’Dwyer et al., 2011 
- Shi et al., 2011 
- Tomonaga et al., 2004  
2. 60S acidic ribosomal 
protein P0 
Ribosomal protein, 
large, P0; RPLP0 
Structural constituent 
of ribosome 
 
3. Inorganic pyrophosphatase PPase Catalytic activity - Friedman et al., 2004 
- Petrova et al., 2008 
- Tomonaga et al., 2004 
4. Chloride intracellular 
channel protein 1 
Nuclear chloride ion 
channel 27; NCC27 
Intracellular ligand-
gated ion channel 
activity 
- Krasnov et al., 2009 
- Lin et al., 2009 
- Petrova et al., 2008 
- Tomonaga et al., 2004 
5. Tumour protein, 
translationally-controlled 1 
Translationally 
controlled tumour 
protein; TCTP 
Calcium ion binding - Friedman et al., 2004 
- O’Dwyer et al., 2011 
6. Nucleophosmin Nucleolar 
phosphoprotein B23; 
Numatrin; B23 
Chaperone activity - O’Dwyer et al., 2011 
7. COP9 signalosome 
complex subunit 8 
COP9 constitutive 
photomorphogenic 
homolog subunit 8; 
SGN8 
Component of the 
COP9 signalosome 
complex 
 
8. Nucleoside diphosphate 
kinase A 
NDP kinase A; NM23 Catalytic activity - Friedman et al., 2004 
- Ma et al., 2009 
- O’Dwyer et al., 2011 
- Shi et al., 2011 
- Tomonaga et al., 2004 
- Wang et al., 2012a 
9. Stathmin Phosphoprotein 19; 
SMN 
Structural molecule 
activity 
- Ma et al., 2009 
- Tomonaga et al., 2004 
10. Protein S100-A9 S100 calcium binding 
protein A9; Calgranulin 
B; S100A9 
Calcium ion binding - Friedman et al., 2004 
- Lin et al., 2009 
- O’Dwyer et al., 2011 
- Stulík et al., 2001 
*   Accessed via The Human Protein Atlas (www.proteinatlas.org) and Human Protein Reference Database (www.hprd.org) 
** Only included CRC studies with surgical resected tissue specimens and coupled 2-D GE / MS approach  
Chapter Five - Discussion 
 
232 
 
Table 5.2: Under-expressed proteins in primary Stage II CRC tumours compared to 
adjacent paired normal colonic mucosa. 
 
 
 
 
 
No. Under-expressed 
Protein 
Alternate Name* Molecular 
Function* 
Reported in CRC 
Studies** 
1. Keratin, type I 
cytoskeletal 20 
Keratin 20; K20 Major cellular 
protein in mature 
enterocytes and 
goblet cells 
- Lin et al., 2009 
- Shi et al., 2011 
2. Actin, alpha cardiac 
muscle 1 
Actin, alpha 
cardiac; ACTC1 
Structural 
constituent of 
cytoskeleton 
 
3. Actin, aortic 
smooth muscle 
Actin, alpha-2, 
smooth muscel, 
aorta; ACTSA 
Structural 
constituent of 
cytoskeleton 
- Ma et al., 2009 
4. Heat shock protein 
beta-1 
Heat shock protein 
27; HSP27 
Chaperone activity - Ma et al., 2009 
- Pei et al., 2007 
- Wang et al., 2012a 
- Xing et al., 2006 
5. MYL9 protein Myosin regulatory 
light polypeptide 9; 
20kDa myosin light 
chain; LC20 
Myosin regulatory 
subunit 
- Friedman et al., 2004 
- Ma et al., 2009 
- Petrova et al., 2008 
 
6. Myosin light 
polypeptide 6 
17 kDa myosin 
light chain; LC17 
Structural 
constituent of 
cytoskeleton 
- Ma et al., 2009 
- Petrova et al., 2008 
 
*   Accessed via The Human Protein Atlas (www.proteinatlas.org) and Human Protein Reference  
     Database (www.hprd.org) 
** Only included CRC studies with surgical resected tissue specimens and coupled 2-D GE / MS  
     approach 
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To a certain extent, the current proteomic profiling on Stage II CRC tumours was in 
accordance to our earlier findings in studying the mRNA expression levels of both 
early- and advanced stage CRC tumours (Section 5.2 – Part B: Differential 
Transcriptome Analysis).  In this comparative screening of protein expression, we had 
uncovered the over-expression of a ribosomal protein, RPLP0, and the under-expression 
of two actin isoforms, ACTC1 and ACTSA.  Consistently, we had also identified the 
mRNA over-expression of the ribosomal proteins, RPL35 and RPS23, as well as the 
mRNA under-expression of the subunit of Arp2/3 complex, ARPC2, in the early stage 
primary CRC tumours [as shown in Figure 4.11, Section 4.2, Chapter 4].  These 
concordant findings between the mRNA and protein expression analyses on the Stage II 
primary CRC tumours might reliably reveal the involvement of ribosomal proteins and 
components of the actin network in the early development of CRC.  Hence, more 
challenging tasks, i.e., investigations on their functional roles in early CRC oncogenesis, 
and their value in the early diagnosis of CRC, lie ahead for elucidating data with regards 
to better CRC management in future. 
As shown in Tables 5.1 and 5.2, most of the identified differentially expressed proteins 
in our study were previously reported in other comparative proteomic studies with 2-D 
GE approach, except RPLP0, SGN8 and ACTC1 proteins.  This shows that the 
comparative proteomic analysis with 2-D GE platform is more reproducible and reliable 
compared to the gene expression analysis at the mRNA level, notwithstanding 
variations in CRC stage of the recruited patients, pH range of the Immobiline DryStrip 
Gels and 2-D gel staining methods (Table 5.3).  Despite considerable similarities in 
these 2-D GE-based proteomic studies, there are also discrepancies in the list of 
identified differentially expressed proteins among different comparative CRC studies.  
Presumably, these might be due to the variation in the demographics of the sample 
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cohort, CRC tumour locations, criteria of tissue specimen collection, number of samples 
included and other statistical criteria (Muto et al., 2011; Petrova et al., 2008). 
Although the combination of 2-D DIGE and LC-MS/MS is not a new platform for 
proteomic profiling, our approaches in stratifying the sample cohort according to the 
tumour stage (i.e., Stage II, III and IV CRC Group) and performing the normal / tumour 
pair-wise analysis within each CRC stage group, are different from other comparative 
protein expression analyses on sporadic CRC tumours.  In previous studies, either the 
primary CRC tumours of a specific disease stage or the pooled CRC specimens of 
different stages were used to characterise the CRC tumour-specific differentially 
expressed proteins (Table 5.3). 
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Table 5.3: Summary of patient characteristics and 2-D GE approaches in different comparative proteomic analyses on sporadic CRC tumours. 
CRC Stage of Recruited 
Patients 
Dukes’ A Dukes’ B Dukes’ A – C Stages I – IV Stages II – IV Stage IV with 
synchronous 
liver metastasis 
 Wang et al., 2012a 
 
O’Dwyer et al., 2011 Alfonso et al., 2005 
 
Krasnov et al., 2009; 
Muto et al., 2011; 
Pei et al., 2007; 
Stulík et al., 2001; 
Xing et al., 2006  
Friedman et al., 2004;  
Lin et al., 2009; 
Petrova et al., 2008;  
Tomonaga et al., 2004  
 
Shi et al., 2011 
 
pH Range of the 
Immobiline DryStrip Gels 
4 – 7 4 – 9 6 – 9 3 – 8  3 – 10 Linear &  
Non-linear 
3 – 11 
 Alfonso et al., 2005; 
Friedman et al., 2004;  
Ma et al., 2009;  
Xing et al., 2006 
Tomonaga et al., 2004 Muto et al., 2011 
 
Krasnov et al., 2009 Lin et al., 2009;  
O’Dwyer et al., 2011; 
Pei et al., 2007;  
Petrova et al., 2008;  
Stulík et al., 2001   
Shi et al., 2011 
 
2-D Gel Staining Methods 2-D DIGE 2-D with  
silver-staining 
2-D with  
coomasie blue-staining 
   
 Alfonso et al., 2005; 
Friedman et al., 2004;   
Lin et al., 2009;  
Muto et al., 2011;  
Shi et al., 2011  
Pei et al., 2007;  
Petrova et al., 2008; 
Stulík et al., 2001;  
Wang et al., 2012a; 
Xing et al., 2006   
Krasnov et al., 2009;  
Ma et al., 2009;  
O’Dwyer et al., 2011; 
Tomonaga et al., 2004 
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In summary, our proteomic analysis had unraveled the Stage II primary CRC tumour-
specific protein expression pattern, which consists of differentially expressed proteins 
that are involved in various key cellular processes, i.e., protein metabolism, signal 
transduction, ion transportation, ribosome biogenesis, energy metabolism, stress 
response, cytoskeleton, as well as cell proliferation, differentiation, locomotion and 
communication.  The over-expression of Hsp60, B23, SMN and S100A9 proteins are 
further discussed below as they are the most remarkable proteins associated with CRC 
oncogenesis, as well as other cancer entities. 
5.3.1 60 kDa Heat shock protein (Hsp60) 
Heat shock proteins (HSPs) are highly evolutionarily conserved proteins which were 
first discovered with their heat shock-inducible expression (Ritossa, 1962).  Later, their 
expression were reported to be induced by other types of environmental and metabolic 
stresses (e.g., hypoxia, heavy metal ions, nicotine, viral agents, anoxia, etc.), hence the 
term “stress proteins” (Boshoff et al., 2004).  These HSPs exhibit potent cytoprotective 
functions that enable cells to adapt and survive in response to various stress stimuli, 
which would otherwise be lethal (Parcellier et al., 2003).  Most of HSPs are molecular 
chaperones which execute housekeeping functions of folding, stabilizing, assembling 
and translocating of proteins in mammalian cells (Bukau and Horwich, 1998; 
Hightower, 1991).  In addition, these stress proteins also responsible for the repair or 
proteosomal degradation of denatured proteins following stress or injury (Hohfeld et al., 
2001).  In both eukaryotes and prokaryotes, HSPs share a high degree of 
phylogenetically conserved structures and functions, reflective of their significance in 
maintaining the viability and survival of cells (Pockley, 2003).  The Hsp60 is one of the 
three major families of the high molecular weight HSPs that are constitutively 
expressed in the mammalian cells (Parcellier et al., 2003).  This mammalian Hsp60 is an 
ATP-dependent chaperone, named chaperonin.  It is constitutively expressed and 
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predominantly compartmentalised within the mitochondrial matrix, where it regulates 
the proper folding of mitochondrial proteins, as well as elimination of the misfolded or 
denatured proteins via ATP-dependent proteolytic degradation (Bukau and Horwich, 
1998; Garrido et al., 2001). 
Under normal physiological condition, the Hsp60 protein is pivotal for the maintenance 
of cellular homeostasis, as well as regulation of cell cycle and apoptosis (Ellis, 1999).  
Hence, any translocation of the Hsp60 protein to extra-mitochondrial or extracellular 
sites, or alteration in its expression level might involve in several pathophysiological 
events, e.g., cardiovascular diseases, autoimmune diseases and malignancies (Garrido et 
al., 2001; Pockley, 2003).  Typically, the release of the intracellular HSPs into 
extracellular milieu is indicative of non-physiological tissue damage.  These 
extracellular HSPs are danger signals and act as signaling molecules for intercellular 
communication in inducing pro-inflammatory responses (Pockley, 2003).  In cancers, 
the Hsp60 protein was demonstrated to be actively secreted by tumour cells via the 
proposed exosomal pathway (Merendino et al., 2010).  The increased expression of the 
Hsp60 protein has been reported in several tumours, i.e., prostate, ovarian, pancreatic, 
colorectal, breast and cervical (Bini et al., 1997; Cappello et al., 2005; Cappello et al., 
2003; Hwang et al., 2009; Piselli et al., 2000; Schneider et al., 1999).  In fact, the 
staining and accumulation of the Hsp60 protein have been demonstrated in the 
cytoplasm of tumour cells, indicative of the involvement of the cytosolic Hsp60 in 
cancer progression.  The over-expression of the Hsp60 protein was also observed in the 
pre-tumoural lesions of prostate, uterine exocervix, colon and rectum (Cappello et al., 
2003a; Cappello et al., 2003).  In addition to its chaperonic activity in altering the 
activity and turnover of cancer-associated proteins, previous studies had proposed other 
non-chaperonic roles of the over-expressed Hsp60 protein in carcinogenesis, i.e., 
restraining the p53 activity and sequestering the Bax-containing complexes to evade 
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apoptosis, mediating the NF-κB-dependent signaling to promote tumour cell survival, as 
well as activating β-catenin to promote cancer invasion and metastasis (Chun et al., 
2010; Garrido et al., 2001; Ghosh et al., 2007; Shan et al., 2003; Tsai et al., 2009).    
5.3.2 Nucleophosmin (B23) 
The B23, or also known as numatrin, is a non-ribosomal nucleolar phosphoprotein that 
exists in two isoforms as a result of alternative splicing, i.e., B23.1 and B23.2 (Chang 
and Olson, 1990; Feuerstein and Mond, 1987a; Yung et al., 1985).  These isoforms are 
expressed in different subcellular locations, whereby the expression level is cell growth-
related for B23.1 but relatively constant for B23.2 (Wang et al., 1993).  The B23.1 is the 
predominant isoform and hereafter referred to as B23 in our discussion.  Physiologically, 
this multifunctional protein is engaged in a range of biological processes, i.e., ribosome 
biogenesis, maintenance of genomic stability, as well as cell proliferation (Chartier et al., 
2007; Lim and Wang, 2006).  The involvement of the B23 protein rely on its RNA and 
DNA binding ability, intrinsic endoribonuclease activity, as well as its regulatory role in 
the cell cycle progression, centromere duplication, DNA histone assembly and ARF-
p53 pathway (Bertwistle et al., 2004; Colombo et al., 2002; Gadad et al., 2011; Herrera 
et al., 1995; Okuda, 2002; Okuda et al., 2000; Savkur and Olson, 1998; Wang et al., 
1994).  The B23 protein has demonstrated both oncogenic and tumour suppressive 
abilities via its interaction with the p53 and ARF proteins (Bertwistle et al., 2004; 
Colombo et al., 2002).  The B23 protein has also been observed to shuttle between the 
nucleus and cytoplasm, and this might relate to its molecular chaperone activities (Borer 
et al., 1989; Szebeni and Olson, 1999). 
Given the fact that B23 protein is the key regulator in several cellular processes, any 
perturbation in its expression or function is expected to implicate in disease 
pathogenesis, e.g., tumourigenesis (Lim and Wang, 2006).  For instance, the mutated 
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B23 protein, as a consequence of mutation in exon 12 of the NPM1 gene, is a hallmark 
of acute myeloid leukemias (Falini et al., 2005).  However, this mutation is absent in 
most of the human solid tumours where the over-expression of B23 protein is frequently 
observed (Jeong et al., 2007).  In fact, the expression level of the B23 protein is higher 
in proliferating cells compared to the resting cells (Chan et al., 1989; Feuerstein et al., 
1988; Feuerstein and Mond, 1987).  This close relationship between the B23 protein 
level and cell proliferation elucidates its over-expression in most of human neoplasms, 
i.e., colorectal, oral, bladder, stomach, prostate, ovary and liver cancers (Chang et al., 
2005; Nozawa et al., 1996; Subong et al., 1999; Tanaka et al., 1992; Tsui et al., 2004; 
Yun et al., 2007; Zhang, 2004).  The high abundance of B23 protein has been 
speculated to inhibit the p53 tumour suppressive activity via direct binding or negative 
regulatory effect on the ARF protein (Gjerset, 2006; Li et al., 2010).  The ARF-induced 
p53-mediated apoptosis in response to oncogenes activation is then impaired, resulting 
in the continued outgrowth of abnormal cells with hyperproliferative oncogenic signals 
(Bertwistle et al., 2004; Gjerset, 2006; Korgaonkar et al., 2005).  Hence, the over-
expression of B23 protein might implicate as one of the early events in carcinogenesis 
(Lim and Wang, 2006). 
5.3.3 Stathmin (SMN) 
The cytoplasmic protein SMN, which is also known as the Oncoprotein 18, is a member 
of the phosphoprotein family that is involved in microtubule dynamics, cytoskeleton 
biogenesis and focal adhesion reorganisation (Curmi et al., 1997; Koppel et al., 1990; 
Sherbet and Cajone, 2005).  This microtubule destabilizing protein is crucial for the 
proper assembly of the mitotic spindle and chromosome movement during mitosis 
(Johnsen et al., 2000; Larsson et al., 1997; Rana et al., 2008; Rubin and Atweh, 2004).  
In addition, it also plays an important role in signal transduction by integrating, 
coordinating and directing diverse extracellular and intracellular signals (Sherbet and 
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Cajone, 2005; Sobel, 1991).  Hence, the aberrant expression of the SMN protein would 
have serious consequences on the biological behaviours of cells, i.e., cell morphology, 
proliferation, differentiation and motility, which then contribute to the proliferative 
potential and invasive behaviours of the cancer cells (Johnsen et al., 2000; Rubin and 
Atweh, 2004; Sherbet and Cajone, 2005; Singer et al., 2007). 
As previously observed in the hepatocarcinogenesis, the over-expression of SMN was 
thought to be an early protumourigenic event.  This might in part associate with the 
genetic alterations in the TP53 gene, a most common early event in oncogenesis.  The 
expression of SMN is down-regulated with wild-type p53, while its elevated level is 
thought to be associated with the p53 gain-of-function mutations (Ahn et al., 1999; Alli 
et al., 2007; Levine, 1997; Singer et al., 2007).  It is then not surprising that the over-
expression of SMN is reported in a variety of human malignancies, i.e., acute leukemia, 
hepatocellular carcinoma, as well as prostate, ovarian, breast and colorectal cancer 
(Alaiya et al., 1997; Curmi et al., 2000; Ghosh et al., 2007a; Hanash et al., 1988; Singer 
et al., 2007; Zheng et al., 2010).  Singer et al. and Tan et al. had previously revealed the 
relationship between the expression of SMN and the migratory ability of cancer cells.  
The invasion and metastasis of the CRC neoplasms were facilitated through the gain in 
motility and loss of cell attachment of the tumour cells as a result of the SMN over-
expression (Singer et al., 2009; Tan et al., 2012; Zheng et al., 2010). 
5.3.4 S100 calcium-binding protein A9 (S100A9) 
More recent insight into the CRC tumourigenesis had established the interaction 
between the tumour microenvironment and tumour cells in contributing to the hallmark 
phenotypes of cancer.  The extracellular matrix, fibroblasts, immune cells and 
endothelial cells constitute the tumour stromal components that are aggressively 
involved in carcinogenesis (Hanahan and Weinberg, 2011; Tlsty and Coussens, 2006).  
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On the other hand, the soluble mediators (which are either released by the tumour cells 
or actively secreted by these stromal cells), are also critical players in this pathologic 
process.  Recent studies had focused on the damage-associated molecular pattern 
(DAMP) molecules, with one of the examples, the S100A9 protein that is widely 
implicated in inflammatory disorders and malignancies, through its release into the 
extracellular milieu (Gebhardt et al., 2006; Németh et al., 2009; Srikrishna and Freeze, 
2009).  In humans, the formation of the stable S100A8/A9 heterodimer (calprotectin) is 
favoured (Leukert et al., 2006).  This functional heterocomplex is crucial in several 
intracellular processes, i.e., calcium sensing, cytoskeleton rearrangement, activation of 
the NADPH oxidase and transportation of the arachidonic acid (Donato, 2001; Kerkhoff 
et al., 2005).  Once the S100A8/A9 is released into the extracellular space, it acts as the 
DAMP ligand that binds to the cell surface receptors, which consequently leads to the 
activation of intracellular signaling cascades and cellular responses contributing to 
potential tumour formation (Srikrishna, 2012).  Both S100A8 and S100A9 are 
intracellular calcium-binding proteins that are predominantly expressed by myeloid 
cells, while their expressions cell- and tissue-specific (Roth et al., 2003). 
Pathologically, the extracellular S100A8/A9 complex is essential for both 
inflammation-induced cancer and cancer-induced inflammation.  This has been 
evidenced by the over-expression of both S100A8 and S100A9 proteins in different 
types of human neoplasms, i.e., gastric, pancreatic, bladder, colorectal, breast, ovarian 
and thyroid cancers (Salama et al., 2008).  The pathologic effects of the S100A8/A9 
heterodimer on CRC tumour cells were mainly mediated by the transmembrane receptor, 
RAGE.  The recognition of the RAGE on S100A8/A9 results in the induction of MAPK 
signaling pathway and activation of NF-κB, which ultimately promotes the proliferation, 
viability and migration of CRC tumour cells in autocrine and paracrine fashion 
(Ghavami et al., 2008; Ichikawa et al., 2011; Kim et al., 2009a; Kolligs et al., 2002; 
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Turovskaya et al., 2008).  A recent finding on the role of S100A8/A9 in the progression 
of CRC neoplasms had reported an up-regulation of the Wnt/β-catenin pathway 
associated with it (Duan et al., 2013).  Moreover, the over-expression of the S100A9 
protein also leads to the recruitment and accumulation of myeloid-derived suppressor 
cells (MDSC) that exhibit immunosuppressive effect and thus, allows immune evasion 
of developing tumours (Dolcetti et al., 2008; Ostrand-Rosenberg, 2010).  In view of its 
implications in tumour progression, as well as its over-expression in both adenoma and 
early stage CRC neoplasms, the S100A9 protein may hold diagnostic value as a tissue / 
serum biomarker for the early detection of CRC for future screening (Kim et al., 2009a).
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6.1 Part A: SNPs Genotyping via Allelic Discrimination Assays 
In the present study, we have genotyped 15 SNPs to investigate their distribution in our 
Malaysian population, as well as their association to CRC susceptibility in our patients’ 
cohort.  None of the genetic variants in the NOD2, XRCC1, EGF and VEGF genes was 
associated to disease susceptibility in our local samples.  As for the screening of the 
common GWAS-identified CRC-associated variants, we also failed to replicate the 
associations between the rs6983267, rs16892766, rs3802842 and rs4779584, to CRC 
risk.  In our local population, only rs4939827 of the SMAD7 gene (chromosome 18q21) 
was associated to CRC, where its homozygous C/C genotype was speculated to confer 
protection from the predisposition of CRC.  To the best of our knowledge, there is yet to 
be any published data relating the 15 SNPs and CRC susceptibility with regards to our 
Malaysian population. 
Given the large amount of epidemiological studies being performed worldwide, the 
findings on the relationship between these genetic variants and CRC risk are still 
inconsistent, and no firm conclusion can be drawn thus far.  This might be attributed to 
the genetic heterogeneity across different study populations, relatively small size of 
sample cohorts, lack of information on tumour location and CRC staging, different 
selection criteria for control groups, and publication bias against negative findings.  In 
our present study, there were a few short-comings that need to be addressed herein.  
First, our sample cohort was relatively small and hence, the statistical power might be 
too low to detect the moderate effects of these low-penetrance genetic variants on CRC 
susceptibility.  Second, we did not consider the effects of possible modifiers or 
confounding factors, i.e., dietary and lifestyle factors, due to the lack of sufficient 
information. 
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For future work, perhaps it would be advisable to address these confounding factors in 
order to obtain a clearer picture on the contribution of these low-penetrance genes on 
CRC, as certain genetic variants might only impact CRC carcinogenesis in concomitant 
with other modifying factors.  It would be more useful to perform the screening of these 
low-penetrance genetic variants using a larger sample cohort with sufficient statistical 
power.  It will also provide a better insight into the impacts of these genetic variants on 
CRC progression if the patients’ cohort is large enough for further stratification 
according to tumour location and cancer stage.  It is also interesting to study the low-
penetrance genetic variants in combination since an ‘adverse combination’ of the less 
favourable genetic variants was thought to exhibit an amplified effect on CRC 
predisposition.  
6.2 Part B: Differential Transcriptome Analysis 
In our current analysis, two distinctive gene expression signatures were identified to 
recognise the early- and advanced stage CRC neoplasms.  The early stage CRC group 
was represented by the under-expression of ARPC2, as well as the over-expression of 
the RPL35, RPS23 and TIMP1 genes.  On the other hand, the advanced stage CRC 
tumours were characterised by the over-expression of the C6orf173, RPL35, RPS23 and 
TIMP1 genes.  We also investigated the mRNA expression patterns of the primary 
sporadic CRC tumours of different tumour sites, i.e., right- and left-sided.  The right-
sided CRC tumours were characterised by a 3-gene signature, i.e., the over-expressed 
C6orf173, RPL35 and TIMP1 genes.  We reported an additional over-expressed RPS23 
gene in the left-sided CRC neoplasms compared to the former group. 
The microarray technology is the most widely-used approach in transcriptomic profiling.  
However, the microarray experiment is often subjected to various sources of variability 
and false positives.  Moreover, the massive data set generated by this approach also 
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presents both statistical and bioinformatic challenges.  Therefore, we chose to perform 
our gene expression analysis with another approach, i.e., the two-step ACP-based PCR.  
The ACP technology with its unique tripartite structure of primers and PCR steps allows 
high specificity and minimises false-positives.  For our study, the sample cohort was 
relatively small, thus we were not able to reach a statistically firm conclusion.  This is 
due to several reasons:- first, there is a lack of a Tissue Bank in our institution and 
hence, the collection of tissue specimens was fully dependent on the number of 
surgically resected CRC patients within our study period.  Second, the voluntariness of 
CRC patients was still low in our population.  Third, the application of stringent 
criteria(s) had hampered the collection of suitable tissue specimens within a short time-
frame.  Nevertheless, our identified gene expression signatures were still convincing 
owing to our stringent sample selection, high specificity of ACP primers and TaqMan 
assays, as well as reliable statistical analysis software. 
Since the identified differentially expressed genes in our present study were biologically 
plausible and clinically relevant to CRC carcinogenesis, further validation of their 
sensitivity and specificity on a larger set of clinical samples is needed.  In future, the 
extensive testing of their distinctive abilities on each stage of CRC progression, i.e., 
Stages I, II, III and IV, would hold more value in the clinical setting.  In addition, the 
identified gene expression signatures in the early stage CRC tumours should also be 
examined based on pre-neoplastic lesions, e.g., adenomas.  It would be interesting to see 
if these changes in gene expression patterns can be observed prior to the development of 
malignancy.  Furthermore, the integration of the imaging and histological information, 
as well as other histochemical parameters should be made possible in future studies.  
Moreover, we should also perform gene expression analysis with different platforms, 
and subsequently exploit a combination of several gene markers to improve the staging, 
prognostication and monitoring of the complex CRC neoplasms. 
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6.3 Part C: Differential Proteome Analysis via A Bottom-Up Proteomics 
Approach 
In the third part of our study, we were able to characterise the protein expression 
patterns of only the Stage II CRC tumours.  The protein abundance analysis between the 
advanced stages of CRC tumours (Stages III and IV) and their paired macroscopically 
normal tumour-adjacent tissues, failed to detect any differentially expressed protein in 
our patients’ cohort.  The proteins that found to be over-expressed in the Stage II CRC 
neoplasms were the Hsp60, RPLP0, PPase, NCC27, TCTP, B23, SGN8, NM23, SMN 
and S100A9.  Meanwhile, the K20, ACTC1, ACTSA, HSP27, LC20 and LC17 proteins 
were under-expressed.  In fact, most of these aberrantly expressed proteins were also 
reported in the neoplastic colonic mucosa via similar approaches in other proteomic 
studies, with the exception of RPLP0, SGN8 and ACTC1 proteins.  This proves the 
reliability of our present 2-D DIGE analysis regardless of the different disease stages of 
recruited CRC tumouric tissue specimens and 2-D GE approaches compared to other 
proteomic studies. 
The short-coming of our current protein expression analysis is the lack of tumouric 
samples from the Stage I CRC patients.  It would be more beneficial if the protein 
expression changes in this earliest stage of CRC progression could be characterised.  
While we did not detect any significant protein abundance changes in the advanced 
stage CRC neoplasms, one of the possibilities would be the proteins that are responsible 
for the late CRC progression might not fall within the pI range of 4 – 7.  It is possible 
that the proteins with significant changes might overlap with other proteins, which 
render them undetectable.  Therefore, the studies on Stages III and IV CRC tumours 
should be repeated by applying different pH ranges or extended lengths of Immobiline 
DryStrip Gels. 
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Improving steps would be to authenticate the identified protein expression patterns in a 
larger sample cohort (consisting of all stages of CRC tumours) with other approaches, 
i.e., Western Blot or recently developed TaqMan Chemistry-Based Protein Assay.  It 
would be more clinically useful if the pre-neoplastic adenomas are included as well.  In 
view of the general wide screening acceptance for serological markers, further analysis 
is needed to investigate whether these over-expressed proteins in the Stage II CRC 
tumours are being released into the circulation and are readily detectable in the patients’ 
serum.  This would be the foremost step in translating the laboratory findings into 
potential bedside application.  On the other hand, the same study approaches could also 
be applied to characterise aberrantly expressed proteins in Malaysian CRC patients of 
better or worse prognosis, as well as those who are responsive or non-responsive to the 
adjuvant therapy.   
Overall, the CRC research in Malaysia is still in its infancy and has a long way to go.  
However, what is needed is a multi-disciplinary and inter-laboratory collaborative effort 
towards a better personalised future CRC management. 
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